SLR_pmcid_tbl,single_studies,question,answer
11127739_Table_2.,Brown et al (1998); Vintzileos et al (2000); Vanara et al (2004); Pinto et al (2014); Mistry et al (2013); Chung et al (2020); Finneran et al (2019),What interventions are examined in these studies?,"Brown et al (1998): Do not perform US, Routine US in 1st trimester, US + NT in 1st trimester, US during 2nd trimester, US during 3rd trimester; Vintzileos et al (2000): US in tertiary center, US in primary- and secondary-level centers; Vanara et al (2004): Structured gestational screening program with US, No structured program; Pinto et al (2014): 4C + outflow â†’ MFM, 4C + outflow â†’ card, 4C â†’ MFM, 4C â†’ card, MFM 4C + outflow â†’ card, NT + outflow, Fetal echocardiography; Mistry et al (2013): Usual management, Universal screening through telemedicine; Chung et al (2020): Ultrasonography, Echocardiography for ICSI only, Echocardiography for all IVF; Finneran et al (2019): Detailed US, Selective echocardiography (only in case of abnormal ultrasonography), Universal echocardiography (all cases of elevated A1c)"
11127739_Table_2.,Brown et al (1998); Vintzileos et al (2000); Vanara et al (2004); Pinto et al (2014); Mistry et al (2013); Chung et al (2020); Finneran et al (2019),What costs are reported in these studies?,"Brown et al (1998): Routine US in 1st trimester: Â£30,450, US + NT in 1st trimester: Â£30,583, US during 2nd trimester: Â£31,139, US during 3rd trimester: Â£31,198; Vintzileos et al (2000): US in tertiary center: USD $270, US in primary- and secondary-level centers: USD $270; Vanara et al (2004): Structured gestational screening program with US: â‚¬400,536,721, No structured program: â‚¬505,006,384; Pinto et al (2014): 4C + outflow â†’ MFM: USD $169.33, 4C + outflow â†’ card: USD $169.84, 4C â†’ MFM: USD $170.37, 4C â†’ card: USD $171.76, MFM 4C + outflow â†’ card: USD $216.53, NT + outflow: USD $316.58, Fetal echocardiography: USD $513.72; Mistry et al (2013): Usual management: Â£12,906, Universal screening through telemedicine: Â£12,876; Chung et al (2020): Ultrasonography: USD $8119, Echocardiography for ICSI only: USD $8408, Echocardiography for all IVF: USD $8560; Finneran et al (2019): Detailed US: USD $195.13, Selective echocardiography: USD $340.29, Universal echocardiography: USD $577.08"
11127739_Table_2.,Brown et al (1998); Vintzileos et al (2000); Vanara et al (2004); Pinto et al (2014); Mistry et al (2013); Chung et al (2020); Finneran et al (2019),What changes in costs are observed in these studies?,"Brown et al (1998): No specific change in costs reported.; Vintzileos et al (2000): No specific change in costs reported.; Vanara et al (2004): -â‚¬104,469,663 for the structured gestational screening program with US.; Pinto et al (2014): USD $0.51 for 4C + outflow â†’ card, USD $1.04 for 4C â†’ MFM, USD $2.43 for 4C â†’ card, USD $47.20 for MFM 4C + outflow â†’ card, USD $147.25 for NT + outflow, USD $344.39 for Fetal echocardiography.; Mistry et al (2013): No specific change in costs reported.; Chung et al (2020): USD $289 for Echocardiography for ICSI only, USD $441 for Echocardiography for all IVF.; Finneran et al (2019): USD $145.16 for Selective echocardiography, USD $381.95 for Universal echocardiography."
11127739_Table_2.,Brown et al (1998); Vintzileos et al (2000); Vanara et al (2004); Pinto et al (2014); Mistry et al (2013); Chung et al (2020); Finneran et al (2019),What levels of effectiveness are reported in these studies?,"Brown et al (1998): 0.53 cases detected, 1.58 cases detected, 5.85 cases detected, 6.30 cases detected; Vintzileos et al (2000): Avoided costs: USD 367âˆ’USD459, Avoided costs: USD 109âˆ’USD201; Vanara et al (2004): 7071 detected malformations, 6386 detected malformations; Pinto et al (2014): 3.53 detected cases, 4.42 detected cases, 2.37 detected cases, 2.96 detected cases, 5.07 detected cases, 5.06 detected cases, 6.59 detected cases; Mistry et al (2013): 23.24 QALY, 23.282 QALY; Chung et al (2020): 1.74487 QALY, 1.74497 QALY, 1.74499 QALY; Finneran et al (2019): 0.007936577"
11127739_Table_2.,Brown et al (1998); Vintzileos et al (2000); Vanara et al (2004); Pinto et al (2014); Mistry et al (2013); Chung et al (2020); Finneran et al (2019),What changes in effectiveness are noted in these studies?,"Brown et al (1998): NR; Vintzileos et al (2000): NA; Vanara et al (2004): 685 avoided malformations; Pinto et al (2014): 0.9, -1.16, -0.57, 1.54, 1.53, 3.06; Mistry et al (2013): NR; Chung et al (2020): 0.0001, 0.00012; Finneran et al (2019): 0.007936577"
11127739_Table_2.,Brown et al (1998): General evaluation of congenital malformations; Vintzileos et al (2000): General evaluation of congenital malformations; Vanara et al (2004): General evaluation of congenital malformations; Pinto et al (2014): Specific evaluation of CHD; Mistry et al (2013): Specific evaluation of CHD; Chung et al (2020): Specific evaluation of CHD; Finneran et al (2019): Specific evaluation of CHD,What are the ICER or net monetary benefits calculated in these studies?,"Brown et al (1998): ICERâ€‰=â€‰Â£57â€¯453/case detected, ICERâ€‰=â€‰Â£19â€¯356/case detected, ICERâ€‰=â€‰Â£5323/case detected, ICERâ€‰=â€‰Â£4952/case detected; Vintzileos et al (2000): USD 97âˆ’USD189 millions, USD 69âˆ’USD161 millions; Vanara et al (2004): ICERâ€‰=â€‰56â€¯637/detected malformation, ICERâ€‰=â€‰79â€¯085/detected malformation; Pinto et al (2014): USD $579, Dominated, Dominated, USD $30â€¯591, Extended dominance, USD $112â€¯560; Mistry et al (2013): Dominant; Chung et al (2020): USD $2â€¯890â€¯000, US $5â€¯692â€¯457; Finneran et al (2019): USD $18â€¯290, USD $28â€¯875"
8795065_Table_3,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What therapeutic areas are addressed in these studies?,NICE TA 531 [42]: Untreated metastatic NSCLC with PD-L1 TPS â‰¥ 50%; NICE TA 557 [41]: Untreated metastatic non-squamous NSCLC; NICE TA 584 [44]: (1) Untreated metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS 1â€“49%; (2) metastatic non-squamous EGFR/ALK-positive NSCLC when targeted therapy is not an option or has failed; NICE TA 600 [43]: Untreated metastatic squamous NSCLC; PBAC 3.01 [47]; resubmission of PBAC 6.04 [45]: Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50; PBAC 6.01 [48]: Metastatic non-squamous EGFR/ALK-negative NSCLC; PBAC 6.04 [45]: Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50; PBAC 7.09 [49]: Untreated metastatic non-squamous EGFR/ALK/ROS1-negative NSCLC with ECOG status 0 or 1; PBAC 7.17 [46]; resubmission of PBAC 6.04 [45]: Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50; pCODR 10101 [50]: Untreated metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50%; pCODR 10153 [51]: Untreated metastatic non-squamous EGFR/ALK-negative NSCLC; SMC 1239/17 [53]: Metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50%; SMC 2127 [54]: Metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS < 50% or non-evaluable; SMC 2187 [55]: Metastatic squamous NSCLC with PD-L1 TPS < 50% or non-evaluable; SMC 2207 [52]; resubmission of SMC 2127 [54]: Metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS < 50% or non-evaluable
8795065_Table_3,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",Which countries are covered in these studies?,NICE TA 531 [42]: UK; NICE TA 557 [41]: UK; NICE TA 584 [44]: UK; NICE TA 600 [43]: UK; PBAC 3.01 [47]; resubmission of PBAC 6.04 [45]: Australia; PBAC 6.01 [48]: Australia; PBAC 6.04 [45]: Australia; PBAC 7.09 [49]: Australia; PBAC 7.17 [46]; resubmission of PBAC 6.04 [45]: Australia; pCODR 10101 [50]: Canada; pCODR 10153 [51]: Canada; SMC 1239/17 [53]: Scotland; SMC 2127 [54]: Scotland; SMC 2187 [55]: Scotland; SMC 2207 [52]; resubmission of SMC 2127 [54]: Scotland
8795065_Table_3,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What perspectives are used in these studies?,NICE TA 531 [42]: UK NHS; NICE TA 557 [41]: UK NHS; NICE TA 584 [44]: UK NHS; NICE TA 600 [43]: UK NHS; PBAC 3.01 [47]; resubmission of PBAC 6.04 [45]: Australian healthcare system; PBAC 6.01 [48]: Australian healthcare system; PBAC 6.04 [45]: Australian healthcare system; PBAC 7.09 [49]: Australian healthcare system; PBAC 7.17 [46]; resubmission of PBAC 6.04 [45]: Australian healthcare system; pCODR 10101 [50]: Canadian healthcare system; pCODR 10153 [51]: Canadian healthcare system; SMC 1239/17 [53]: Scotland payer; SMC 2127 [54]: Scotland payer; SMC 2187 [55]: Scotland payer; SMC 2207 [52]; resubmission of SMC 2127 [54]: Scotland payer
8795065_Table_3,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What are the base-case populations considered in these studies?,NICE TA 531 [42]: Untreated metastatic NSCLC with PD-L1 TPS â‰¥ 50%; NICE TA 557 [41]: Untreated metastatic non-squamous NSCLC; NICE TA 584 [44]: (1) Untreated metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS 1â€“49%; (2) metastatic non-squamous EGFR/ALK-positive NSCLC when targeted therapy is not an option or has failed; NICE TA 600 [43]: Untreated metastatic squamous NSCLC; PBAC 3.01 [47]; resubmission of PBAC 6.04 [45]: Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50; PBAC 6.01 [48]: Metastatic non-squamous EGFR/ALK-negative NSCLC; PBAC 6.04 [45]: Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50; PBAC 7.09 [49]: Untreated metastatic non-squamous EGFR/ALK/ROS1-negative NSCLC with ECOG status 0 or 1; PBAC 7.17 [46]; resubmission of PBAC 6.04 [45]: Locally advanced or metastatic squamous or non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50; pCODR 10101 [50]: Untreated metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50%; pCODR 10153 [51]: Untreated metastatic non-squamous EGFR/ALK-negative NSCLC; SMC 1239/17 [53]: Metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50%; SMC 2127 [54]: Metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS < 50% or non-evaluable; SMC 2187 [55]: Metastatic squamous NSCLC with PD-L1 TPS < 50% or non-evaluable; SMC 2207 [52]; resubmission of SMC 2127 [54]: Metastatic non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS < 50% or non-evaluable
8795065_Table_3,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What types of models are employed in these studies?,NICE TA 531 [42]: Partitioned survival; NICE TA 557 [41]: Partitioned survival; NICE TA 584 [44]: Partitioned survival; NICE TA 600 [43]: Partitioned survival; PBAC 3.01 [47]; resubmission of PBAC 6.04 [45]: Markov; PBAC 6.01 [48]: Partitioned survival; PBAC 6.04 [45]: Markov; PBAC 7.09 [49]: Partitioned survival; PBAC 7.17 [46]; resubmission of PBAC 6.04 [45]: Markov; pCODR 10101 [50]: Partitioned survival; pCODR 10153 [51]: Partitioned survival; SMC 1239/17 [53]: Partitioned survival; SMC 2127 [54]: Partitioned survival; SMC 2187 [55]: Partitioned survival; SMC 2207 [52]; resubmission of SMC 2127 [54]: Partitioned survival
8795065_Table_3,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What time horizons are used in these studies?,NICE TA 531 [42]: 20 years; NICE TA 557 [41]: 20 years; NICE TA 584 [44]: 20 years; NICE TA 600 [43]: 20 years; PBAC 3.01 [47]; resubmission of PBAC 6.04 [45]: 6 years; PBAC 6.01 [48]: 7.5 years; PBAC 6.04 [45]: 6 years; PBAC 7.09 [49]: 7.5 years; PBAC 7.17 [46]; resubmission of PBAC 6.04 [45]: 6 years; pCODR 10101 [50]: 10 years; pCODR 10153 [51]: 10 years; SMC 1239/17 [53]: 20 years; SMC 2127 [54]: 20 years; SMC 2187 [55]: 30 years; SMC 2207 [52]; resubmission of SMC 2127 [54]: 20 years
8795065_Table_3,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What interventions are compared in these studies?,NICE TA 531 [42]: Pembrolizumab vs. CTX; NICE TA 557 [41]: Pembrolizumab + CTX vs. pembrolizumab; pembrolizumab + CTX vs. CTX; NICE TA 584 [44]: Atezolizumab + CTX vs. CTX; NICE TA 600 [43]: Pembrolizumab + CTX vs. pembrolizumab; pembrolizumab + CTX vs. CTX; PBAC 3.01 [47]; resubmission of PBAC 6.04 [45]: Pembrolizumab vs. CTX; PBAC 6.01 [48]: Atezolizumab + CTX vs. CTX; PBAC 6.04 [45]: Pembrolizumab vs. CTX; PBAC 7.09 [49]: Pembrolizumab + CTX vs. pembrolizumab; pembrolizumab + CTX vs. CTX; PBAC 7.17 [46]; resubmission of PBAC 6.04 [45]: Pembrolizumab vs. CTX; pCODR 10101 [50]: Pembrolizumab vs. CTX; pCODR 10153 [51]: Pembrolizumab + CTX vs. CTX; SMC 1239/17 [53]: Pembrolizumab vs. CTX; SMC 2127 [54]: Pembrolizumab + CTX vs. CTX; SMC 2187 [55]: Pembrolizumab + CTX vs. CTX; SMC 2207 [52]; resubmission of SMC 2127 [54]: Pembrolizumab + CTX vs. CTX
8795065_Table_2,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What are the titles or identifiers of these studies?,"Aggarwal et al. [28]: Aggarwal et al. [28]; Aggarwal et al. [29]: Aggarwal et al. [29]; Bhadhuri et al. [9], adaptation of Huang et al. [17]: Bhadhuri et al. [9], adaptation of Huang et al. [17]; Chouaid et al. [10]: Chouaid et al. [10]; Chouaid et al. [30]: Chouaid et al. [30]; Criss et al. [11]: Criss et al. [11]; Georgieva et al. [31]: Georgieva et al. [31]; Georgieva et al. [13]: Georgieva et al. [13]; Giuliani and Bonetti [14]: Giuliani and Bonetti [14]; Guirgis [32]: Guirgis [32]; Harding et al. [33], publication corresponding to TA 557 [41]: Harding et al. [33], publication corresponding to TA 557 [41]; Harding et al. [34], publication corresponding to TA 600 [43]: Harding et al. [34], publication corresponding to TA 600 [43]; Hu and Goldman [36]: Hu and Goldman [36]; Hu and Hay [15]: Hu and Hay [15]; Hu et al. [35]: Hu et al. [35]; Huang et al. [17]: Huang et al. [17]; Huang et al. [16], adaptation of Huang et al. [17]: Huang et al. [16], adaptation of Huang et al. [17]; Insinga et al. [18]: Insinga et al. [18]; Insinga et al. [19]: Insinga et al. [19]; Kim et al. [37]: Kim et al. [37]; Liao et al. [20]: Liao et al. [20]; Loong et al. [21], adaptation of Huang et al. [17]: Loong et al. [21], adaptation of Huang et al. [17]; Pinheiro et al. [38]: Pinheiro et al. [38]; Roth et al. [39]: Roth et al. [39]"
8795065_Table_2,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",Which countries are covered in these studies?,"Aggarwal et al. [28]: USA; Aggarwal et al. [29]: USA; Bhadhuri et al. [9], adaptation of Huang et al. [17]: Switzerland; Chouaid et al. [10]: France; Chouaid et al. [30]: France; Criss et al. [11]: USA; Georgieva et al. [31]: USA, UK; Georgieva et al. [13]: USA, UK; Giuliani and Bonetti [14]: Italy; Guirgis [32]: USA; Harding et al. [33], publication corresponding to TA 557 [41]: England; Harding et al. [34], publication corresponding to TA 600 [43]: England; Hu and Goldman [36]: UK; Hu and Hay [15]: UK; Hu et al. [35]: UK; Huang et al. [17]: USA; Huang et al. [16], adaptation of Huang et al. [17]: USA; Insinga et al. [18]: USA; Insinga et al. [19]: USA; Kim et al. [37]: USA; Liao et al. [20]: China; Loong et al. [21], adaptation of Huang et al. [17]: Hong Kong; Pinheiro et al. [38]: Portugal"
8795065_Table_2,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What perspectives are used in these studies?,"Aggarwal et al. [28]: US payer; Aggarwal et al. [29]: US payer; Bhadhuri et al. [9], adaptation of Huang et al. [17]: Swiss payer perspective; Chouaid et al. [10]: French healthcare system; Chouaid et al. [30]: French healthcare system; Criss et al. [11]: US healthcare system; Georgieva et al. [31]: US cost and UK NHS; Georgieva et al. [13]: US cost and UK NHS; Giuliani and Bonetti [14]: NA; Guirgis [32]: NR; Harding et al. [33], publication corresponding to TA 557 [41]: England, NHS; Harding et al. [34], publication corresponding to TA 600 [43]: England, NHS; Hu and Goldman [36]: UK NHS; Hu and Hay [15]: UK NHS; Hu et al. [35]: UK NHS; Huang et al. [17]: US payer; Huang et al. [16], adaptation of Huang et al. [17]: Third-party US public payer; Insinga et al. [18]: US payer; Insinga et al. [19]: US payer; Kim et al. [37]: US payer; Liao et al. [20]: China societal; Loong et al. [21], adaptation of Huang et al. [17]: Hong Kong Hospital Authority; Pinheiro et al. [38]: Portugal societal; Roth et al. [39]: US payer"
8795065_Table_2,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What are the base-case populations considered in these studies?,"Aggarwal et al. [28]: Metastatic non-squamous EGFR/ALK-negative NSCLC; Aggarwal et al. [29]: Metastatic non-squamous NSCLC; Bhadhuri et al. [9], adaptation of Huang et al. [17]: Untreated metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50%; Chouaid et al. [10]: Chemotherapy-naÃ¯ve metastatic squamous and non-squamous EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50%; Chouaid et al. [30]: Untreated metastatic non-squamous NSCLC; Criss et al. [11]: Metastatic non-squamous NSCLC; Georgieva et al. [31]: Advanced NSCLC with PD-L1 â‰¥ 50%; Georgieva et al. [13]: Advanced EGFR/ALK-negative NSCLC with PD-L1 â‰¥ 50%; Giuliani and Bonetti [14]: Untreated metastatic EGFR/ALK/ROS1-negative NSCLC; Guirgis [32]: Advanced or metastatic NSCLC; Harding et al. [33], publication corresponding to TA 557 [41]: Untreated metastatic non-squamous EGFR/ALK-negative NSCLC; Harding et al. [34], publication corresponding to TA 600 [43]: Untreated metastatic squamous NSCLC with PD-L1 â‰¥ 50%; Hu and Goldman [36]: Chemotherapy-naÃ¯ve metastatic NSCLC with PD-L1 TPS â‰¥ 50%; Hu and Hay [15]: Untreated locally advanced or metastatic NSCLC with PD-L1 TPS â‰¥ 50%; Hu et al. [35]: Metastatic NSCLC with PD-L1 TPS â‰¥ 50%; Huang et al. [17]: Untreated metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 50%; Huang et al. [16], adaptation of Huang et al. [17]: Chemotherapy-naÃ¯ve advanced or metastatic EGFR/ALK-negative NSCLC with PD-L1 TPS â‰¥ 1%; Insinga et al. [18]: Untreated metastatic non-squamous EGFR/ALK-negative NSCLC; Insinga et al. [19]: Untreated metastatic squamous EGFR/ALK-negative NSCLC; Kim et al. [37]: Metastatic squamous NSCLC; Liao et al. [20]: Advanced NSCLC with PD-L1 â‰¥ 50%; Loong et al. [21], adaptation of Huang et al. [17]: Metastatic EGFR/ALK-negative NSCLC; Pinheiro et al. [38]: Untreated metastatic NSCLC with PD-L1 â‰¥ 50%; Roth et al. [39]: "
8795065_Table_2,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What types of models are employed in these studies?,"Aggarwal et al. [28]: Partitioned survival; Aggarwal et al. [29]: Partitioned survival; Bhadhuri et al. [9], adaptation of Huang et al. [17]: Partitioned survival; Chouaid et al. [10]: Partitioned survival; Chouaid et al. [30]: Partitioned survival; Criss et al. [11]: Microsimulation; Georgieva et al. [31]: Markov; Georgieva et al. [13]: Markov microsimulation; Giuliani and Bonetti [14]: NA (analysis of pharmacological costs); Guirgis [32]: Unclear; Harding et al. [33], publication corresponding to TA 557 [41]: Partitioned survival; Harding et al. [34], publication corresponding to TA 600 [43]: Partitioned survival; Hu and Goldman [36]: Markov; Hu and Hay [15]: Markov; Hu et al. [35]: Markov; Huang et al. [17]: Partitioned survival; Huang et al. [16], adaptation of Huang et al. [17]: Partitioned survival; Insinga et al. [18]: Partitioned survival; Insinga et al. [19]: Partitioned survival; Kim et al. [37]: Partitioned survival; Liao et al. [20]: Markov; Loong et al. [21], adaptation of Huang et al. [17]: Partitioned survival; Pinheiro et al. [38]: Partitioned survival; Roth et al. [39]: NR"
8795065_Table_2,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What time horizons are used in these studies?,"Aggarwal et al. [28]: 10 years; Aggarwal et al. [29]: Lifetime; Bhadhuri et al. [9], adaptation of Huang et al. [17]: 20 years; Chouaid et al. [10]: 10 years; Chouaid et al. [30]: 10 years; Criss et al. [11]: Lifetime; Georgieva et al. [31]: 5 years; Georgieva et al. [13]: Lifetime; Giuliani and Bonetti [14]: NA; Guirgis [32]: NR; Harding et al. [33], publication corresponding to TA 557 [41]: 20 years; Harding et al. [34], publication corresponding to TA 600 [43]: 30 years; Hu and Goldman [36]: 10 years; Hu and Hay [15]: Lifetime; Hu et al. [35]: Lifetime; Huang et al. [17]: Lifetime (20 years); Huang et al. [16], adaptation of Huang et al. [17]: 20 years; Insinga et al. [18]: 20 years; Insinga et al. [19]: 20 years; Kim et al. [37]: Lifetime; Liao et al. [20]: 10 years; Loong et al. [21], adaptation of Huang et al. [17]: 10 years; Pinheiro et al. [38]: Lifetime; Roth et al. [39]: NR"
8795065_Table_2,"NICE TA 531,NICE TA 557 [41],NICE TA 600 [43],PBAC 3.01 [47],PBAC 6.01 [48],PBAC 6.04 [45],PBAC 7.09 [49],pCODR 10101 [50],PBAC 7.17 [46]",What interventions are compared in these studies?,"Aggarwal et al. [28]: Pembrolizumab + CTX vs. CTX; Aggarwal et al. [29]: Pembrolizumab + CTX vs. CTX, Pembrolizumab vs. CTX, Atezolizumab + CTX vs. CTX; Bhadhuri et al. [9], adaptation of Huang et al. [17]: Pembrolizumab vs. CTX; Chouaid et al. [10]: Pembrolizumab vs. CTX; Chouaid et al. [30]: Pembrolizumab + CTX vs. CTX; Criss et al. [11]: Atezolizumab + CTX vs. CTX, Atezolizumab + CTX vs. pembrolizumab + CTX vs. CTX; Georgieva et al. [31]: Pembrolizumab vs. CTX; Georgieva et al. [13]: Pembrolizumab vs. CTX; Giuliani and Bonetti [14]: Pembrolizumab vs. CTX, Nivolumab vs. CTX; Guirgis [32]: Pembrolizumab vs. CTX; Harding et al. [33], publication corresponding to TA 557 [41]: Pembrolizumab + CTX vs. CTX, Pembrolizumab + CTX vs. pembrolizumab; Harding et al. [34], publication corresponding to TA 600 [43]: Pembrolizumab + CTX vs. CTX; Hu and Goldman [36]: Pembrolizumab vs. CTX; Hu and Hay [15]: Pembrolizumab vs. CTX; Hu et al. [35]: Pembrolizumab + CTX vs. CTX; Huang et al. [17]: Pembrolizumab vs. CTX; Huang et al. [16], adaptation of Huang et al. [17]: Pembrolizumab vs. CTX; Insinga et al. [18]: Pembrolizumab + CTX vs. CTX, Pembrolizumab + CTX vs. pembrolizumab; Insinga et al. [19]: Pembrolizumab + CTX vs. CTX, Pembrolizumab + CTX vs. pembrolizumab; Kim et al. [37]: Pembrolizumab + CTX vs. CTX; Liao et al. [20]: Pembrolizumab vs. CTX; Loong et al. [21], adaptation of Huang et al. [17]: Pembrolizumab vs. CTX; Pinheiro et al. [38]: Pembrolizumab vs. CTX"
10948140_Table_3.,"Kawalec et al: 2015, 77; Ren et al: 2020, 102; Fujii et al: 2015, 62; Stawowczyk et al: 2014, 120; Price et al: 2014, 101; BrÃrgen et al: 2010, 43",What are the references for these studies?,"Kawalec et al: 2015, 77; Ren et al: 2020, 102; Fujii et al: 2015, 62; Stawowczyk et al: 2014, 120; Price et al: 2014, 101; BrÃrgen et al: 2010, 43"
10948140_Table_3.,"Kawalec et al: 2015, 77; Ren et al: 2020, 102; Fujii et al: 2015, 62; Stawowczyk et al: 2014, 120; Price et al: 2014, 101; BrÃrgen et al: 2010, 43",What study designs are used in these studies?,"Kawalec et al, 201577: CEA + CUA; Ren et al, 2020102: CEA + CUA; Fujii et al, 201562: CEA, BIA; Stawowczyk et al, 2014120: CUA; Price et al, 2014101: CMA; BrÃ¼ggenjÃ¼rgen et al, 201043: CMA"
10948140_Table_3.,"Kawalec et al: 2015, 77; Ren et al: 2020, 102; Fujii et al: 2015, 62; Stawowczyk et al: 2014, 120; Price et al: 2014, 101; BrÃrgen et al: 2010, 43",Which countries are covered in these studies?,"Kawalec et al, 201577: Poland; Ren et al, 2020102: China; Fujii et al, 201562: Brazil; Stawowczyk et al, 2014120: Poland; Price et al, 2014101: Sweden; BrÃ¼ggenjÃ¼rgen et al, 201043: Germany"
10948140_Table_3.,"Kawalec et al: 2015, 77; Ren et al: 2020, 102; Fujii et al: 2015, 62; Stawowczyk et al: 2014, 120; Price et al: 2014, 101; BrÃrgen et al: 2010, 44",What populations are examined in these studies?,"Kawalec et al, 201577: Patients with arterial hypertension; Ren et al, 2020102: Hypertensive adults; Fujii et al, 201562: Systemic arterial hypertension; Stawowczyk et al, 2014120: Hypertensive patients; Price et al, 2014101: Moderate-to-severe COPD patients; BrÃ¼ggenjÃ¼rgen et al, 201043: Asthma"
10948140_Table_3.,"Kawalec et al: 2015, 77; Ren et al: 2020, 102; Fujii et al: 2015, 62; Stawowczyk et al: 2014, 120; Price et al: 2014, 101; BrÃrgen et al: 2010, 45",What interventions or stct brands are evaluated in these studies?,"Kawalec et al, 201577: Indapamide + amlodipine (Tertens-AM); Ren et al, 2020102: Olmesartan + amlodipine (Sevikar); Fujii et al, 201562: Bisoprolol + amlodipine (Concor AM); Stawowczyk et al, 2014120: Indapamide + amlodipine (Natrixam); Price et al, 2014101: Indacaterol + glycopyrronium (Utibron); BrÃ¼ggenjÃ¼rgen et al, 201043: Beclomethasone dipropionate + formoterol fumarate (CHF 1535)"
10948140_Table_3.,"Kawalec et al: 2015, 77; Ren et al: 2020, 102; Fujii et al: 2015, 62; Stawowczyk et al: 2014, 120; Price et al: 2014, 101; BrÃrgen et al: 2010, 46",What are the main messages conveyed by these studies?,"Kawalec et al, 201577: STCT was less expensive than treatment with LDCs. STCT dominates LDCs, in both NHF and patientâ€™s perspective for patients with higher adherence.; Ren et al, 2020102: STCT dominates LDCs.; Fujii et al, 201562: STCT dominates LDCs.; Stawowczyk et al, 2014120: Public payer perspective: STCT dominates LDCs. Patientâ€™s perspective: Net monetary benefit was higher with STCT.; Price et al, 2014101: STCT dominates LDCs in all horizons, and in PSA iterations.; BrÃ¼ggenjÃ¼rgen et al, 201043: STCT dominates LDCs."
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What are the names or identifiers of these studies?,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38]
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What types of economic evaluations are conducted in these studies?,Saylan et al. (2013) [49]: CUA; Machado et al. (2007) [45]: CEA; Kongsakon and Bunchapattanasakda (2008) [40]: CEA; Machado et al. (2008) [46]: CEA; Leelahanaj (2010) [41]: CUA; Wang et al. (2020) [52]: CEA; Parvathy et al. (2016) [33]: CEA; Siskind et al. (2008) [44]: CUA; Strand et al. (2016) [47]: CUA; Prukkanone et al. (2012) [42]: CUA; Bertram et al. (2021) [50]: CEA; Chisholm and Saxena (2012) [51]: CUA; Gureje et al. (2007) [48]: CUA; Weobong et al. (2017) [36]: CUA; Nakimuli-Mpungu et al. (2020) [43]: CUA; Buttorff et al. (2012) [31]: CEA/CUA; Fuhr et al. (2019) [32]: CEA; Patel et al. (2017) [35]: CUA; Hamdani et al. (2020) [38]: CEA
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What study designs or model types are used in these studies?,Saylan et al. (2013) [49]: Model (microsimulation); Machado et al. (2007) [45]: Model (decision tree); Kongsakon and Bunchapattanasakda (2008) [40]: Model (decision tree); Machado et al. (2008) [46]: Model (decision tree); Leelahanaj (2010) [41]: Model (decision tree); Wang et al. (2020) [52]: RCT (437); Parvathy et al. (2016) [33]: Follow-up (30); Siskind et al. (2008) [44]: Model (Markov cohort); Strand et al. (2016) [47]: Model (mathematical population model); Prukkanone et al. (2012) [42]: Model (microsimulation); Bertram et al. (2021) [50]: Model (state transition model); Chisholm and Saxena (2012) [51]: Model (state transition model); Gureje et al. (2007) [48]: Model (mathematical population model); Weobong et al. (2017) [36]: RCT (495); Nakimuli-Mpungu et al. (2020) [43]: RCT (1140); Buttorff et al. (2012) [31]: RCT (2796); Fuhr et al. (2019) [32]: RCT (280); Patel et al. (2017) [35]: RCT (495); Hamdani et al. (2020) [38]: RCT (346)
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What perspectives are considered in these studies?,Saylan et al. (2013) [49]: Payer; Machado et al. (2007) [45]: Payer (government); Kongsakon and Bunchapattanasakda (2008) [40]: Health care providers; societal; Machado et al. (2008) [46]: Payer (government); Leelahanaj (2010) [41]: Health care provider; Wang et al. (2020) [52]: Patient; Parvathy et al. (2016) [33]: n/a; Siskind et al. (2008) [44]: n/a; Strand et al. (2016) [47]: Provider; Prukkanone et al. (2012) [42]: Health sector; Bertram et al. (2021) [50]: Health system; Chisholm and Saxena (2012) [51]: Health sector; Gureje et al. (2007) [48]: n/a; Weobong et al. (2017) [36]: Health system; societal; Nakimuli-Mpungu et al. (2020) [43]: Health care sector; payer; Buttorff et al. (2012) [31]: n/a; Fuhr et al. (2019) [32]: Health system; societal; Patel et al. (2017) [35]: Health care system; societal; Hamdani et al. (2020) [38]: Health system
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What time horizons and discount rates are applied in these studies?,"Saylan et al. (2013): Lifetime, 3.5%; Machado et al. (2007): 6 months, n/a; Kongsakon and Bunchapattanasakda (2008): 6 months, n/a; Machado et al. (2008): 6 months, n/a; Leelahanaj (2010): 6 weeks, n/a; Wang et al. (2020): 8 weeks, n/a; Parvathy et al. (2016): 8 weeks, n/a; Siskind et al. (2008): Lifetime, 3%; Strand et al. (2016): 100 years, 3%; Prukkanone et al. (2012): 5 years, 3%; Bertram et al. (2021): 100 years, 3%; Chisholm and Saxena (2012): 10 years, 3%; Gureje et al. (2007): 1 year, n/a; Weobong et al. (2017): 1 year, n/a; Nakimuli-Mpungu et al. (2020): 1 year, n/a; Buttorff et al. (2012): 1 year, n/a; Fuhr et al. (2019): 9 months, n/a; Patel et al. (2017): 3 months, n/a; Hamdani et al. (2020): 1 year, n/a"
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What cost items are included in these studies?,"Saylan et al. (2013): Medications, healthcare staff and hospitalisations; Machado et al. (2007): Medications, hospitalisations, healthcare staff and laboratory investigations; Kongsakon and Bunchapattanasakda (2008): Medications, healthcare staff, hospitalisations and productivity impacts; Machado et al. (2008): Medications, hospitalisations, healthcare staff and laboratory investigations; Leelahanaj (2010): Medications and hospitalisations; Wang et al. (2020): Medications; Parvathy et al. (2016): Medications; Siskind et al. (2008): Healthcare staff and intervention delivery; Strand et al. (2016): Healthcare staff, hospitalisations, intervention delivery, medications and laboratory investigations; Prukkanone et al. (2012): Medications, patient time and transportation costs; Bertram et al. (2021): Healthcare staff, intervention delivery, medications and laboratory investigations; Chisholm and Saxena (2012): Hospitalisations, healthcare staff, medications, intervention delivery and laboratory investigations; Gureje et al. (2007): Healthcare staff, medications and laboratory investigations; Weobong et al. (2017): Healthcare staff, medications, laboratory investigations, hospitalisations, transportation costs, patient and caregiver time and productivity impacts; Nakimuli-Mpungu et al. (2020): Medications, healthcare staff, informal care, intervention delivery and hospitalisations; Buttorff et al. (2012): Hospitalisations, healthcare staff, medications, laboratory investigations, informal care, patient and caregiver time and productivity impacts; Fuhr et al. (2019): Hospitalisations, healthcare staff, medications, laboratory investigations, intervention delivery, transportation costs, patient and caregiver time and productivity impacts; Patel et al. (2017): Healthcare staff, hospitalisations, laboratory investigations, medications and productivity impacts; Hamdani et al. (2020): Hospitalisations, medications, informal care, patient and caregiver time"
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What currencies and reference years are used in these studies?,"Saylan et al. (2013) [49]: Turkish lira ($/TL), 2010; Machado et al. (2007) [45]: Brazilian real ($Brz), 2006; Kongsakon and Bunchapattanasakda (2008) [40]: Thai baht, 2007; Machado et al. (2008) [46]: US dollar (US$), 2007; Leelahanaj (2010) [41]: Thai baht, 2009; Wang et al. (2020) [52]: Chinese yuan renminbi (CNÂ¥), 2018; Parvathy et al. (2016) [33]: Indian rupee (Rs), 2015; Siskind et al. (2008) [44]: $Int, 2003; Strand et al. (2016) [47]: US dollar (US$), 2013; Prukkanone et al. (2012) [42]: Thai baht, 2005; Bertram et al. (2021) [50]: $Int, 2010; Chisholm and Saxena (2012) [51]: $Int, 2005; Gureje et al. (2007) [48]: Nigerian Naira, 2000; Weobong et al. (2017) [36]: $Int, 2015; Nakimuli-Mpungu et al. (2020) [43]: US dollar (US$), 2017; Buttorff et al. (2012) [31]: US dollar (US$), 2009; Fuhr et al. (2019) [32]: US dollar (US$), 2017; Patel et al. (2017) [35]: $Int, 2015; Hamdani et al. (2020) [38]: Pakistani rupees, 2016"
9998021_Table_2,Saylan et al.: 2013 [49]; Machado et al.: 2007 [45]; Kongsakon and Bunchapattanasakda: 2008 [40]; Machado et al.: 2008 [46]; Leelahanaj: 2010 [41]; Wang et al.: 2020 [52]; Parvathy et al.: 2016 [33]; Siskind et al.: 2008 [44]; Strand et al.: 2016 [47]; Prukkanone et al.: 2012 [42]; Bertram et al.: 2021 [50]; Chisholm and Saxena: 2012 [51]; Gureje et al.: 2007 [48]; Weobong et al.: 2017 [36]; Nakimuli-Mpungu et al.: 2020 [43]; Buttorff et al.: 2012 [31]; Fuhr et al.: 2019 [32]; Patel et al.: 2017 [35]; Hamdani et al.: 2020 [38],What health outcomes are measured in these studies?,"Saylan et al. (2013) [49]: QALYs; Machado et al. (2007) [45]: Remission; Kongsakon and Bunchapattanasakda (2008) [40]: Remission; Machado et al. (2008) [46]: Remission; Leelahanaj (2010) [41]: QALYs, remission; Wang et al. (2020) [52]: Mood symptoms (using the MADRS) and functioning (using SDS) of patients; Parvathy et al. (2016) [33]: Depression symptoms (measured with the HDRS); Siskind et al. (2008) [44]: QALYs; Strand et al. (2016) [47]: DALYs averted; Prukkanone et al. (2012) [42]: DALYs averted; Bertram et al. (2021) [50]: HLYs gained; Chisholm and Saxena (2012) [51]: DALYs averted; Gureje et al. (2007) [48]: DALYs averted; Weobong et al. (2017) [36]: QALYs; Nakimuli-Mpungu et al. (2020) [43]: DALYs averted; Buttorff et al. (2012) [31]: QALYs (based on WHO's Disability Schedule), working days lost and psychiatric symptom score; Fuhr et al. (2019) [32]: Depressive symptoms (measured with PHQ-9); Patel et al. (2017) [35]: QALYs; Hamdani et al. (2020) [38]: Depression case (PHQ-9 cut-off â‰¥ 10)HADS Depressi"
9998021_Table_3,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47],What are the titles or identifiers of these studies?,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47]
9998021_Table_3,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47],What interventions and comparators are analyzed in these studies?,"Saylan et al. (2013): Aripiprazole vs olanzapine; aripiprazole vs quetiapine; Machado et al. (2007): SNRIs, SSRIs and TCAs; Kongsakon and Bunchapattanasakda (2008): Escitalopram vs fluoxetine; escitalopram vs venlafaxine; Machado et al. (2008): Venlafaxine, amitriptyline, and fluoxetine; Leelahanaj (2010): Aripiprazole vs placebo; Wang et al. (2020): Vortioxetine vs venlafaxine; Parvathy et al. (2016): Fluoxetine vs venlafaxine; Siskind et al. (2008): Group IPT vs no treatment; Group IPT vs Group IPT with booster; Strand et al. (2016): TCAs, SSRIs, PT and combination (a drug with PT)"
9998021_Table_3,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47],What are the differences in cost between the interventions and comparators in these studies?,"Saylan et al. (2013): Aripiprazole vs olanzapine: âˆ’ $/TL485, Aripiprazole vs quetiapine: âˆ’ $/TL593; Machado et al. (2007): SNRIs vs TCAs: âˆ’ $Brz198, SNRI vs SSRIs: âˆ’ $Brz618, TCA vs SSRIs: âˆ’ $Brz420; Kongsakon and Bunchapattanasakda (2008): Escitalopram vs fluoxetine: âˆ’ 2002 baht, Escitalopram vs venlafaxine: âˆ’ 1768 baht; Machado et al. (2008): Venlafaxine vs amitriptyline: + US$550, venlafaxine vs fluoxetine: + US$411, fluoxetine vs amitriptyline: + US$139; Leelahanaj (2010): + 2561 baht; Wang et al. (2020): For mood and tolerability: + CNÂ¥3245, For mood and functioning: + CNÂ¥4002; Parvathy et al. (2016): (+ 19.98Rs); Siskind et al. (2008): Group IPT vs no treatment: +$Int375, Group IPT with booster vs Group IPT: + $Int49; Strand et al. (2016): Annual costs (in million US$) Acute therapy TCAs: 11.44, SSRIs: 13.31, PT: 48.90, TCAs/PT: 49.97, SSRIs/PT: 51.24, Maintenance therapy TCAs/T: 44.55, SSRIs/PT: 47.21"
9998021_Table_3,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47],What are the differences in effect between the interventions and comparators in these studies?,"Saylan et al. (2013): Aripiprazole vs olanzapine: + 0.04 QALYs, Aripiprazole vs quetiapine: + 0.06 QALYs; Machado et al. (2007): SNRIs vs TCAs: + 1.7%, SNRIs vs SSRIs: + 4.1%, TCAs vs SSRIs: + 2.4%; Kongsakon and Bunchapattanasakda (2008): Escitalopram vs fluoxetine: + 4.76%, escitalopram vs venlafaxine: + 3.12%; Machado et al. (2008): Venlafaxine vs amitriptyline: + 1.8%, venlafaxine vs fluoxetine: + 9%, fluoxetine vs amitriptyline: - 7.2%; Leelahanaj (2010): + 10.3% (remission rate); Wang et al. (2020): Treatment success for mood and tolerability: + 9%, for mood and functioning: + 4.5%; Parvathy et al. (2016): - 6 improvement in HDRS score; Siskind et al. (2008): Group IPT vs no treatment: + 0.245 QALYs, Group IPT with booster vs Group IPT: + 0.124 QALYs"
9998021_Table_3,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47],"What are the ICER values in the base-case analysis for these studies, expressed in 2021 US dollars?","Saylan et al. (2013): Aripiprazole was dominant; Machado et al. (2007): SNRIs was dominant; Kongsakon and Bunchapattanasakda (2008): Escitalopram was dominant; Machado et al. (2008): US$31,595/remission[39,995.1]; Leelahanaj (2010): 3201 baht per QALY[333.4]; Wang et al. (2020): ICER (CNÂ¥/successfully treated patients) for mood and tolerability: 13,938[4211.7], for mood and functioning: 27,876[8423.3]; Parvathy et al. (2016): Venlafaxine was dominant; Siskind et al. (2008): + $Int1150/QALY[1428]"
9998021_Table_3,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47],How do these studies analyze uncertainty in their findings?,"Saylan et al. (2013): SA: Shows no change in the conclusion UA: Aripiprazole has a higher chance of being cost effective at threshold values ranging from 0 to 100,000 TL per QALY gained; Machado et al. (2007): SA: The findings were robust for the change in the probability of switching therapy UA: SNRIs had a higher chance of generating a cheaper cost per patient; Kongsakon and Bunchapattanasakda (2008): SA: Univariate analysis shows no change in ICER UA: Escitalopram dominates fluoxetine and venlafaxine in 99% and 88.2% of cases, respectively; Machado et al. (2008): SA: robust to variation in the costs and clinical parameters UA: Monte Carlo simulations show the finding is unaffected by variations in multiple parameter inputs; Leelahanaj (2010): SA: Remission rate and drug unit cost influence ICER value No uncertainty analysis undertaken; Wang et al. (2020): SA: Impact of using regional price (no change in conclusion) UA: No; Parvathy et al. (2016): No sensitivity or uncertainty analyses undertaken; Siskind et al. (2008): SA: The finding was largely stable except for the cost and utility parameters No uncertainty analysis undertaken; Strand et al. (2016): No information on uncertainty analysis provided"
9998021_Table_3,Saylan et al.: Saylan et al. (2013) [49]; Machado et al.: Machado et al. (2007) [45]; Kongsakon and Bunchapattanasakda: Kongsakon and Bunchapattanasakda (2008) [40]; Machado et al.: Machado et al. (2008) [46]; Leelahanaj: Leelahanaj (2010) [41]; Wang et al.: Wang et al. (2020) [52]; Parvathy et al.: Parvathy et al. (2016) [33]; Siskind et al.: Siskind et al. (2008) [44]; Strand et al.: Strand et al. (2016) [47],What conclusions do the authors draw in these studies?,"Saylan et al. (2013): Adjunctive treatment with aripiprazole is suggested for MDD; Machado et al. (2007): SNRIs are a preferred option; Kongsakon and Bunchapattanasakda (2008): Escitalopram is a cost-effective treatment option in Thailand; Machado et al. (2008): Amitriptyline (dominant over fluoxetine) is a more cost-effective choice; Leelahanaj (2010): Aripiprazole is not a cost-effective adjunctive therapy (a higher ICER); Wang et al. (2020): Vortioxetine is a cost-effective treatment for MDD; Parvathy et al. (2016): Venlafaxine is cost effective; Siskind et al. (2008): Group IPT with booster has an attractive ICER, and the decision is reliant on decision makersâ€™ willingness to pay"
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What are the titles of these studies?,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18)
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What abstracts are provided for these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What backgrounds and objectives are outlined in these studies?,Huntington et al. (35): Background and objectives are outlined.; Rodriguez et al. (18): Background and objectives are outlined.
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What health economic analysis plans are included in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What study populations are described in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What settings and locations are these studies conducted in?,Vickerman et al. (25): Not specified; Blandford et al. (26): Specified; Schackman et al. (27): Specified; Rydzak and Goldie (28): Not specified; Owusu-Edusei 2011 (29): Specified; Kuznik 2013 (30): Specified; Kahn 2014 (31): Not specified; Larson 2014 (22): Specified; Owusu-Edusei et al. (19): Specified; Albright et al. (32): Specified; Kuznik et al. (33): Specified; Terris-Prestholt et al. (21): Specified; Bristow et al. (17): Specified; Hersh et al. (34): Specified; Huntington et al. (35): Specified; Romero et al. (36): Specified; Rodriguez et al. (18): Specified
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What comparators are used in these studies?,Vickerman et al. (25): N; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What perspectives are used in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): N; Owusu-Edusei 2011 (29): N; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): N; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What time horizons are considered in these studies?,Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): N; Terris-Prestholt et al. (21): N; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What discount rates are applied in these studies?,Vickerman et al. (25): Not specified; Blandford et al. (26): Not applicable; Schackman et al. (27): Yes; Rydzak and Goldie (28): Not specified; Owusu-Edusei 2011 (29): Yes; Kuznik 2013 (30): Yes; Kahn 2014 (31): Yes; Larson 2014 (22): Yes; Owusu-Edusei et al. (19): Yes; Albright et al. (32): Yes; Kuznik et al. (33): Yes; Terris-Prestholt et al. (21): Yes; Bristow et al. (17): Yes; Hersh et al. (34): Yes; Huntington et al. (35): Yes; Romero et al. (36): Yes; Rodriguez et al. (18): Yes
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),How are outcomes selected in these studies?,Vickerman et al. (25): Not specified; Blandford et al. (26): Specified; Schackman et al. (27): Specified; Rydzak and Goldie (28): Specified; Owusu-Edusei 2011 (29): Specified; Kuznik 2013 (30): Specified; Kahn 2014 (31): Specified; Larson 2014 (22): Not specified; Owusu-Edusei et al. (19): Specified; Albright et al. (32): Specified; Kuznik et al. (33): Not specified; Terris-Prestholt et al. (21): Not specified; Bristow et al. (17): Specified; Hersh et al. (34): Specified; Huntington et al. (35): Specified; Romero et al. (36): Specified; Rodriguez et al. (18): Specified
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),How are outcomes measured in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),How are outcomes valued in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),How are resources and costs measured and valued in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),"What currency, price date, and conversion methods are used in these studies?",Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What rationales and descriptions of models are provided in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): N; Larson 2014 (22): N; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): N; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What analytics and assumptions are made in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): N; Larson 2014 (22): N; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): N; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),How is heterogeneity characterized in these studies?,Vickerman et al. (25): Yes; Blandford et al. (26): Yes; Schackman et al. (27): Yes; Rydzak and Goldie (28): Yes; Owusu-Edusei 2011 (29): Yes; Kuznik 2013 (30): Yes; Kahn 2014 (31): No; Larson 2014 (22): No; Owusu-Edusei et al. (19): Yes; Albright et al. (32): Yes; Kuznik et al. (33): Yes; Terris-Prestholt et al. (21): Yes; Bristow et al. (17): Yes; Hersh et al. (34): Yes; Huntington et al. (35): Yes; Romero et al. (36): Yes; Rodriguez et al. (18): Yes
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),How are distributional effects characterized in these studies?,Vickerman et al. (25): Not characterized; Blandford et al. (26): Not characterized; Schackman et al. (27): Not characterized; Rydzak and Goldie (28): Not characterized; Owusu-Edusei 2011 (29): Not characterized; Kuznik 2013 (30): Characterized; Kahn 2014 (31): Characterized; Larson 2014 (22): Not characterized; Owusu-Edusei et al. (19): Not characterized; Albright et al. (32): Not characterized; Kuznik et al. (33): Characterized; Terris-Prestholt et al. (21): Characterized; Bristow et al. (17): Not characterized; Hersh et al. (34): Not characterized; Huntington et al. (35): Not characterized; Romero et al. (36): Not characterized; Rodriguez et al. (18): Characterized
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),How is uncertainty characterized in these studies?,Vickerman et al. (25): Uncertainty is not characterized.; Blandford et al. (26): Uncertainty is not characterized.; Schackman et al. (27): Uncertainty is characterized.; Rydzak and Goldie (28): Uncertainty is characterized.; Owusu-Edusei 2011 (29): Uncertainty is characterized.; Kuznik 2013 (30): Uncertainty is characterized.; Kahn 2014 (31): Uncertainty is characterized.; Larson 2014 (22): Uncertainty is characterized.; Owusu-Edusei et al. (19): Uncertainty is characterized.; Albright et al. (32): Uncertainty is characterized.; Kuznik et al. (33): Uncertainty is characterized.; Terris-Prestholt et al. (21): Uncertainty is characterized.; Bristow et al. (17): Uncertainty is characterized.; Hersh et al. (34): Uncertainty is characterized.; Huntington et al. (35): Uncertainty is characterized.; Romero et al. (36): Uncertainty is characterized.; Rodriguez et al. (18): Uncertainty is characterized.
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What approaches to engagement with patients and others are used in these studies?,Vickerman et al. (25): Not specified; Blandford et al. (26): Not specified; Schackman et al. (27): Not specified; Rydzak and Goldie (28): Not specified; Owusu-Edusei 2011 (29): Not specified; Kuznik 2013 (30): Not specified; Kahn 2014 (31): Not specified; Larson 2014 (22): Not specified; Owusu-Edusei et al. (19): Not specified; Albright et al. (32): Not specified; Kuznik et al. (33): Not specified; Terris-Prestholt et al. (21): Not specified; Bristow et al. (17): Not specified; Hersh et al. (34): Not specified; Huntington et al. (35): Not specified; Romero et al. (36): Not specified; Rodriguez et al. (18): Not specified
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What study parameters are defined in these studies?,Vickerman et al. (25): N; Blandford et al. (26): N; Schackman et al. (27): N; Rydzak and Goldie (28): N; Owusu-Edusei 2011 (29): N; Kuznik 2013 (30): N; Kahn 2014 (31): N; Larson 2014 (22): N; Owusu-Edusei et al. (19): N; Albright et al. (32): N; Kuznik et al. (33): N; Terris-Prestholt et al. (21): N; Bristow et al. (17): N; Hersh et al. (34): N; Huntington et al. (35): N; Romero et al. (36): N; Rodriguez et al. (18): N
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What summaries of the main results are provided in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What effects of uncertainty are discussed in these studies?,Schackman et al. (27): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What effects of engagement with patients and others are reported in these studies?,Vickerman et al. (25): Y; Blandford et al. (26): N; Schackman et al. (27): Y; Rydzak and Goldie (28): N; Owusu-Edusei 2011 (29): N; Kuznik 2013 (30): N; Kahn 2014 (31): N; Larson 2014 (22): N; Owusu-Edusei et al. (19): N; Albright et al. (32): N; Kuznik et al. (33): N; Terris-Prestholt et al. (21): N; Bristow et al. (17): N; Hersh et al. (34): N; Huntington et al. (35): N; Romero et al. (36): N; Rodriguez et al. (18): N
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),"What findings, limitations, generalisability, and current knowledge are discussed in these studies?",Vickerman et al. (25): Y; Blandford et al. (26): Y; Schackman et al. (27): Y; Rydzak and Goldie (28): Y; Owusu-Edusei 2011 (29): Y; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): Y; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What sources of funding are disclosed for these studies?,Vickerman et al. (25): N; Blandford et al. (26): N; Schackman et al. (27): Y; Rydzak and Goldie (28): N; Owusu-Edusei 2011 (29): N; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): Y; Albright et al. (32): Y; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): N; Bristow et al. (17): Y; Hersh et al. (34): Y; Huntington et al. (35): Y; Romero et al. (36): Y; Rodriguez et al. (18): Y
10993388_Table_2,Vickerman et al. (25): Vickerman et al. (25); Blandford et al. (26): Blandford et al. (26); Schackman et al. (27): Schackman et al. (27); Rydzak and Goldie (28): Rydzak and Goldie (28); Owusu-Edusei 2011 (29): Owusu-Edusei 2011 (29); Kuznik 2013 (30): Kuznik 2013 (30); Kahn 2014 (31): Kahn 2014 (31); Larson 2014 (22): Larson 2014 (22); Owusu-Edusei et al. (19): Owusu-Edusei et al. (19); Albright et al. (32): Albright et al. (32); Kuznik et al. (33): Kuznik et al. (33); Terris-Prestholt et al. (21): Terris-Prestholt et al. (21); Bristow et al. (17): Bristow et al. (17); Hersh et al. (34): Hersh et al. (34); Huntington et al. (35): Huntington et al. (35); Romero et al. (36): Romero et al. (36); Rodriguez et al. (18): Rodriguez et al. (18),What conflicts of interest are reported in these studies?,Vickerman et al. (25): N; Blandford et al. (26): N; Schackman et al. (27): Y; Rydzak and Goldie (28): N; Owusu-Edusei 2011 (29): N; Kuznik 2013 (30): Y; Kahn 2014 (31): Y; Larson 2014 (22): Y; Owusu-Edusei et al. (19): NA; Albright et al. (32): NA; Kuznik et al. (33): Y; Terris-Prestholt et al. (21): N; Bristow et al. (17): Y; Hersh et al. (34): NA; Huntington et al. (35): NA; Romero et al. (36): Y; Rodriguez et al. (18): Y
6386015_TableÂ 1,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland,Which countries are these studies conducted in?,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland
6386015_TableÂ 1,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland,What disease classification systems are used in these studies?,Erhardt et al. [63] Sweden: NYHA; Schadlich et al. [70] Germany: NYHA; Anderson et al. [53] South Africa: NYHA; Hart et al. [65] Spain: NYHA; Ademi et al. [51] Australia: NYHA; Ademi et al. [52] Australia: NYHA; Lee et al. [41] UK and Spain: NYHA; Thanh et al. [50] Canada: Unclear; CADTH [47] Canada: NYHA; SMC [35] Scotland: Unclear
6386015_TableÂ 1,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland,What types of heart failure are examined in these studies?,Erhardt et al. [63]: Unclear; Schadlich et al. [70]: Unclear; Anderson et al. [53]: Unclear; Hart et al. [65]: Unclear; Ademi et al. [51]: Chronic; Ademi et al. [52]: Chronic; Lee et al. [41]: Chronic; Thanh et al. [50]: Unclear; CADTH [47]: Chronic; SMC [35]: Unclear
6386015_TableÂ 1,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland,What model specifications are detailed in these studies?,"Erhardt et al. [63] Sweden: Core model/adaptation: Adaptation, Study type: Cost effectiveness, Model type: â€˜Real-worldâ€™ partition survival analysis, Perspective: Third-party payer, Time horizon: 3.8 years, Discount rate: 5% for both costs and health outcomes; Schadlich et al. [70] Germany: Core model/adaptation: Core model, Study type: Cost effectiveness, Model type: Partition survival model, Perspective: Payer, Time horizon: 3.8 years, Discount rate: 5% for costs; Anderson et al. [53] South Africa: Core model/adaptation: Adaptation, Study type: Cost utility, Model type: Partition survival model, Perspective: Third-party payer, Time horizon: 3.8 years, Discount rate: 0%, 5% and 10% for costs. 5% for health outcomes; Hart et al. [65] Spain: Core model/adaptation: Adaptation, Study type: Cost effectiveness, Model type: Area under the survival curve analysis of survival and rehospitalization probability, Perspective: Payer, Time horizon: 3.8 years, Discount rate: 6% for both costs and health outcomes; Ademi et al. [51] Australia: Core model/adaptation: Core model, Study type: Cost utility, Model type: Markov model with four transition states with 1-year cycle lengths, Perspective: Payer, Time horizon: 10 years, Discount rate: 5% for both costs and health outcomes; Ademi et al. [52] Australia: Core model/adaptation: Core model, Study type: Cost utility, Model type: Five-health-state Markov model with 1-year cycle lengths, Perspective: Payer, Time horizon: 10 years, Discount rate: 5% for both costs and health outcomes; Lee et al. [41] UK and Spain: Core model/adaptation: Core model, Study type: Cost utility, Model type: Discrete-event simulation model determining risk of hospitalization for HF, new-onset of AF, AEs, treatment discontinuation, and mortality, Perspective: Payers, Time horizon: Lifetime, Discount rate: 3.5% for health outcomes for the UK model and 3% for the Spanish model; Thanh et al. [50] Canada: Core model/adaptation: Adaptation, Study type: Cost utility, Model type: Discrete-event simulation model of hospitalizations, AEs, AF, device implantation, discontinuation, and death, Perspective: Healthcare, Time horizon: Lifetime, Discount rate: 3% for both costs and health outcomes; CADTH [47] Canada: Core model/adaptation: Core model, Study type: Cost utility, Model type: Discrete-event simulation model of hospitalization, AEs, discontinuation, and AF, resulting in either mortality or device implantation, Perspective: Ministry of Health (governmental), Time horizon: Lifetime, Discount rate: 5% for both costs and health outcomes"
6386015_TableÂ 1,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland,What modelling outcomes are assessed in these studies?,"Erhardt et al. [63]: LYG, costs, ICERs, WTP; Schadlich et al. [70]: LYG, costs, ICERs; Anderson et al. [53]: LYG, costs, ICERs; Hart et al. [65]: LYG, costs, ICERs; Ademi et al. [51]: QALYs, LYG, costs, ICERs, WTP; Ademi et al. [52]: QALYs, LYG, costs, ICERs, WTP; Lee et al. [41]: QALYs, LYG, costs, ICERs, WTP; Thanh et al. [50]: QALYs, LYG, costs, ICERs, WTP; CADTH [47]: QALYs, LYG, costs, ICERs"
6386015_TableÂ 1,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland,What types of scenario or sensitivity analyses are performed in these studies?,Erhardt et al.: OWSA; the key model drivers were varied to establish their effect on the outcome; Schadlich et al.: DSA; Anderson et al.: Analysis established best- and worst-case scenarios; Hart et al.: Establishes the effect of additional costs and non-hospital costs on the ICER for the intervention; Ademi et al. [51]: Univariate analysis; Ademi et al. [52]: Scenario analysis; Lee et al.: DSA and PSA; Thanh et al.: Scenario analysis and OWSA; CADTH: DSA and PSA
6386015_TableÂ 1,Erhardt et al. [63]: Sweden; Schadlich et al. [70]: Germany; Anderson et al. [53]: South Africa; Hart et al. [65]: Spain; Ademi et al. [51]: Australia; Ademi et al. [52]: Australia; Lee et al. [41]: UK and Spain; Thanh et al. [50]: Canada; CADTH [47]: Canada; SMC [35]: Scotland,What are the key model drivers identified in these studies?,"Erhardt et al.: Hospital costs, Number of rehospitalizations for HF; Schadlich et al.: Treatment duration, Number of rehospitalizations per patient, Inpatient treatment for decompensated HF; Anderson et al.: Treatment duration; Hart et al.: Treatment duration, Length of hospital stay; Ademi et al. [51]: Efficacy measures (predominantly those regarding CV mortality), Drug cost; Ademi et al. [52]: Number of hospitalizations; Lee et al.: Drug cost, Cost of disease management and monitoring, Number of hospitalizations; Thanh et al.: Drug cost, Scale parameters of Weibull distributions estimating time to event of device implantation, CV hospitalization for patients receiving intervention; CADTH: Not reported"
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What are the names or identifiers of these studies?,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38]
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What evidence sources are utilized in these studies?,Van Loon (2010) [37]: Prospective study; Rabalais (2012) [32]: Literature search; Auguste & Meads (2014) [34]: SLR; Greuter (2017) [35]: Prospective study; Smith & Mehanna (2017) [39]: RCT; Fu (2021) [36]: RCT; Greuter (2022) [33]: Population-based registry; Rosen (2022) [38]: Literature search
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What levels of evidence are reported in these studies?,Van Loon (2010) [37]: IPD; Rabalais (2012) [32]: Aggregated data; Auguste & Meads (2014) [34]: Aggregated data; Greuter (2017) [35]: IPD; Smith & Mehanna (2017) [39]: IPD; Fu (2021) [36]: IPD; Greuter (2022) [33]: IPD; Rosen (2022) [38]: Aggregated data
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What modelling techniques and levels are applied in these studies?,Van Loon (2010) [37]: STM (cohort); Rabalais (2012) [32]: DT; Auguste & Meads (2014) [34]: STM (cohort); Greuter (2017) [35]: DT; Smith & Mehanna (2017) [39]: STM (cohort); Fu (2021) [36]: STM (cohort); Greuter (2022) [33]: PSM; Rosen (2022) [38]: DT
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What cycle lengths are used in these studies?,Van Loon (2010) [37]: 6 months; Rabalais (2012) [32]: N/A; Auguste & Meads (2014) [34]: 3 months; Greuter (2017) [35]: N/A; Smith & Mehanna (2017) [39]: 1 month; Fu (2021) [36]: 3 months; Greuter (2022) [33]: 3 weeks; Rosen (2022) [38]: N/A
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What types of analysis regarding health outcomes are conducted in these studies?,Van Loon (2010): CUA (QALY); Rabalais (2012): CEA (therapy efficacy); Auguste & Meads (2014): CUA (QALY); Greuter (2017): CEA (TP); Smith & Mehanna (2017): CUA (QALY); Fu (2021): CUA (QALY); Greuter (2022): CUA (QALY); Rosen (2022): CEA (TP)
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],Which quality of life questionnaires are employed in these studies?,Van Loon (2010) [37]: Not reported; Rabalais (2012) [32]: Not reported; Auguste & Meads (2014) [34]: EuroQol 5D; Greuter (2017) [35]: Not reported; Smith & Mehanna (2017) [39]: EuroQol 5D; Fu (2021) [36]: Not reported; Greuter (2022) [33]: EORTC QLQ-C30; Rosen (2022) [38]: Not reported
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What discount rates are applied in these studies?,"Van Loon (2010): [1] Health 1.5%, [2] costs 4%; Rabalais (2012): Not reported; Auguste & Meads (2014): [1] Health 3.5%, [2] costs 3.5%; Greuter (2017): Not reported; Smith & Mehanna (2017): [1] Health 3.5%, [2] costs 3.5%; Fu (2021): [1] Health 1.5%, [2] costs 1.5%; Greuter (2022): [1] Health 1.5%, [2] costs 4%; Rosen (2022): Not reported"
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What willingness-to-pay thresholds are considered in these studies?,"Van Loon (2010): â‚¬80,000/QALY; Rabalais (2012): Not reported; Auguste & Meads (2014): Â£20,000â€“Â£30,000/QALY; Greuter (2017): Not reported; Smith & Mehanna (2017): Â£20,000/QALY; Fu (2021): CAD $50,000/QALY; Greuter (2022): â‚¬50,000/QALY; Rosen (2022): Not reported"
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What are the ICER values of the most cost-effective strategies in these studies?,"Van Loon (2010): â‚¬69,086 per QALY compared to conventional imaging; Rabalais (2012): $14,492 to achieve optimal therapy efficacy; Auguste & Meads (2014): over Â£1 million per QALY compared to conventional imaging; Greuter (2017): â‚¬927 per TP compared to using no imaging; Smith & Mehanna (2017): an average per-person lifetime cost saving of Â£1485 and an additional 0.13 QALYs; Fu (2021): CAD $8193 per QALY compared to conventional imaging; Greuter (2022): Therapy dropout is not cost effective for positive interim PET/CT (iNMB = âˆ’â‚¬5281) but is cost effective for negative interim PET/CT (iNMB = â‚¬5449); Rosen (2022): â‚¬4397 per TP compared to conventional imaging"
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],Do these studies include a probabilistic analysis?,Van Loon (2010): Yes; Rabalais (2012): No; Auguste & Meads (2014): Yes; Greuter (2017): No; Smith & Mehanna (2017): Yes; Fu (2021): Yes; Greuter (2022): Yes; Rosen (2022): Yes
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What outcomes and visualizations are presented in these studies?,"Van Loon (2010) [37]: [1] CEAC, [2] EVPI; Rabalais (2012) [32]: N/A; Auguste & Meads (2014) [34]: [1] CE plane, [2] CEAC, [3] EVPI; Greuter (2017) [35]: N/A; Smith & Mehanna (2017) [39]: [1] CE plane, [2] CEAC; Fu (2021) [36]: [1] CE plane, [2] CEAC; Greuter (2022) [33]: [1] CE plane, [2] CEAC; Rosen (2022) [38]: [1] CE plane"
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],Is PET/CT considered cost-effective in these studies?,Van Loon (2010): Yes; Rabalais (2012): Yes; Auguste & Meads (2014): No; Greuter (2017): Yes; Smith & Mehanna (2017): Yes; Fu (2021): Yes; Greuter (2022): Depending on subgroup; Rosen (2022): Yes
11782410_Table_3,Van Loon: Van Loon (2010) [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014) [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What software is used in these studies?,Van Loon (2010) [37]: Not reported; Rabalais (2012) [32]: Not reported; Auguste & Meads (2014) [34]: TreeAge Pro 2011; Greuter (2017) [35]: Not reported; Smith & Mehanna (2017) [39]: SAS 9.3; Fu (2021) [36]: TreeAge Pro 2018; Greuter (2022) [33]: Not reported; Rosen (2022) [38]: R (version not reported)
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2014,Who are the first authors and what are the publication years of these studies?,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2014
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2015,Which countries are covered in these studies?,Franco et al (2006) [40]: Netherlands; Gaziano et al (2006) [6]: Low and middle income countries; Lim et al (2007) [38]: low and middle income (23 countries); Newman et al (2008) [41]: USA; Rubinstein et al (2009) [25]: Argentina; Rubinstein et al (2010) [39]: Argentina; van Gils et al (2011) [42]: Netherlands; Khonputsa et al (2012) [43]: Thailand; Ito et al (2012) [44]: USA; Bautista et al (2013) [30]: Latin America; Zomer et al (2013) [45]: Australia; Ong et al (2013) [46]: Australia; Megiddo et al (2014) [47]: India
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2016,What study designs are employed in these studies?,Franco et al (2006): CEA; Gaziano et al (2006): CEA; Lim et al (2007): Non; Newman et al (2008): CEA; Rubinstein et al (2009): CEA; Rubinstein et al (2010): CEA; van Gils et al (2011): CEA; Khonputsa et al (2012): CEA; Ito et al (2012): CEA; Bautista et al (2013): CEA; Zomer et al (2013): CEA; Ong et al (2013): CEA; Megiddo et al (2014): CEA
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2017,What types of prevention are analyzed in these studies?,Franco et al (2006) [40]: primary; Gaziano et al (2006) [6]: Primary & Secondary; Lim et al (2007) [38]: Primary & Secondary; Newman et al (2008) [41]: primary; Rubinstein et al (2009) [25]: primary; Rubinstein et al (2010) [39]: primary; van Gils et al (2011) [42]: primary; Khonputsa et al (2012) [43]: primary; Ito et al (2012) [44]: Secondary; Bautista et al (2013) [30]: Primary; Zomer et al (2013) [45]: Primary; Ong et al (2013) [46]: primary; Megiddo et al (2014) [47]: Secondary
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2018,What perspectives are used in these studies?,Franco et al (2006): Payer; Gaziano et al (2006): Health care; Lim et al (2007): Health care; Newman et al (2008): healthcare; Rubinstein et al (2009): Payer; Rubinstein et al (2010): healthcare; van Gils et al (2011): payer; Khonputsa et al (2012): healthcare; Ito et al (2012): societal; Bautista et al (2013): Healthcare; Zomer et al (2013): Health care; Ong et al (2013): Health care; Megiddo et al (2014): Healthcare
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2019,What model types are utilized in these studies?,Franco et al (2006) [40]: Markov; Gaziano et al (2006) [6]: Markov; Lim et al (2007) [38]: A microsimulation model; Newman et al (2008) [41]: Markov; Rubinstein et al (2009) [25]: WHO-CHOICE; Rubinstein et al (2010) [39]: NR; van Gils et al (2011) [42]: Markov; Khonputsa et al (2012) [43]: Markov; Ito et al (2012) [44]: Markov; Bautista et al (2013) [30]: Markov; Zomer et al (2013) [45]: Markov; Ong et al (2013) [46]: Markov; Megiddo et al (2014) [47]: WHO-CHOICE
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2020,What time horizons are considered in these studies?,Franco et al (2006) [40]: 10-years; Gaziano et al (2006) [6]: life time; Lim et al (2007) [38]: 10-years; Newman et al (2008) [41]: 10 years; Rubinstein et al (2009) [25]: 10 years; Rubinstein et al (2010) [39]: 5-years; van Gils et al (2011) [42]: lifetime; Khonputsa et al (2012) [43]: lifetime; Ito et al (2012) [44]: lifetime; Bautista et al (2013) [30]: lifetime; Zomer et al (2013) [45]: 10-years; Ong et al (2013) [46]: lifetime; Megiddo et al (2014) [47]: life time
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2021,What interventions are evaluated in these studies?,"Franco et al (2006): Polypill (a statin, three blood pressure lowering, folic acid, aspirin); Gaziano et al (2006): Polypill (81 mg aspirin, 40 mg lovastatin, 10 mg lisinopril, and 5 mg amlodipine); Lim et al (2007): SP: (aspirin, an angiotensin-converting-enzyme inhibitor, a Î² blocker, and a statin), PP: (aspirin, an angiotensin-converting-enzyme inhibitor, thiazide and a statin); Newman et al (2008): Polypill (simvastatin 40 mg, captopril 12.5 mg, hydrochlorothiazide 12.5 mg, and atenolol 25 mg); Rubinstein et al (2009): Polypill (thiazides 25 mg, enalapril 10 mg, atorvastatin 10 mg and aspirin 100 mg); Rubinstein et al (2010): Polypill (hydrochlorothiazide 25 mg, enalapril 10 mg, atorvastatin 10 mg and aspirin 100 mg); van Gils et al (2011): Polypill (simvastatin 20 mg, thiazide 12.5 mg, ramipril 5 mg, atenolol 50 mg, aspirin 100 mg); Khonputsa et al (2012): Polypill (three BP-lowering drugs and a statin); Ito et al (2012): Polypill (aspirin, a b-blocker, an ACEI or ARB, statin); Bautista et al (2013): Polypill (thiazide, 12.5 mg; atenolol, 50 mg; ramipril, 5 mg, simvastatin, 20 mg, aspirin 100 mg); Zomer et al (2013): Polypill (three blood-pressure lowering, simvastatin, aspirin); Ong et al (2013): Polypill (a statin, a diuretic, a beta blocker, a calcium channel blocker); Megiddo et al (2014): Polypill (Aspirin, atorvastatin, ramipril, atenolol)"
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2022,What comparators are used in these studies?,"Franco et al (2006): Aspirin; Gaziano et al (2006): no treatment; Lim et al (2007): no treatment; Newman et al (2008): current standard of care; Rubinstein et al (2009): 1- lowering salt intake 2- education through mass-media; Rubinstein et al (2010): no treatment; van Gils et al (2011): Usual care; Khonputsa et al (2012): do-nothing; Ito et al (2012): usual care, mailed education; Bautista et al (2013): do nothing; Zomer et al (2013): null scenario; Ong et al (2013): null scenario; Megiddo et al (2014): aspirin (75 mg once daily)"
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2023,What effectiveness units are reported in these studies?,"Franco et al (2006): YLs; Gaziano et al (2006): QALY; Lim et al (2007): Number of deaths averted; Newman et al (2008): QALY; Rubinstein et al (2009): DALY; Rubinstein et al (2010): DALY; van Gils et al (2011): QALY, YLs; Khonputsa et al (2012): DALY; Ito et al (2012): QALY; Bautista et al (2013): QALY; Zomer et al (2013): YLs, QALY; Ong et al (2013): DALY; Megiddo et al (2014): DALY"
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2024,What are the original ICERs reported in these studies?,"Franco et al (2006): Non; Gaziano et al (2006): 1- US$746â€“890/QALY (risk of CVD> 25%)2-US$1039â€“1221/QALY (risk of CVD>5%); Lim et al (2007): US$ 2,625 per Death averted; Newman et al (2008): Dominant; Rubinstein et al (2009): $3,599(20% CVD risk),$4,113 (10% CVD risk)$4,533(5% CVD risk), per DALY averted; Rubinstein et al (2010): Cost-saving; van Gils et al (2011): â‚¬7200â€“10200 per LYâ‚¬8500â€“12300 per QALY; Khonputsa et al (2012): Dominant; Ito et al (2012): Polypill:$133,000polypill plus mailed education:$113,000polypill plus disease management $142,900 per QALY; Bautista et al (2013): $158â€“804 perQALY in women365â€“933 per QALY in men base on CVD risk; Zomer et al (2013): $301,583 per YLs$214,865per QALY; Ong et al (2013): Dominant; Megiddo et al (2014): $1,690per DALY averted"
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2025,Do these studies include sensitivity analyses?,Franco et al (2006): DSA PSA; Gaziano et al (2006): DSA PSA; Lim et al (2007): PSA; Newman et al (2008): DSA; Rubinstein et al (2009): DSA; Rubinstein et al (2010): PSA Monte Carlo simulation; van Gils et al (2011): PSA; Khonputsa et al (2012): PSA; Ito et al (2012): DSA; Bautista et al (2013): DSA; Zomer et al (2013): PSA Monte Carlo simulation; Ong et al (2013): Monte Carlo simulation DSA; Megiddo et al (2014): Latin
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2026,What discount rates are applied in these studies?,"Franco et al (2006): 4%; Gaziano et al (2006): 3%; Lim et al (2007): NR; Newman et al (2008): 3; Rubinstein et al (2009): 3%; Rubinstein et al (2010): 3%; van Gils et al (2011): 0%, 1.5%, 3%, 4%, 5%; Khonputsa et al (2012): 3%; Ito et al (2012): 3%; Bautista et al (2013): 3%; Zomer et al (2013): 5%; Ong et al (2013): NR; Megiddo et al (2014): Latin"
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2027,What thresholds are used in these studies?,"Franco et al (2006): 30,000; Gaziano et al (2006): 3-GNI per capita; Lim et al (2007): NR; Newman et al (2008): $50,000/life-year threshold; Rubinstein et al (2009): 3-GNP per capita; Rubinstein et al (2010): GDP pre capita(US$ 6,644); van Gils et al (2011): â‚¬20,000Per LY or QALY; Khonputsa et al (2012): 1â€“3 time GDP per-capita; Ito et al (2012): $100,000 perQALY gained; Bautista et al (2013): GDP per Capita; Zomer et al (2013): $50,000 per QALY or YLs; Ong et al (2013): $50,000 perDALY; Megiddo et al (2014): Latin"
9333258_Table_1,Franco et al: 2006; Gaziano et al: 2006; Lim et al: 2007; Newman et al: 2008; Rubinstein et al: 2009; Rubinstein et al: 2010; van Gils et al: 2011; Khonputsa et al: 2012; Ito et al: 2012; Bautista et al: 2013; Zomer et al: 2013; Ong et al: 2013; Megiddo et al: 2028,What are the adjusted ICERs in 2020 US dollars for these studies?,"Franco et al (2006): Non; Gaziano et al (2006): 1â€“746â€“890 per QALY2â€“1,360â€“1,599 per QALY; Lim et al (2007): 3,329 per Death averted; Newman et al (2008): Dominant; Rubinstein et al (2009): 4,274 (20% CVD risk)4,884 (10% CVD risk)5383(5% CVD risk) per DALY averted; Rubinstein et al (2010): Cost-saving; van Gils et al (2011): 11,279â€“15,979 per LY13,317â€“19,269 per QALY; Khonputsa et al (2012): Dominant; Ito et al (2012): Polypill: 151,160polypill plus mailed education:128,429polypill plus disease managemen 162,412 per QALY; Bautista et al (2013): 176â€“895 perQALY in women365â€“933 per QALY in men; Zomer et al (2013): 252,320 per YLs179,767per QALY; Ong et al (2013): Dominant; Megiddo et al (2014): Latin"
7340703_Table_1,Author A: Althausen et al.; Author B: Pearson et al.; Author C: Shields et al.; Author D: Liu et al.; Author E: Nicholson et al.; Author F: SÃ¸rensen et al.; Author G: Herteleer et al.,Who are the authors of these studies?,Author A: Althausen et al.; Author B: Pearson et al.; Author C: Shields et al.; Author D: Liu et al.; Author E: Nicholson et al.; Author F: SÃ¸rensen et al.; Author G: Herteleer et al.
7340703_Table_1,Author A: Althausen et al.; Author B: Pearson et al.; Author C: Shields et al.; Author D: Liu et al.; Author E: Nicholson et al.; Author F: SÃ¸rensen et al.; Author G: Herteleer et al.,In which years were these studies published?,Althausen et al.: 2013; Pearson et al.: 2010; Shields et al.: 2016; Liu et al.: 2019; Nicholson et al.: 2019; SÃ¸rensen et al.: 2019; Herteleer et al.: 2020
7340703_Table_1,Author A: Althausen et al.; Author B: Pearson et al.; Author C: Shields et al.; Author D: Liu et al.; Author E: Nicholson et al.; Author F: SÃ¸rensen et al.; Author G: Herteleer et al.,Which countries are represented in these studies?,Althausen et al.: USA; Pearson et al.: Canada; Shields et al.: USA; Liu et al.: USA; Nicholson et al.: UK; SÃ¸rensen et al.: Denmark; Herteleer et al.: Belgium
7340703_Table_1,Author A: Althausen et al.; Author B: Pearson et al.; Author C: Shields et al.; Author D: Liu et al.; Author E: Nicholson et al.; Author F: SÃ¸rensen et al.; Author G: Herteleer et al.,What types of studies are conducted in these articles?,Althausen et al.: Retrospective case-control design; Pearson et al.: Formal cost-effectiveness analysis based on a prospective data; Shields et al.: Retrospective database study; Liu et al.: Formal cost-effectiveness analysis based on a prospective and retrospective data; Nicholson et al.: Formal cost-analysis based on RCT study; SÃ¸rensen et al.: Decision analytical modeling based on RCT study; Herteleer et al.: Retrospective study
7340703_Table_1,Author A: Althausen et al.; Author B: Pearson et al.; Author C: Shields et al.; Author D: Liu et al.; Author E: Nicholson et al.; Author F: SÃ¸rensen et al.; Author G: Herteleer et al.,What QHES scores do these studies receive?,Althausen et al.: 45; Pearson et al.: 96; Shields et al.: 57; Liu et al.: 100; Nicholson et al.: 73; SÃ¸rensen et al.: 75; Herteleer et al.: 62
7340703_Table_1,Author A: Althausen et al.; Author B: Pearson et al.; Author C: Shields et al.; Author D: Liu et al.; Author E: Nicholson et al.; Author F: SÃ¸rensen et al.; Author G: Herteleer et al.,What levels of evidence are assigned to these studies?,Althausen et al.: 3; Pearson et al.: 1; Shields et al.: 2; Liu et al.: 2; Nicholson et al.: ; SÃ¸rensen et al.: 1; Herteleer et al.: 3
10993388_Table_4,Vickerman et al.: ; Blandfod 2007; Owusu-Edusei et al.; Kahn et al.; Larson et al.; Owusu-Edusei et al.: ; Albright et al.: ; Kuznik et al.,What perspectives are used in these studies?,Vickerman et al.: Not reported; Blandfod 2007: The perspective of the Eastern Cape Provincial Department of Health; Schackman et al.: Societal perspective; Rydzak and Goldie: Not reported; Owusu-Edusei et al.: Not reported; Kuznik et al.: National health care system; Kahn et al.: Societal perspective; Larson et al.: Providerâ€™s perspective; Owusu-Edusei et al.: Chinese national health departmentsâ€™ perspective; Albright et al.: Health care perspective; Kuznik et al.: The perspectives of the national healthcare payer
10993388_Table_4,Vickerman et al.: ; Blandfod 2007; Owusu-Edusei et al.; Kahn et al.; Larson et al.; Owusu-Edusei et al.: ; Albright et al.: ; Kuznik et al.,What time horizons are considered in these studies?,Vickerman et al.: Not reported; Blandfod 2007: The period of gestation; Schackman et al.: A normal life expectancy; Rydzak and Goldie: Lifetime; Owusu-Edusei et al.: Lifetime; Kuznik et al.: Not reported; Kahn et al.: 4 years; Larson et al.: Life expectancy; Owusu-Edusei et al.: The life expectancy; Albright et al.: Lifetime; Kuznik et al.: Not reported
10993388_Table_4,Vickerman et al.: ; Blandfod 2007; Owusu-Edusei et al.; Kahn et al.; Larson et al.; Owusu-Edusei et al.: ; Albright et al.: ; Kuznik et al.,What currencies and reference years are used in these studies?,Vickerman et al.: 2005 US $; Blandfod 2007: 2002 US $; Schackman et al.: 2004 US $; Rydzak and Goldie: 2004 US $; Owusu-Edusei et al.: 2008 US $; Kuznik et al.: 2011 US $; Kahn et al.: 2010 US $; Larson et al.: 2012 US $; Owusu-Edusei et al.: 2010 US $; Albright et al.: 2014 US $; Kuznik et al.: 2012 US $
10993388_Table_4,Vickerman et al.: ; Blandfod 2007; Owusu-Edusei et al.; Kahn et al.; Larson et al.; Owusu-Edusei et al.: ; Albright et al.: ; Kuznik et al.,What discount rates are applied in these studies?,Vickerman et al.: Not reported; Blandfod 2007: Not applicable; Schackman et al.: 3%; Rydzak and Goldie: Not reported; Owusu-Edusei et al.: 3%; Kuznik et al.: 3%; Kahn et al.: 3%; Larson et al.: 3%; Owusu-Edusei et al.: 3%; Albright et al.: 5%; Kuznik et al.: 3%
10993388_Table_4,Vickerman et al.: ; Blandfod 2007; Owusu-Edusei et al.; Kahn et al.; Larson et al.; Owusu-Edusei et al.: ; Albright et al.: ; Kuznik et al.,What costs are included in these studies?,"Vickerman et al.: Cost for RPR intervention (including start-up, shaker, centrifuge, fridge, training, total drug, RPR test, other supplies, laboratory staff, medical and other staff, and transport for requisitions); cost for POC test intervention (included POC test and penicillin).; Blandfod 2007: Total test costs (supplies, labor), supply costs, labor costs, and treatment costs.; Schackman et al.: Labor cost, rapid test cost, RPR test cost, syphilis treatment cost, postnatal care cost, and indirect cost.; Rydzak and Goldie: Direct medical costs (including labor, counseling, laboratory equipment, and testing); treatment supplies (including penicillin, swabs, and syringes, and hospitalization for treatment of adverse pregnancy outcomes); and non-medical.; Owusu-Edusei et al.: Post-test counseling cost, patient cost (including travel, testing time, and treatment time), test cost, treatment cost, and pregnancy outcome cost.; Kuznik et al.: ICS test cost, the cost of the nursing time required to administer the test, drug cost, drug delivery equipment cost, and the cost of the nursing time to administer the therapy.; Kahn et al.: Test cost (the syphilis test kit, labor, and supplies), costs of treatment, and the cost of each mother-to-child transmission of syphilis adverse birth outcomes.; Larson et al.: Test costs, treatment costs, and health workers' training costs.; Owusu-Edusei et al.: Test costs, treatment costs, and treatment of adverse pregnancy outcomes costs.; Albright et al.: The cost of testing, maternal follow-up and treatment, penicillin desensitization, maternal delivery, and neonatal care.; Kuznik et al.: Costs included were the ICS test, three injections of benzathine"
10993388_Table_4,Vickerman et al.: ; Blandfod 2007; Owusu-Edusei et al.; Kahn et al.; Larson et al.; Owusu-Edusei et al.: ; Albright et al.: ; Kuznik et al.,What results are reported in these studies?,"Vickerman et al.: In addition to the definitive test, all POC tests saved more DALY than the RPR test on average and averted adverse birth outcomes. Except for Bioline, all POC tests were less cost-effective than RPR tests.; Blandfod 2007: On-site ICS averted most CS cases, with an incremental cost-effectiveness ratio of $114 per case compared to off-site RPR/TPHA.; Schackman et al.: The CER of rapid testing with immediate treatment was $6.83/DALY and $9.95/DALY in rural settings and urban settings, respectively.; Rydzak and Goldie: Single ICS screening could save $170,030 per 1,000 women in their lifetime compared to no screening.; Owusu-Edusei et al.: The ICS strategy was the most cost-saving, with a total cost of $76,000 and two adverse pregnancy outcomes per 1,000 pregnancies, which was followed by the Dual-POC strategy with a total cost of $79,000 and 5 adverse pregnancy outcomes.; Kuznik et al.: The average cost/DALY averted of syphilis screening was $11 in all 43 sub-Saharan African countries.; Kahn et al.: Scaled-up screening and treatment strategy were highly cost-effective, with an ICE of $24 â€“111 per DALY averted in different scenarios.; Larson et al.: The cost per DALY saved from screening and treatment strategy was $628. If all positives were treated, the cost per DALY saved falls to $66.; Owusu-Edusei et al.: The costs per DALY saved from syphilis-only, HIV-and-syphilis, and HIV-only were $168, $359, and $5636, respectively. The ICER of the HIV and syphilis strategy was $140 per additional DALY avoided compared with the HIV-only strategy.; Albright et al.: The incremental cost of universal third-trimester repeat screening was $419,842 per CS prevented."
11332733_Table_2,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010,Who are the authors and in which years were these studies published?,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010
11332733_Table_2,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010,What study designs are employed in these studies?,Cartelle A.L.: Retrospective single-center observational analysis; Fang K.: Retrospective single-center observational analysis; Gupta A.: Cross-sectional descriptive analysis; Latenstein A.E.J.: Multicenter observational analysis; Pranger B.K.: Retrospective multicenter observational analysis; Bartholdy A.: Retrospective single-center observational analysis; Dieguez-Castillo C.: Cross-sectional single-center observational analysis; Eidt-Koch D.: Multicenter cross-sectional observational analysis
11332733_Table_2,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010,What comorbidities are considered in these studies?,Cartelle A.L.: Chronic pancreatitis (disabled versus non-disabled); Fang K.: Pancreatectomy for pancreatic tumors; Gupta A.: NR; Latenstein A.E.J.: Patients with a history of pancreas surgery; Pranger B.K.: Patients following pancreatic resection; Bartholdy A.: Walled-off necrosis; Dieguez-Castillo C.: Chronic pancreatitis; Eidt-Koch D.: Cystic fibrosis
11332733_Table_2,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010,What are the sample sizes used in these studies?,Cartelle A.L. 2022: 404; Fang K. 2022: 101; Gupta A. 2022: NR â€“ results are specific to EPI; Latenstein A.E.J. 2021: 153; Pranger B.K. 2021: 230; Bartholdy A. 2020: 125; Dieguez-Castillo C. 2020: 30; Eidt-Koch D. 2010: 301
11332733_Table_2,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010,What population demographics are described in these studies?,"Cartelle A.L.: NR; Fang K.: Median (range) age at baseline: 45.3 years (10.0â€“75.0), Gender: Female 74 (73.3%), Male 27 (26.7%); Gupta A.: NR â€“ No patients were included; the study is analyzing costs of EPI treatments; Latenstein A.E.J.: Median (IQR) age at operation: 63.0 years (54.0â€“70.0), Gender: Female 66 (43.0%), Male 87 (57.0%); Pranger B.K.: Median (IQR) age at operation: 32.0 years (25.0â€“37.0), Gender: Female 143 (62.2%), Male 87 (37.8%); Bartholdy A.: Median (range) age at baseline: 57.0 years (21.0â€“80.0), Gender: Female 57 (45.6%), Male 68 (54.4%); Dieguez-Castillo C.: Mean age at baseline: 55.8 years, Gender: Female 2 (6.7%), Male 28 (93.3%); Eidt-Koch D.: Mean age: 19.9 years, Gender: NR"
11332733_Table_2,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010,What key findings are reported in these studies?,"Cartelle A.L.: Disabled patients also had higher rates of ED visits for opioid pain medication (16.7% vs 4.2%) and higher average number of flares requiring hospitalizations (4.1 vs 1.9).; Fang K.: Mean length of hospital stay was 11.6 days (Â±8.1). Re-operation rate was 1.0%.; Gupta A.: For a 15-day supply of PERTs, average retail prices ranged from $1288 USD to $1860 USD. For cash paying patients with coupons, the lowest price for these drugs ranged from $1072 USD to $1514 USD.; Latenstein A.E.J.: Median (IQR) length of hospital stay: 11 days[7â€“21]; Pranger B.K.: Median (IQR) procedure time: 300 minutes (250â€“430).; Bartholdy A.: Readmission rate: 45 (36%) patients had one or more WON-related readmissions, and 50 (40%) patients had one or more non-WON-related readmissions.; Dieguez-Castillo C.: Number of patients requiring PERTs: 21 (70%). Number of patients requiring surgical treatment: 10 (20%).; Eidt-Koch D.: Treatment costs were higher in patients with EPI compared to those without EPI: 23,305 EUR (EPI patients) versus 16,284 EUR (non-EPI patients)."
11332733_Table_2,Cartelle A.L.: 2022; Fang K.: 2022; Gupta A.: 2022; Latenstein A.E.J.: 2021; Pranger B.K.: 2021; Bartholdy A.: 2020; Dieguez-Castillo C.: 2020; Eidt-Koch D.: 2010,What are the values of 'n' in these studies?,Cartelle A.L.: 404; Fang K.: 101; Gupta A.: NR; Latenstein A.E.J.: 153; Pranger B.K.: 230; Bartholdy A.: 125; Dieguez-Castillo C.: 30; Eidt-Koch D.: 301
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 53,What are the identifiers for these studies?,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 53
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 54,What are the titles of these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: #; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 55,What are the abstracts of these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 56,What do the introductions of these studies cover?,Gaziano et al (2006) [6]: The introduction provides background information and the rationale for the study.; Franco et al (2006) [40]: The introduction provides background information and the rationale for the study.; Lim et al (2007) [38]: The introduction provides background information and the rationale for the study.; Newman et al (2008) [41]: The introduction provides background information and the rationale for the study.; Rubinstein et al (2009) [25]: The introduction provides background information and the rationale for the study.; Rubinstein et al (2010) [39]: The introduction provides background information and the rationale for the study.; van Gils et al (2011) [42]: The introduction provides background information and the rationale for the study.; Khonputsa et al (2012) [43]: The introduction provides background information and the rationale for the study.; Ito et al (2012) [44]: The introduction provides background information and the rationale for the study.; Bautista (2013) [30]: The introduction provides background information and the rationale for the study.; Zomer et al (2013) [45]: The introduction provides background information and the rationale for the study.; Ong et al (2013) [46]: The introduction provides background information and the rationale for the study.; Megiddo et al (2014) [47]: The introduction provides background information and the rationale for the study.; Arrabal et al (2015) [48]: The introduction provides background information and the rationale for the study.; Becerra et al (2015) [28]: The introduction provides background information and the rationale for the study.; Wald et al (2016) [26]: The introduction provides background information and the rationale for the study.; Barrios et al (2017) [27]: The introduction provides background information and the rationale for the study.; Jowett et al (2017) [49]: The introduction provides background information and the rationale for the study.; Barth et al (2017) [50]: The introduction provides background information and the rationale for the study.; Ferket et al (2017) [24]: The introduction provides background information and the rationale for the study.; Singh et al (2018) [29]: The introduction provides background information and the rationale for the study.; Lin et al (2019) [51]: The introduction provides background information and the rationale for the study.; Gaziano et al (2019) [52]: The introduction provides background information and the rationale for the study.; Ntaios et al (2019) [53]: The introduction provides background information and the rationale for the study.
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 57,What are the population characteristics in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: #; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 58,What are the settings and locations of these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 59,What perspectives are used in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 60,What comparators are described in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 61,What time horizons are used in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: Ã—; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: Ã—; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: NA; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: NA; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 62,What discount rates are applied in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: #; Lim et al (2007) [38]: Ã—; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 63,What outcomes and relevance are reported in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 64,How is effectiveness measured in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 65,What preference-based outcomes are reported in these studies?,Gaziano et al (2006) [6]: NA; Franco et al (2006) [40]: NA; Lim et al (2007) [38]: NA; Newman et al (2008) [41]: NA; Rubinstein et al (2009) [25]: Ã—; Rubinstein et al (2010) [39]: NA; van Gils et al (2011) [42]: NA; Khonputsa et al (2012) [43]: NA; Ito et al (2012) [44]: NA; Bautista (2013) [30]: NA; Zomer et al (2013) [45]: NA; Ong et al (2013) [46]: NA; Megiddo et al (2014) [47]: NA; Arrabal et al (2015) [48]: NA; Becerra et al (2015) [28]: NA; Wald et al (2016) [26]: NA; Barrios et al (2017) [27]: NA; Jowett et al (2017) [49]: NA; Barth et al (2017) [50]: NA; Ferket et al (2017) [24]: NA; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: NA; Ntaios et al (2019) [53]: NA
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 66,What costs are analyzed in these studies?,Gaziano et al (2006) [6]: Costs are analyzed.; Franco et al (2006) [40]: Costs are not analyzed.; Lim et al (2007) [38]: Costs are analyzed.; Newman et al (2008) [41]: Costs are analyzed.; Rubinstein et al (2009) [25]: Costs are analyzed.; Rubinstein et al (2010) [39]: Costs are analyzed.; van Gils et al (2011) [42]: Costs are analyzed.; Khonputsa et al (2012) [43]: Costs are analyzed.; Ito et al (2012) [44]: Costs are analyzed.; Bautista (2013) [30]: Costs are analyzed.; Zomer et al (2013) [45]: Costs are analyzed.; Ong et al (2013) [46]: Costs are analyzed.; Megiddo et al (2014) [47]: Costs are analyzed.; Arrabal et al (2015) [48]: Costs are analyzed.; Becerra et al (2015) [28]: Costs are analyzed.; Wald et al (2016) [26]: Costs are analyzed.; Barrios et al (2017) [27]: Costs are analyzed.; Jowett et al (2017) [49]: Costs are analyzed.; Barth et al (2017) [50]: Costs are analyzed.; Ferket et al (2017) [24]: Costs are analyzed.; Singh et al (2018) [29]: Costs are analyzed.; Lin et al (2019) [51]: Costs are analyzed.; Gaziano et al (2019) [52]: Costs are analyzed.; Ntaios et al (2019) [53]: Costs are analyzed.
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 67,"What currency, date, and conversion details are provided in these studies?",Gaziano et al (2006) [6]: Not provided; Franco et al (2006) [40]: Not provided; Lim et al (2007) [38]: Not provided; Newman et al (2008) [41]: Not provided; Rubinstein et al (2009) [25]: Not provided; Rubinstein et al (2010) [39]: Provided; van Gils et al (2011) [42]: Not provided; Khonputsa et al (2012) [43]: Not provided; Ito et al (2012) [44]: Not provided; Bautista (2013) [30]: Not provided; Zomer et al (2013) [45]: Not provided; Ong et al (2013) [46]: Not provided; Megiddo et al (2014) [47]: Not provided; Arrabal et al (2015) [48]: Not provided; Becerra et al (2015) [28]: Not provided; Wald et al (2016) [26]: Not provided; Barrios et al (2017) [27]: Not provided; Jowett et al (2017) [49]: Not provided; Barth et al (2017) [50]: Provided; Ferket et al (2017) [24]: Not provided; Singh et al (2018) [29]: Not applicable; Lin et al (2019) [51]: Not provided; Gaziano et al (2019) [52]: Not provided; Ntaios et al (2019) [53]: Not provided
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 68,How is the model choice described in these studies?,Gaziano et al (2006) [6]: Described; Franco et al (2006) [40]: Not described; Lim et al (2007) [38]: Not described; Newman et al (2008) [41]: Described; Rubinstein et al (2009) [25]: Described; Rubinstein et al (2010) [39]: Described; van Gils et al (2011) [42]: Described; Khonputsa et al (2012) [43]: Described; Ito et al (2012) [44]: Described; Bautista (2013) [30]: Described; Zomer et al (2013) [45]: Described; Ong et al (2013) [46]: Described; Megiddo et al (2014) [47]: Described; Arrabal et al (2015) [48]: Described; Becerra et al (2015) [28]: Described; Wald et al (2016) [26]: Not described; Barrios et al (2017) [27]: Described; Jowett et al (2017) [49]: Described; Barth et al (2017) [50]: Described; Ferket et al (2017) [24]: Described; Singh et al (2018) [29]: Not described; Lin et al (2019) [51]: Described; Gaziano et al (2019) [52]: Described; Ntaios et al (2019) [53]: Described
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 69,What model assumptions are made in these studies?,Gaziano et al (2006) [6]: Model assumptions are described.; Franco et al (2006) [40]: Model assumptions are not described.; Lim et al (2007) [38]: Model assumptions are not described.; Newman et al (2008) [41]: Model assumptions are described.; Rubinstein et al (2009) [25]: Model assumptions are described.; Rubinstein et al (2010) [39]: Model assumptions are described.; van Gils et al (2011) [42]: Model assumptions are described.; Khonputsa et al (2012) [43]: Model assumptions are described.; Ito et al (2012) [44]: Model assumptions are described.; Bautista (2013) [30]: Model assumptions are described.; Zomer et al (2013) [45]: Model assumptions are described.; Ong et al (2013) [46]: Model assumptions are described.; Megiddo et al (2014) [47]: Model assumptions are described.; Arrabal et al (2015) [48]: Model assumptions are described.; Becerra et al (2015) [28]: Model assumptions are described.; Wald et al (2016) [26]: Model assumptions are not described.; Barrios et al (2017) [27]: Model assumptions are described.; Jowett et al (2017) [49]: Model assumptions are described.; Barth et al (2017) [50]: Model assumptions are described.; Ferket et al (2017) [24]: Model assumptions are described.; Singh et al (2018) [29]: Model assumptions are not described.; Lin et al (2019) [51]: Model assumptions are described.; Gaziano et al (2019) [52]: Model assumptions are described.; Ntaios et al (2019) [53]: Model assumptions are described.
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 70,What analysis methods are used in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: #; Lim et al (2007) [38]: Ã—; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: NA; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 71,What parameters of values are considered in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: #; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 72,What incremental costs are reported in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: Ã—; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: #; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 73,What sensitivity analyses are conducted in these studies?,Gaziano et al (2006) [6]: Conducted sensitivity analyses.; Franco et al (2006) [40]: Conducted sensitivity analyses.; Lim et al (2007) [38]: Did not conduct sensitivity analyses.; Newman et al (2008) [41]: Conducted sensitivity analyses.; Rubinstein et al (2009) [25]: Conducted sensitivity analyses.; Rubinstein et al (2010) [39]: Conducted sensitivity analyses.; van Gils et al (2011) [42]: Conducted sensitivity analyses.; Khonputsa et al (2012) [43]: Conducted sensitivity analyses.; Ito et al (2012) [44]: Conducted sensitivity analyses.; Bautista (2013) [30]: Conducted sensitivity analyses.; Zomer et al (2013) [45]: Conducted sensitivity analyses.; Ong et al (2013) [46]: Conducted sensitivity analyses.; Megiddo et al (2014) [47]: Conducted sensitivity analyses.; Arrabal et al (2015) [48]: Conducted sensitivity analyses.; Becerra et al (2015) [28]: Conducted sensitivity analyses.; Wald et al (2016) [26]: Conducted sensitivity analyses.; Barrios et al (2017) [27]: Conducted sensitivity analyses.; Jowett et al (2017) [49]: Conducted sensitivity analyses.; Barth et al (2017) [50]: Conducted sensitivity analyses.; Ferket et al (2017) [24]: Conducted sensitivity analyses.; Singh et al (2018) [29]: Did not conduct sensitivity analyses.; Lin et al (2019) [51]: Conducted sensitivity analyses.; Gaziano et al (2019) [52]: Conducted sensitivity analyses.; Ntaios et al (2019) [53]: Conducted sensitivity analyses.
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 74,How is heterogeneity explained in these studies?,Gaziano et al (2006) [6]: Heterogeneity is explained.; Franco et al (2006) [40]: Heterogeneity is not explained.; Lim et al (2007) [38]: Heterogeneity is not explained.; Newman et al (2008) [41]: Heterogeneity is explained.; Rubinstein et al (2009) [25]: Heterogeneity is explained.; Rubinstein et al (2010) [39]: Heterogeneity is partially explained.; van Gils et al (2011) [42]: Heterogeneity is explained.; Khonputsa et al (2012) [43]: Heterogeneity is explained.; Ito et al (2012) [44]: Heterogeneity is explained.; Bautista (2013) [30]: Heterogeneity is explained.; Zomer et al (2013) [45]: Heterogeneity is explained.; Ong et al (2013) [46]: Heterogeneity is explained.; Megiddo et al (2014) [47]: Heterogeneity is explained.; Arrabal et al (2015) [48]: Heterogeneity is explained.; Becerra et al (2015) [28]: Heterogeneity is explained.; Wald et al (2016) [26]: Heterogeneity is explained.; Barrios et al (2017) [27]: Heterogeneity is explained.; Jowett et al (2017) [49]: Heterogeneity is explained.; Barth et al (2017) [50]: Heterogeneity is partially explained.; Ferket et al (2017) [24]: Heterogeneity is explained.; Singh et al (2018) [29]: Heterogeneity is not explained.; Lin et al (2019) [51]: Heterogeneity is explained.; Gaziano et al (2019) [52]: Heterogeneity is explained.; Ntaios et al (2019) [53]: Heterogeneity is explained.
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 75,What findings and limitations are discussed in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: #; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 76,What are the funding sources for these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 77,What potential conflicts of interest are disclosed in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: âˆš; Lim et al (2007) [38]: Ã—; Newman et al (2008) [41]: Ã—; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: Ã—; Bautista (2013) [30]: Ã—; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: Ã—; Megiddo et al (2014) [47]: Ã—; Arrabal et al (2015) [48]: Ã—; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: âˆš; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: Ã—; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: Ã—; Ntaios et al (2019) [53]: Ã—
9333258_Table_2,Gaziano et al (2006) [6]: 6; Franco et al (2006) [40]: 40; Lim et al (2007) [38]: 38; Newman et al (2008) [41]: 41; Rubinstein et al (2009) [25]: 25; Rubinstein et al (2010) [39]: 39; van Gils et al (2011) [42]: 42; Khonputsa et al (2012) [43]: 43; Ito et al (2012) [44]: 44; Bautista (2013) [30]: 30; Zomer et al (2013) [45]: 45; Ong et al (2013) [46]: 46; Megiddo et al (2014) [47]: 47; Arrabal et al (2015) [48]: 48; Becerra et al (2015) [28]: 28; Wald et al (2016) [26]: 26; Barrios et al (2017) [27]: 27; Jowett et al (2017) [49]: 49; Barth et al (2017) [50]: 50; Ferket et al (2017) [24]: 24; Singh et al (2018) [29]: 29; Lin et al (2019) [51]: 51; Gaziano et al (2019) [52]: 52; Ntaios et al (2019) [53]: 78,What are the total costs or outcomes reported in these studies?,Gaziano et al (2006) [6]: âˆš; Franco et al (2006) [40]: #; Lim et al (2007) [38]: âˆš; Newman et al (2008) [41]: âˆš; Rubinstein et al (2009) [25]: âˆš; Rubinstein et al (2010) [39]: âˆš; van Gils et al (2011) [42]: âˆš; Khonputsa et al (2012) [43]: âˆš; Ito et al (2012) [44]: âˆš; Bautista (2013) [30]: âˆš; Zomer et al (2013) [45]: âˆš; Ong et al (2013) [46]: âˆš; Megiddo et al (2014) [47]: âˆš; Arrabal et al (2015) [48]: âˆš; Becerra et al (2015) [28]: âˆš; Wald et al (2016) [26]: NA; Barrios et al (2017) [27]: âˆš; Jowett et al (2017) [49]: âˆš; Barth et al (2017) [50]: âˆš; Ferket et al (2017) [24]: âˆš; Singh et al (2018) [29]: âˆš; Lin et al (2019) [51]: âˆš; Gaziano et al (2019) [52]: âˆš; Ntaios et al (2019) [53]: âˆš
11332733_Table_3,Morawski J.H.: 2012,Who are the authors and what years are these studies from?,Morawski J.H.: 2012
11332733_Table_3,Morawski J.H.: 2012,What model designs are used in these studies?,"Morawski J.H. 2012: Markov model â€“ 3 health states (uncontrolled EPI, controlled EPI, and death) from a payer perspective"
11332733_Table_3,Morawski J.H.: 2012,"Which countries, intervention currencies, and currency years are reported in these studies?","Morawski J.H. 2012: Country: Poland, Intervention Currency: EUR, Currency Year: 2011"
11332733_Table_3,Morawski J.H.: 2012,What time horizons are considered in these studies?,"Morawski J.H. 2012: 20 years, 10 years (sensitivity analysis), 5 years (sensitivity analysis)"
11332733_Table_3,Morawski J.H.: 2012,What are the total costs reported in these studies?,"Morawski J.H. 2012: 8223 for 20 years, 5816 for 10 years (sensitivity analysis), 3473 for 5 years (sensitivity analysis)"
11332733_Table_3,Morawski J.H.: 2012,What are the QALYs (Quality-Adjusted Life Years) calculated in these studies?,"Morawski J.H. 2012: 9.45 for 20 years, 6.36 for 10 years (sensitivity analysis), 3.64 for 5 years (sensitivity analysis)"
11332733_Table_3,Morawski J.H.: 2012,What are the ICERs (Incremental Cost-Effectiveness Ratios) per QALY in these studies?,"Morawski J.H.: 20 years: 6312, 10 years (sensitivity analysis): 6666, 5 years (sensitivity analysis): 7036"
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What are the titles or identifiers of these studies?,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38]
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],Where are these studies conducted?,Van Loon (2010)a [37]: NL; Rabalais (2012) [32]: US; Auguste & Meads (2014)b [34]: UK; Greuter (2017) [35]: NL; Smith & Mehanna (2017) [39]: UK; Fu (2021) [36]: CAN; Greuter (2022) [33]: NL; Rosen (2022) [38]: GER
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What objectives do these studies aim to achieve?,"Van Loon (2010)a [37]: To evaluate the cost effectiveness of a PET/CT-based follow-up as opposed to a conventional follow-up in patients with NSCLC treated with CRT; Rabalais (2012) [32]: To study the cost effectiveness of PET/CT for the management of the neck in patients with N2 neck cancer treated with CRT; Auguste & Meads (2014)b [34]: To undertake a cost-effectiveness analysis that compares PET/CT plus standard practice with standard practice alone in the diagnosis of recurrent or persistent cervical cancer during routine surveillance and a follow-up in women treated with CRT; Greuter (2017) [35]: To assess the effects and costs of four response evaluation strategies including PET/CT to detect local residual disease in patients with advanced squamous cell OPC treated with CRT; Smith & Mehanna (2017) [39]: To provide vital evidence for the cost effectiveness of a PET/CT guided management strategy for patients with N2 or N3 head and neck cancers treated with CRT; Fu (2021) [36]: To compare the long-term cost utility of CT surveillance, PET/CTâ€“guided surveillance and PRND for the management of patients with advanced nodal HPV+ OPC treated with CRT; Greuter (2022) [33]: To assess the cost effectiveness of shortening therapy duration based on interim PET/CT scans in patients with DLBCL treated with R-CHOP; Rosen (2022) [38]: To determine the cost effectiveness of FET PET compared with conventional MRI for early identification of responders to adjuvant CHEMO in patients with glioma"
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What patient populations are included in these studies?,Van Loon (2010)a [37]: Patients with advanced staged NSCLC; Rabalais (2012) [32]: Patients with advanced nodal neck cancer; Auguste & Meads (2014)b [34]: Patients with persistent and late-stage cervical cancer; Greuter (2017) [35]: Patients with advanced staged squamous cell OPC; Smith & Mehanna (2017) [39]: Patients with advanced nodal head and neck cancers; Fu (2021) [36]: Patients with HPV+ advanced nodal OPC; Greuter (2022) [33]: Patients with DLBCL; Rosen (2022) [38]: Patients with glioblastoma
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What therapy strategies are evaluated in these studies?,Van Loon (2010)a [37]: CRT; Rabalais (2012) [32]: CRT; Auguste & Meads (2014)b [34]: CRT; Greuter (2017) [35]: CRT; Smith & Mehanna (2017) [39]: CRT; Fu (2021) [36]: CRT; Greuter (2022) [33]: CHEMO; Rosen (2022) [38]: CRT
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],Which lines of therapy are considered in these studies?,"Van Loon (2010)a [37]: First-line, Second-line; Rabalais (2012) [32]: First-line; Auguste & Meads (2014)b [34]: First-line; Greuter (2017) [35]: First-line; Smith & Mehanna (2017) [39]: First-line; Fu (2021) [36]: First-line; Greuter (2022) [33]: First-line; Rosen (2022) [38]: Adjuvant"
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What medications are prescribed in these studies?,"Van Loon (2010)a [37]: [1] Docetaxel, [2] erlotinib; Rabalais (2012) [32]: Not reported; Auguste & Meads (2014)b [34]: Carboplatin/5-fluorouracil; Greuter (2017) [35]: Not reported; Smith & Mehanna (2017) [39]: TPF; Fu (2021) [36]: Not reported; Greuter (2022) [33]: R-CHOP; Rosen (2022) [38]: Temozolomide"
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What imaging methods are used as comparators in these studies?,"Van Loon (2010)a [37]: [1] X-ray, [2] CT, [3] PET/CT; Rabalais (2012) [32]: [1] None, [2] CT, [3] PET/CT; Auguste & Meads (2014)b [34]: [1] MRI and/or CT, [2] MRI and/or CT plus PET/CT; Greuter (2017) [35]: [1] None, [2] MRI, [3] PET/CT; Smith & Mehanna (2017) [39]: [1] None, [2] PET/CT; Fu (2021) [36]: [1] None, [2] CT, [3] PET/CT; Greuter (2022) [33]: [1] PET/CT, [2] PET/CT plus interim PET/CT; Rosen (2022) [38]: [1] Interim MRI, [2] interim PET"
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],Which PET radiopharmaceuticals are used in these studies?,Van Loon (2010)a [37]: [18F]FDG; Rabalais (2012) [32]: Not reported; Auguste & Meads (2014)b [34]: [18F]FDG; Greuter (2017) [35]: [18F]FDG; Smith & Mehanna (2017) [39]: [18F]FDG; Fu (2021) [36]: [18F]FDG; Greuter (2022) [33]: [18F]FDG; Rosen (2022) [38]: [18F]FET
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],Do these studies involve patients with histologically proven cancer?,Van Loon (2010)a [37]: Not reported; Rabalais (2012) [32]: Not reported; Auguste & Meads (2014)b [34]: Yes; Greuter (2017) [35]: Yes; Smith & Mehanna (2017) [39]: Yes; Fu (2021) [36]: Not reported; Greuter (2022) [33]: Not reported; Rosen (2022) [38]: Yes
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What are the times to imaging reported in these studies?,Van Loon (2010)a [37]: End-of-therapy imagingd; Rabalais (2012) [32]: End-of-therapy imagingd; Auguste & Meads (2014)b [34]: End-of-therapy imagingd; Greuter (2017) [35]: End-of-therapy imagingd; Smith & Mehanna (2017) [39]: End-of-therapy imagingd; Fu (2021) [36]: End-of-therapy imagingd; Greuter (2022) [33]: Early imaging after two cycles of therapy; Rosen (2022) [38]: Early imaging after two cycles of therapy
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What time horizons are considered in these studies?,Van Loon (2010)a [37]: 5 years; Rabalais (2012) [32]: 1 year; Auguste & Meads (2014)b [34]: Lifetime; Greuter (2017) [35]: Therapy duration; Smith & Mehanna (2017) [39]: Lifetime; Fu (2021) [36]: Lifetime; Greuter (2022) [33]: 5 years; Rosen (2022) [38]: Therapy duration
11782410_Table_1,Van Loon: Van Loon (2010)a [37]; Rabalais: Rabalais (2012) [32]; Auguste & Meads: Auguste & Meads (2014)b [34]; Greuter (2017): Greuter (2017) [35]; Smith & Mehanna: Smith & Mehanna (2017) [39]; Fu: Fu (2021) [36]; Greuter (2022): Greuter (2022) [33]; Rosen: Rosen (2022) [38],What sources of funding are reported for these studies?,Van Loon (2010)a [37]: Not reported; Rabalais (2012) [32]: Non-industry; Auguste & Meads (2014)b [34]: Non-industry; Greuter (2017) [35]: Non-industry; Smith & Mehanna (2017) [39]: Non-industry; Fu (2021) [36]: Non-industry; Greuter (2022) [33]: Non-industry; Rosen (2022) [38]: Not reported
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],What references are cited in these studies?,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38]
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],What are the ICER values reported in these studies?,"Hiligsmann et al. [27]: All ages: â‚¬38,526 (women), â‚¬106,113 (men); 60â€“69 years: â‚¬155,006 (women), â‚¬218,176 (men); 70â€“79 years: â‚¬24,997 (women), â‚¬92,676 (men); 80+ years: â‚¬1907 (women), â‚¬27,683 (men); Ethgen et al. [21]: Osteoporosis: 50 years: â‚¬300,277 (women), â‚¬203,563 (men); 60 years: â‚¬174,359 (women), â‚¬121,582 (men); 70 years: â‚¬74,707 (women), â‚¬61,349 (men); 80 years: â‚¬19,910 (women), â‚¬24,231 (men); Prevalent fracture: 50 years: â‚¬168,701 (women), â‚¬118,823 (men); 60 years: â‚¬96,744 (women), â‚¬70,057 (men); 70 years: â‚¬35,687 (women), â‚¬31,423 (men); 80 years: â‚¬3369 (women), â‚¬8916 (men); Hiligsmann et al. [28]: 60 years: â‚¬40,578 (women), â‚¬23,477 (men); 70 years: â‚¬7912 (women), â‚¬10,250 (men); 80 years: âˆ’â‚¬12,815 (cost saving, women), âˆ’â‚¬6723 (cost saving, men); Kreck et al. [18]: BMD T-score âˆ’3.0: 65 years: â‚¬407,375 (women), â‚¬1,042,295 (men); Van Staa et al. [20]: GC 5 mg: <60 years: Â£41,000 (women), Â£40,000 (men); 60â€“79 years: Â£17,000 (women), Â£43,000 (men); 80+ years: Â£5000 (women), Â£35,000 (men); GC 15 mg: <60 years: Â£17,000 (women), Â£22,000 (men); 60â€“79 years: Â£13,000 (women), Â£34,000 (men); 80+ years: Â£15,000 (women), Â£33,000 (men); Fleurence et al. [39]: General population: Hip pad: $11,722 (women), $47,426 (men); Hip pad + VitD/CA: $25,123 (women), $80,998 (men); High-risk population: Hip pad: âˆ’$450 (cost saving, women), $17,017 (men); Hip pad + VitD/CA: $6572 (women), $33,565 (men); Pisu et al. [16]: Vs no screening: âˆ’$49,261 (cost saving, women), âˆ’$4487 (cost saving, men); Vs usual care: âˆ’$38,305 (cost saving, women), âˆ’$4729 (cost saving, men); Schwenkglenks et al. [36]: 65 years: CHF70,995 (women), CHF197,460 (men); 75 years: CHF35,412 (women), CHF123,094 (men); 85 years: CHF28,170 (women), CHF118,945 (men)"
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],Are these studies considered cost-effective?,Hiligsmann et al. [27]: No; Ethgen et al. [21]: No; Hiligsmann et al. [28]: Yes; Kreck et al. [18]: No; Van Staa et al. [20]: No; Fleurence et al. [39]: No; Pisu et al. [16]: Yes; Schwenkglenks et al. [36]: No; DPhil et al. [38]: Yes
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],What scenarios are analyzed in these studies?,"Hiligsmann et al. [27]: All ages, 60â€“69 years, 70â€“79 years, 80+ years; Ethgen et al. [21]: Osteoporosis (50 years, 60 years, 70 years, 80 years), Prevalent fracture (50 years, 60 years, 70 years, 80 years); Hiligsmann et al. [28]: 60 years, 70 years, 80 years; Kreck et al. [18]: BMD T-score âˆ’ 3.0 (65 years); Van Staa et al. [20]: GC 5 mg (< 60 years, 60â€“79 years, 80+ years), GC 15 mg (< 60 years, 60â€“79 years, 80+ years); Fleurence et al. [39]: General population (Hip pad, Hip pad + VitD/CA), High-risk population (Hip pad, Hip pad + VitD/CA); Pisu et al. [16]: Vs no screening, Vs usual care; Schwenkglenks et al. [36]: 65 years, 75 years, 85 years; DPhil et al. [38]: FLS vs usual care, OG vs FLS"
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],What outcomes are reported for women in these studies?,"Hiligsmann et al. [27]: ICERs for different age groups, cost-effectiveness varies by age, generally more cost-effective for older women.; Ethgen et al. [21]: ICERs for osteoporosis and prevalent fracture scenarios, cost-effectiveness varies by age, generally more cost-effective for older women.; Hiligsmann et al. [28]: ICERs for different ages, cost-effective for women at all ages studied.; Kreck et al. [18]: ICER for BMD T-score âˆ’3.0 at 65 years, not cost-effective for women.; Van Staa et al. [20]: ICERs for different GC dosages and age groups, cost-effectiveness varies, generally more cost-effective for women at higher GC dosages.; Fleurence et al. [39]: ICERs for general and high-risk populations with hip pad and VitD/CA interventions, cost-effectiveness varies, generally more cost-effective for women in high-risk populations.; Pisu et al. [16]: Cost savings reported for women compared to no screening and usual care, cost-effective for women.; Schwenkglenks et al. [36]: ICERs for different ages, not cost-effective for women at 65 years, cost-effective for older women.; DPhil et al. [38]: ICERs for FLS vs usual care and OG vs FLS, cost-effective for women in both comparisons."
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],What outcomes are reported for men in these studies?,"Hiligsmann et al. [27]: ICERs for men across different age groups, with cost-effectiveness not achieved in any scenario.; Ethgen et al. [21]: ICERs for men with osteoporosis and prevalent fracture across different ages, with cost-effectiveness achieved in some scenarios.; Hiligsmann et al. [28]: ICERs for men at ages 60, 70, and 80, with cost-effectiveness achieved in all scenarios.; Kreck et al. [18]: ICER for men with BMD T-score âˆ’3.0 at age 65, not cost-effective.; Van Staa et al. [20]: ICERs for men on GC 5 mg and GC 15 mg across different age groups, with cost-effectiveness achieved in some scenarios.; Fleurence et al. [39]: ICERs for men in general and high-risk populations using hip pad and hip pad + VitD/CA, with cost-effectiveness achieved in some scenarios.; Pisu et al. [16]: Cost savings for men vs no screening and vs usual care, with cost-effectiveness achieved in both scenarios.; Schwenkglenks et al. [36]: ICERs for men at ages 65, 75, and 85, with cost-effectiveness not achieved in any scenario.; DPhil et al. [38]: ICERs for men in FLS vs usual care and OG vs FLS, with cost-effectiveness achieved in both scenarios."
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],"What differences are noted between women and men in these studies, using women as the reference?","Hiligsmann et al. [27]: Men have higher ICERs than women across all age groups, and the cost-effectiveness is generally worse for men.; Ethgen et al. [21]: For osteoporosis, men have lower ICERs than women, except at 80 years where men have a higher ICER. For prevalent fracture, men have lower ICERs than women, except at 80 years where men have a higher ICER.; Hiligsmann et al. [28]: Men have lower ICERs than women across all age groups, and both genders are cost-effective.; Kreck et al. [18]: Men have a much higher ICER than women at 65 years, and neither is cost-effective.; Van Staa et al. [20]: For GC 5 mg, men have similar or higher ICERs than women, with cost-effectiveness only for women in older age groups. For GC 15 mg, men have higher ICERs than women, with cost-effectiveness only for women in older age groups.; Fleurence et al. [39]: In the general population, men have higher ICERs than women, with cost-effectiveness only for women. In the high-risk population, men have higher ICERs than women, with cost-effectiveness for both genders in some scenarios.; Pisu et al. [16]: Both men and women are cost-saving compared to no screening and usual care, with men having slightly less cost-saving than women.; Schwenkglenks et al. [36]: Men have higher ICERs than women across all age groups, with cost-effectiveness only for women in older age groups.; DPhil et al. [38]: Men have slightly lower ICERs than women for FLS vs usual care, but higher ICERs for OG vs FLS, with both genders being cost-effective."
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],What specific data is provided for women in these studies?,Hiligsmann et al. [27]: ICER values for different age groups and cost-effectiveness for women.; Ethgen et al. [21]: ICER values for osteoporosis and prevalent fracture scenarios for women.; Hiligsmann et al. [28]: ICER values for different ages and cost-effectiveness for women.; Kreck et al. [18]: ICER value for BMD T-score âˆ’3.0 at 65 years for women.; Van Staa et al. [20]: ICER values for different GC dosages and age groups for women.; Fleurence et al. [39]: ICER values for hip pad and hip pad + VitD/CA in general and high-risk populations for women.; Pisu et al. [16]: Cost-saving ICER values vs no screening and vs usual care for women.; Schwenkglenks et al. [36]: ICER values for different ages for women.; DPhil et al. [38]: ICER values for FLS vs usual care and OG vs FLS for women.
10020287_Table_3,Hiligsmann et al. [27]: Hiligsmann et al. [27]; Ethgen et al. [21]: Ethgen et al. [21]; Hiligsmann et al. [28]: Hiligsmann et al. [28]; Kreck et al. [18]: Kreck et al. [18]; Van Staa et al. [20]: Van Staa et al. [20]; Fleurence et al. [39]: Fleurence et al. [39]; Pisu et al. [16]: Pisu et al. [16]; Schwenkglenks et al. [36]: Schwenkglenks et al. [36]; DPhil et al. [38]: DPhil et al. [38],What specific data is provided for men in these studies?,"Hiligsmann et al. [27]: ICER values for different age groups and cost-effectiveness status for men.; Ethgen et al. [21]: ICER values for osteoporosis and prevalent fracture scenarios across different ages and cost-effectiveness status for men.; Hiligsmann et al. [28]: ICER values for different ages and cost-effectiveness status for men.; Kreck et al. [18]: ICER value for BMD T-score âˆ’3.0 at 65 years and cost-effectiveness status for men.; Van Staa et al. [20]: ICER values for GC 5 mg and GC 15 mg across different age groups and cost-effectiveness status for men.; Fleurence et al. [39]: ICER values for general and high-risk populations with different interventions and cost-effectiveness status for men.; Pisu et al. [16]: ICER values for screening vs no screening and vs usual care, both cost-saving, and cost-effectiveness status for men.; Schwenkglenks et al. [36]: ICER values for different ages and cost-effectiveness status for men.; DPhil et al. [38]: ICER values for FLS vs usual care and OG vs FLS, and cost-effectiveness status for men."
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",Which countries are covered in these studies?,"Grant et al. 2020 [55]: CA; Wu et al. 2020 [49]: CN; Earla and Sansgiry 2019 [30]: US; Perera et al. 2019 [56]: AU; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What base-case scenarios are considered in these studies?,"Grant et al. 2020 [55] (CA): 5 years; Wu et al. 2020 [49] (CN): 10 years; Earla and Sansgiry 2019 [30] (US): 15 years; Perera et al. 2019 [56] (AU): Lifetime; Park et al. 2019 [42] (KR): Lifetime; Zueger et al. 2018 [52] (US): 5 years; Zaca 2018 [50] (IT): 10 years; Liang et al. 2018 [19] (SG): 10 years; Dâ€™Angiolella et al. 2017 [29] (IT): Lifetime; Ademi et al. 2017 [25] (CH): Lifetime; Ramos et al. 2017 [43] (NL): Lifetime; CADTH (HTA), 2016 [58] (CA): 20 years; NICE (HTA), 2016 [17] (UK): Lifetime; SMC (HTA), 2016 [59] (SC): Lifetime"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the ICER/QALY values at different time horizons used in sensitivity and scenario analyses in these studies?,"Grant et al. 2020: {'2 years': 'CA$50,766', '5 years': 'CA$24,426'}; Wu et al. 2020: {'5 years': '$3,685', '10 years': '$2,033', '20 years': '$1,874'}; Zueger et al. 2018: {'2 years': '$223,344', '10 years': '$89,824', '30 years': '$67,997'}; Liang et al. 2018: {'2 years': 'SG$271,291', '20 years': 'SG$54,777'}; Ramos et al. 2017: {'1 year': 'â‚¬88,710', '3 years': 'â‚¬55,555', '5 years': 'â‚¬41,576', '10 years': 'â‚¬27,350'}; Ademi et al. 2017: {'2 years': 'CHF58,679'}"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What time horizons are considered in these studies?,"Grant et al. 2020 [55] (CA): 5 years; Wu et al. 2020 [49] (CN): 10 years; Earla and Sansgiry 2019 [30] (US): 15 years; Perera et al. 2019 [56] (AU): Lifetime; Park et al. 2019 [42] (KR): Lifetime; Zueger et al. 2018 [52] (US): 5 years; Zaca 2018 [50] (IT): 10 years; Liang et al. 2018 [19] (SG): 10 years; Dâ€™Angiolella et al. 2017 [29] (IT): Lifetime; Ademi et al. 2017 [25] (CH): Lifetime; Ramos et al. 2017 [43] (NL): Lifetime; CADTH (HTA), 2016 [58] (CA): 20 years; NICE (HTA), 2016 [17] (UK): Lifetime; SMC (HTA), 2016 [59] (SC): Lifetime"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the ICER/QALY values reported in these studies?,"Grant et al. 2020 [55] (CA): CA$34,727; Wu et al. 2020 [49] (CN): $2,481; Earla and Sansgiry 2019 [30] (US): $75,270#; Perera et al. 2019 [56] (AU): AU$77,889; Park et al. 2019 [42] (KR): $12,722; Zueger et al. 2018 [52] (US): US$142,891; Zaca 2018 [50] (IT): â€“â‚¬98,500/; Liang et al. 2018 [19] (SG): SG$74,592; Dâ€™Angiolella et al. 2017 [29] (IT): â‚¬19,487; Ademi et al. 2017 [25] (CH): CHF25,684; Ramos et al. 2017 [43] (NL): â‚¬17,600; CADTH (HTA), 2016 [58] (CA): CA$29,999; NICE (HTA), 2016 [17] (UK): Â£17,939; SMC (HTA), 2016 [59] (SC): Â£18,348"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 1-year mark in these studies?,"Grant et al. 2020: â€“; Wu et al. 2020: â€“; Earla and Sansgiry 2019: â€“; Perera et al. 2019: â€“; Park et al. 2019: â€“; Zueger et al. 2018: â€“; Zaca 2018: â€“; Liang et al. 2018: â€“; Dâ€™Angiolella et al. 2017: â€“; Ademi et al. 2017: â€“; Ramos et al. 2017: â‚¬88,710; CADTH (HTA), 2016: â€“; NICE (HTA), 2016: â€“; SMC (HTA), 2016: â€“"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 2-year mark in these studies?,"Grant et al. 2020: CA$50,766; Wu et al. 2020: â€“; Earla and Sansgiry 2019: â€“; Perera et al. 2019: â€“; Park et al. 2019: â€“; Zueger et al. 2018: â€“; Zaca 2018: â€“; Liang et al. 2018: SG$271,291; Dâ€™Angiolella et al. 2017: â€“; Ademi et al. 2017: CHF58,679; Ramos et al. 2017: â€“; CADTH (HTA), 2016: â€“; NICE (HTA), 2016: â€“; SMC (HTA), 2016: â€“"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 3-year mark in these studies?,"Grant et al. 2020: â€“; Wu et al. 2020: â€“; Earla and Sansgiry 2019: â€“; Perera et al. 2019: â€“; Park et al. 2019: â€“; Zueger et al. 2018: $223,344; Zaca 2018: â€“; Liang et al. 2018: â€“; Dâ€™Angiolella et al. 2017: â€“; Ademi et al. 2017: â€“; Ramos et al. 2017: â‚¬55,555; CADTH (HTA), 2016: â€“; NICE (HTA), 2016: â€“; SMC (HTA), 2016: â€“"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 5-year mark in these studies?,"Grant et al. 2020: CA$24,426; Zueger et al. 2018: US$89,824; Ramos et al. 2017: â‚¬41,576"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 10-year mark in these studies?,"Wu et al. 2020 [49] (CN): $3,685; Perera et al. 2019 [56] (AU): AU$109,302; Zueger et al. 2018 [52] (US): $89,824; Liang et al. 2018 [19] (SG): SG$54,777; Ramos et al. 2017 [43] (NL): â‚¬27,350"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 15-year mark in these studies?,"Grant et al. 2020: â€“; Wu et al. 2020: â€“; Earla and Sansgiry 2019: â€“; Perera et al. 2019: AU$78,373; Park et al. 2019: â€“; Zueger et al. 2018: $89,824; Zaca 2018: â€“; Liang et al. 2018: â€“; Dâ€™Angiolella et al. 2017: â‚¬26,180; Ademi et al. 2017: â€“; Ramos et al. 2017: â‚¬27,350; CADTH (HTA), 2016: CA$42,787; NICE (HTA), 2016: â€“; SMC (HTA), 2016: â€“"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 20-year mark in these studies?,"Wu et al. 2020 [49] (CN): $2,033; Zueger et al. 2018 [52] (US): Not available; Zaca 2018 [50] (IT): Not available; Liang et al. 2018 [19] (SG): Not available; Dâ€™Angiolella et al. 2017 [29] (IT): Not available; Ademi et al. 2017 [25] (CH): Not available; Ramos et al. 2017 [43] (NL): Not available; CADTH (HTA), 2016 [58] (CA): Not available; NICE (HTA), 2016 [17] (UK): Not available; SMC (HTA), 2016 [59] (SC): Not available"
10060315_Table_2,"Grant et al. 2020 [55]; Wu et al. 2020 [49]; Earla and Sansgiry 2019 [30] Perera et al. 2019 [56]; Park et al. 2019 [42]: KR; Zueger et al. 2018 [52]: US; Zaca 2018 [50]: IT; Liang et al. 2018 [19]: SG; Dâ€™Angiolella et al. 2017 [29]: IT; Ademi et al. 2017 [25]: CH; Ramos et al. 2017 [43]: NL; CADTH (HTA), 2016 [58]: CA; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the outcomes or results at the 30-year mark in these studies?,"Zueger et al. 2018: US$67,997; Zaca 2018: Dominant"
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,What references are cited in these studies?,Hiligsmann et al. [27]: Vit D-fortified dairy products; Ethgen et al. [21]: CA/Vit D dietary supplementation; Silverman et al. [25]: Denosumab; Hiligsmann et al. [28]: CA/Vit D supplementation; Parthan et al. [26]: Denosumab; Hiligsmann et al. [40]: Strontium ranelate; Kouta et al. [23]: Selective branded alendronate therapy + BMD test; Kreck et al. [18]: Branded ibandronate+ calcium/colecalciferol; Schousboe et al. [22]: Branded bisphosphonate + bone densitometry
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,What interventions are evaluated in these studies?,Hiligsmann et al. [27]: Vit D-fortified dairy products; Ethgen et al. [21]: CA/Vit D dietary supplementation; Silverman et al. [25]: Denosumab; Hiligsmann et al. [28]: CA/Vit D supplementation; Parthan et al. [26]: Denosumab; Hiligsmann et al. [40]: Strontium ranelate; Kouta et al. [23]: Selective branded alendronate therapy + BMD test; Kreck et al. [18]: Branded ibandronate+ calcium/colecalciferol; Schousboe et al. [22]: Branded bisphosphonate + bone densitometry
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,What comparators are used in these studies?,"Hiligsmann et al. [27]: Usual care; Ethgen et al. [21]: The absence of appropriate intake; Silverman et al. [25]: Bisphosphonates (generic alendronate, branded zoledronate, branded risedronate, branded ibandronate), and teriparatide; Hiligsmann et al. [28]: No treatment (no CA/Vit D supplementation); Parthan et al. [26]: Bisphosphonates (generic alendronate, branded zoledronate, generic risedronate, branded ibandronate), strontium ranelate, and teriparatide; Hiligsmann et al. [40]: No treatment (no active drug treatment); Kouta et al. [23]: (Universal branded alendronate therapy without BMD test) or (no BMD test and no therapy); Kreck et al. [18]: Fluoride strategy (sodium fluoride + calcium/colecalciferol), and calcium strategy (calcium/colecalciferol alone); Schousboe et al. [22]: No intervention (no drug treatment, no screening)"
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,What are the durations of the interventions in these studies?,"Hiligsmann et al. [27]: 1 year (two dairy products per day); Ethgen et al. [21]: 1 year: a daily dairy supplementation containing 1000 mg of CA and 800 IU of Vit D; Silverman et al. [25]: 5 years: denosumab, bisphosphonates 2 years: teriparatide; Hiligsmann et al. [28]: 3 years; Parthan et al. [26]: 5 years: bisphosphonates, strontium ranelate, denosumab 2 years: teriparatide; Hiligsmann et al. [40]: 3 years; Kouta et al. [23]: 5 years: branded alendronate; Kreck et al. [18]: 42 months; Schousboe et al. [22]: 5 years: oral bisphosphonate"
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,In which years are the valuations conducted in these studies?,Hiligsmann et al. [27]: 2015 EUR; Ethgen et al. [21]: 2014 EUR; Silverman et al. [25]: 2013 USD; Hiligsmann et al. [28]: 2012 EUR; Parthan et al. [26]: 2012 EUR; Hiligsmann et al. [40]: 2010 EUR; Kouta et al. [23]: 2008 USD; Kreck et al. [18]: 2004 EUR; Schousboe et al. [22]: 2004 USD
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,What results are reported in these studies?,"Hiligsmann et al. [27]: In men aged over 60 years, the intake of two Vit D-fortified dairy products per day had an ICER of â‚¬106,113/QALY compared to usual care. The ICER was below a threshold of â‚¬30,000 /QALY in men aged over 80 years; Ethgen et al. [21]: The daily intake of Vit-D-rich dairy products was cost effective in general men aged over 70 years and in male patients at increased risk of osteoporotic fractures; Silverman et al. [25]: Denosumab had an ICER of $16,888/QALY compared to generic alendronate and dominated all other treatments; Hiligsmann et al. [28]: Compared to no treatment, CA/Vit D supplementation had an ICER of â‚¬23,477/QALY and â‚¬10,250/QALY in men aged 60 years and 70 years, respectively, which was cost saving in men aged 80 years, suggesting CA/Vit D supplementation was cost effective for men with osteoporosis aged over 60 years; Parthan et al. [26]: Compared to other treatments, denosumab had the lowest costs and highest QALYs, indicating denosumab dominated all other treatments; Hiligsmann et al. [40]: Compared to no treatment, strontium ranelate had an ICER of â‚¬49,798/QALY and â‚¬25,584/QALY using ITT and PPS efficacy data, respectively in entire patients. The ICER falls below thresholds in partial patients with a BMD T-score â‰¤ -2.5 or with PVF. Strontium ranelate could be considered cost effective compared with no treatment for male osteoporosis; Kouta et al. [23]: The ICERs for the strategy of a BMD test and selective alendronate therapy for patients with osteoporosis and universal alendronate therapy without a BMD test were US$66,800/QALY and $178,700/QALY, respectively, which was cost effective for those with osteoporosis; Kreck et al. [18]: The calcium strategy dominated the fluoride strategy. Compared to the calcium strategy, the ibandronate strategy had an ICER of â‚¬1,042,295/QALY in male patients aged over 65 years with a BMD T-score at baseline of -3.0. The ibandronate strategy is not cost effective; Schousboe et al. [22]: Compared with no intervention, the densitometry and follow-up treatment strategy had an ICER less than USD 50,000/QALY for men aged 65 years or older with a prior clinical fracture and for men aged 80 years or older without a prior fracture. The strategy may be cost effective in these patients"
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,What base-case analyses are performed in these studies?,"Hiligsmann et al. [27]: One-way SA; Ethgen et al. [21]: None; Silverman et al. [25]: One-way and probabilistic SA; Hiligsmann et al. [28]: One-way and probabilistic SA; Parthan et al. [26]: One-way and probabilistic SA; Hiligsmann et al. [40]: One-way and probabilistic SA; Kouta et al. [23]: One-way SA; Kreck et al. [18]: One-way, two-way, and probabilistic SA; Schousboe et al. [22]: One-way and probabilistic SA"
10020287_Table_2,Hiligsmann et al. [27]; Ethgen et al. [21]; Silverman et al. [25]; Hiligsmann et al. [28]; Parthan et al. [26]; Hiligsmann et al. [40]: ; Kouta et al. [23ç; Kreck et al. [18]; Schousboe et al. [22]:,What sensitivity analyses are conducted in these studies?,"Hiligsmann et al. [27]: One-way SA; Ethgen et al. [21]: None; Silverman et al. [25]: One-way and probabilistic SA; Hiligsmann et al. [28]: One-way and probabilistic SA; Parthan et al. [26]: One-way and probabilistic SA; Hiligsmann et al. [40]: One-way and probabilistic SA; Kouta et al. [23]: One-way SA; Kreck et al. [18]: One-way, two-way, and probabilistic SA; Schousboe et al. [22]: One-way and probabilistic SA"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",Which countries are covered in these studies?,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What parameter descriptions are provided in these studies?,"Borges et al. 2020 [26] (PT): Coefficient of constant; Chin et al. 2020 [27] (AU): Incidence of CV death, enalapril; McMurray et al. 2018 [41] (DK): Coefficient of CV mortality: Age2; Lacey et al. 2018 [38] (CR): Coefficient of constant; McMurray et al. 2018 [41] (CO): Coefficient of constant; Lacey et al. 2018 [39] (BR): Coefficient of constant; Liang et al. 2018 [19] (SG): CV mortality, HR; Lee et al. 2018 [40] (SG): Coefficient of constant; Krittyaphong et al. 2018 [36] (TH): CV mortality risk (from non-hospitalization), enalapril; Dâ€™Angiolella et al. 2017 [29] (IT): TE of sac/val on CV mortality; Ramos et al. 2017 [43] (NL): Coefficient of CV mortality: Age2; Fann et al. 2017 [31] (TW): Coefficient of constant; King et al. 2016 [35] (US): Risk of CV mortality, sac/val; PBAC (HTA), 2016 [60] (AU): CV mortality; van der Pol et al. 2019 [48] (DE): TE of sac/val on death, RR; Zueger et al. 2018 [52] (US): TE of sac/val on death, RR; McMurray et al. 2018 [41] (UK): All-cause mortality- Gompertz (coef.): Sac/Val; Gandjour and Ostwald 2018 [32] (DE): TE of sac/val on death, HR; Zaca 2018 [50] (IT): TE of sac/val on death vs ICD, HR; Ademi et al. 2017 [25] (CH): All-cause mortality (coef.): sac/val; van der Pol et al. 2017 [21] (NL): TE of sac/val on death, RR; Gaziano et al. 2016 [18] (US): TE of sac/val on death, HR; NICE (HTA), 2016 [17] (UK): All-cause mortality; SMC (HTA), 2016 [59] (SC): All-cause mortality"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What base-case scenarios are considered in these studies?,"Borges et al. 2020 [26] (PT): Coefficient of constant: âˆ’12.665; Chin et al. 2020 [27] (AU): Incidence of CV death, enalapril: â€“; McMurray et al. 2018 [41] (DK): Coefficient of CV mortality: Age2: 0.001; Lacey et al. 2018 [38] (CR): Coefficient of constant: âˆ’12.665; McMurray et al. 2018 [41] (CO): Coefficient of constant: âˆ’12.665; Lacey et al. 2018 [39] (BR): Coefficient of constant: âˆ’12.665; Liang et al. 2018 [19] (SG): CV mortality, HR: 0.80; Krittyaphong et al. 2018 [36] (TH): CV mortality risk (from non-hospitalization), enalapril: 0.0168; Dâ€™Angiolella et al. 2017 [29] (IT): TE of sac/val on CV mortality: â€“; Ramos et al. 2017 [43] (NL): Coefficient of CV mortality: Age2: 0.001; King et al. 2016 [35] (US): Risk of CV mortality, sac/val: â€“; van der Pol et al. 2019 [48] (DE): TE of sac/val on death, RR: 0.84; Zueger et al. 2018 [52] (US): TE of sac/val on death, RR: 0.84; McMurray et al. 2018 [41] (UK): All-cause mortality- Gompertz (coef.): Sac/Val: âˆ’0.161; Gandjour and Ostwald 2018 [32] (DE): TE of sac/val on death, HR: 0.84; Zaca 2018 [50] (IT): TE of sac/val on death vs ICD, HR: 1.02; Ademi et al. 2017 [25] (CH): All-cause mortality (coef.): sac/val: âˆ’0.161; van der Pol et al. 2017 [21] (NL): TE of sac/val on death, RR: 0.84; Gaziano et al. 2016 [18] (US): TE of sac/val on death, HR: 0.84"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What one-way sensitivity analyses are conducted in these studies?,"Borges et al. 2020 [26] (PT): Coefficient of constant; Chin et al. 2020 [27] (AU): Incidence of CV death, enalapril; McMurray et al. 2018 [41] (DK): Coefficient of CV mortality: Age2; Lacey et al. 2018 [38] (CR): Coefficient of constant; McMurray et al. 2018 [41] (CO): Coefficient of constant; Lacey et al. 2018 [39] (BR): Coefficient of constant; Liang et al. 2018 [19] (SG): CV mortality, HR; Krittyaphong et al. 2018 [36] (TH): CV mortality risk (from non-hospitalization), enalapril; Dâ€™Angiolella et al. 2017 [29] (IT): TE of sac/val on CV mortality; Ramos et al. 2017 [43] (NL): Coefficient of CV mortality: Age2; King et al. 2016 [35] (US): Risk of CV mortality, sac/val; van der Pol et al. 2019 [48] (DE): TE of sac/val on death, RR; Zueger et al. 2018 [52] (US): TE of sac/val on death, RR; McMurray et al. 2018 [41] (UK): All-cause mortality- Gompertz (coef.): Sac/Val; Gandjour and Ostwald 2018 [32] (DE): TE of sac/val on death, HR; Zaca 2018 [50] (IT): TE of sac/val on death vs ICD, HR; Ademi et al. 2017 [25] (CH): All-cause mortality (coef.): sac/val; van der Pol et al. 2017 [21] (NL): TE of sac/val on death, RR; Gaziano et al. 2016 [18] (US): TE of sac/val on death, HR"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What values are reported in these studies?,"Borges et al. 2020 [26] (PT): Coefficient of constant, Base-case: âˆ’12.665, One-way sensitivity analysis: Value: âˆ’13.935 to âˆ’11.396, ICER/QALY: â‚¬14,570 to â‚¬36,059; Chin et al. 2020 [27] (AU): Incidence of CV death, enalapril, One-way sensitivity analysis: ICER/QALY: AU$31,461 to AU$76,100; McMurray et al. 2018 [41] (DK): Coefficient of CV mortality: Age2, Base-case: 0.001, One-way sensitivity analysis: Value: 0.000 to 0.001, ICER/QALY: Kr116,122 to Kr285,710; Lacey et al. 2018 [38] (CR): Coefficient of constant, Base-case: âˆ’12.665, One-way sensitivity analysis: Value: âˆ’13.934 to âˆ’11.395, ICER/QALY: â‚¡5,068,070 to â‚¡8,581,518; McMurray et al. 2018 [41] (CO): Coefficient of constant, Base-case: âˆ’12.665, One-way sensitivity analysis: Value: âˆ’13.934 to âˆ’11.395, ICER/QALY: COP$24.1 Mn to COP$55.0 Mn; Lacey et al. 2018 [39] (BR): Coefficient of constant, Base-case: âˆ’12.665, One-way sensitivity analysis: Value: âˆ’13.934 to âˆ’11.395, ICER/QALY: BRL19,833 to BRL47,674; Liang et al. 2018 [19] (SG): CV mortality, HR, Base-case: 0.80, One-way sensitivity analysis: Value: 0.62 to 1.00, ICER/QALY: SG$41,019 to SG$1,447,103; Krittyaphong et al. 2018 [36] (TH): CV mortality risk (from non-hospitalization), enalapril, Base-case: 0.0168, One-way sensitivity analysis: Value: 0.0150 to 0.0188, ICER/QALY: THB120,290 to THB290,000; Dâ€™Angiolella et al. 2017 [29] (IT): TE of sac/val on CV mortality, One-way sensitivity analysis: ICER/QALY: â‚¬19,487; Ramos et al. 2017 [43] (NL): Coefficient of CV mortality: Age2, Base-case: 0.001, One-way sensitivity analysis: Value: 0.000 to 0.001, ICER/QALY: â‚¬13,375 to â‚¬33,393; King et al. 2016 [35] (US): Risk of CV mortality, sac/val, One-way sensitivity analysis: ICER/QALY: US$23,657 to Dominated; van der Pol et al. 2019 [48] (DE): TE of sac/val on death, RR, Base-case: 0.84, One-way sensitivity analysis: Value: 0.76 to 0.93, ICER/QALY: â‚¬11,000 to â‚¬135,000"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What ICER/QALY values are calculated in these studies?,"Borges et al. 2020 [26] (PT): â‚¬22,702; Chin et al. 2020 [27] (AU): AU$40,513; McMurray et al. 2018 [41] (DK): Kr174,000; Lacey et al. 2018 [38] (CR): â‚¡6,108,752; McMurray et al. 2018 [41] (CO): COP$39.5 Mn; Lacey et al. 2018 [39] (BR): BRL28,154; Liang et al. 2018 [19] (SG): SG$74,592; Krittyaphong et al. 2018 [36] (TH): THB162,276; Dâ€™Angiolella et al. 2017 [29] (IT): â‚¬19,487; Ramos et al. 2017 [43] (NL): â‚¬17,600; King et al. 2016 [35] (US): US$50,959; PBAC (HTA), 2016 [60] (AU): <â€‰AU$45,000; van der Pol et al. 2019 [48] (DE): â‚¬19,300; Zueger et al. 2018 [52] (US): US$143,891; McMurray et al. 2018 [41] (UK): Â£17,200; Gandjour and Ostwald 2018 [32] (DE): â‚¬26,278; Zaca 2018 [50] (IT): â€“â‚¬98,500; Ademi et al. 2017 [25] (CH): ; van der Pol et al. 2017 [21] (NL): â‚¬19,113; Gaziano et al. 2016 [18] (US): US$45,017; NICE (HTA), 2016 [17] (UK): Â£17,939; SMC (HTA), 2016 [59] (SC): Â£18,348"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What specific values are analyzed in these studies?,"Borges et al. 2020 [26] (PT): Coefficient of constant; Chin et al. 2020 [27] (AU): Incidence of CV death, enalapril; McMurray et al. 2018 [41] (DK): Coefficient of CV mortality: Age2; Lacey et al. 2018 [38] (CR): Coefficient of constant; McMurray et al. 2018 [41] (CO): Coefficient of constant; Lacey et al. 2018 [39] (BR): Coefficient of constant; Liang et al. 2018 [19] (SG): CV mortality, HR; Krittyaphong et al. 2018 [36] (TH): CV mortality risk (from non-hospitalization), enalapril; Dâ€™Angiolella et al. 2017 [29] (IT): TE of sac/val on CV mortality; Ramos et al. 2017 [43] (NL): Coefficient of CV mortality: Age2; King et al. 2016 [35] (US): Risk of CV mortality, sac/val; van der Pol et al. 2019 [48] (DE): TE of sac/val on death, RR; Zueger et al. 2018 [52] (US): TE of sac/val on death, RR; McMurray et al. 2018 [41] (UK): All-cause mortality- Gompertz (coef.): Sac/Val; Gandjour and Ostwald 2018 [32] (DE): TE of sac/val on death, HR; Zaca 2018 [50] (IT): TE of sac/val on death vs ICD, HR; Ademi et al. 2017 [25] (CH): All-cause mortality (coef.): sac/val; van der Pol et al. 2017 [21] (NL): TE of sac/val on death, RR; Gaziano et al. 2016 [18] (US): TE of sac/val on death, HR"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the ICER/QALY results in these studies?,"Borges et al. 2020 [26] (PT): â‚¬22,702; Chin et al. 2020 [27] (AU): AU$40,513; McMurray et al. 2018 [41] (DK): Kr174,000; Lacey et al. 2018 [38] (CR): â‚¡6,108,752; McMurray et al. 2018 [41] (CO): COP$39.5 Mn; Lacey et al. 2018 [39] (BR): BRL28,154; Liang et al. 2018 [19] (SG): SG$74,592; Krittyaphong et al. 2018 [36] (TH): THB162,276; Dâ€™Angiolella et al. 2017 [29] (IT): â‚¬19,487; Ramos et al. 2017 [43] (NL): â‚¬17,600; King et al. 2016 [35] (US): US$50,959; PBAC (HTA), 2016 [60] (AU): <â€‰AU$45,000; van der Pol et al. 2019 [48] (DE): â‚¬19,300; Zueger et al. 2018 [52] (US): US$143,891; McMurray et al. 2018 [41] (UK): Â£17,200; Gandjour and Ostwald 2018 [32] (DE): â‚¬26,278; Zaca 2018 [50] (IT): â€“â‚¬98,500; Ademi et al. 2017 [25] (CH): ; van der Pol et al. 2017 [21] (NL): â‚¬19,113; Gaziano et al. 2016 [18] (US): US$45,017; NICE (HTA), 2016 [17] (UK): Â£17,939; SMC (HTA), 2016 [59] (SC): Â£18,348"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the lower 95% confidence intervals reported in these studies?,"Borges et al. 2020 [26] (PT): -13.935; Chin et al. 2020 [27] (AU): â€“; McMurray et al. 2018 [41] (DK): 0.000; Lacey et al. 2018 [38] (CR): -13.934; McMurray et al. 2018 [41] (CO): -13.934; Lacey et al. 2018 [39] (BR): -13.934; Liang et al. 2018 [19] (SG): 0.62; Lee et al. 2018 [40] (SG): â€“; Krittyaphong et al. 2018 [36] (TH): 0.0150; Dâ€™Angiolella et al. 2017 [29] (IT): â€“; Ramos et al. 2017 [43] (NL): 0.000; Fann et al. 2017 [31] (TW): â€“; King et al. 2016 [35] (US): â€“; PBAC (HTA), 2016 [60] (AU): â€“; van der Pol et al. 2019 [48] (DE): 0.76; Zueger et al. 2018 [52] (US): 0.76; McMurray et al. 2018 [41] (UK): -0.261; Gandjour and Ostwald 2018 [32] (DE): 0.74; Zaca 2018 [50] (IT): 0.82; Ademi et al. 2017 [25] (CH): -0.061; van der Pol et al. 2017 [21] (NL): 0.76; Gaziano et al. 2016 [18] (US): 0.76; NICE (HTA), 2016 [17] (UK): â€“; SMC (HTA), 2016 [59] (SC): â€“"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What are the upper 95% confidence intervals reported in these studies?,"Borges et al. 2020 [26] (PT): â‚¬36,059; Chin et al. 2020 [27] (AU): AU$76,100; McMurray et al. 2018 [41] (DK): Kr285,710; Lacey et al. 2018 [38] (CR): â‚¡8,581,518; McMurray et al. 2018 [41] (CO): COP$55.0 Mn; Lacey et al. 2018 [39] (BR): BRL47,674; Liang et al. 2018 [19] (SG): SG$1,447,103; Krittyaphong et al. 2018 [36] (TH): THB290,000; Ramos et al. 2017 [43] (NL): â‚¬33,393; King et al. 2016 [35] (US): Dominated; van der Pol et al. 2019 [48] (DE): â‚¬135,000; Zueger et al. 2018 [52] (US): US$225,000; McMurray et al. 2018 [41] (UK): Â£26,500; Gandjour and Ostwald 2018 [32] (DE): â‚¬38,466; Zaca 2018 [50] (IT): â‚¬55,000; Ademi et al. 2017 [25] (CH): CHF38,104; van der Pol et al. 2017 [21] (NL): â‚¬45,000; Gaziano et al. 2016 [18] (US): US$75,301; SMC (HTA), 2016 [59] (SC): Â£34,000"
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What lower 95% confidence intervals are calculated in these studies?,Borges et al. 2020 [26] (PT): -13.935; McMurray et al. 2018 [41] (DK): 0.000; Lacey et al. 2018 [38] (CR): -13.934; McMurray et al. 2018 [41] (CO): -13.934; Lacey et al. 2018 [39] (BR): -13.934; Liang et al. 2018 [19] (SG): 0.62; Krittyaphong et al. 2018 [36] (TH): 0.0150; Ramos et al. 2017 [43] (NL): 0.000; van der Pol et al. 2019 [48] (DE): 0.76; Zueger et al. 2018 [52] (US): 0.76; McMurray et al. 2018 [41] (UK): -0.261; Gandjour and Ostwald 2018 [32] (DE): 0.74; Zaca 2018 [50] (IT): 0.82; Ademi et al. 2017 [25] (CH): -0.061; van der Pol et al. 2017 [21] (NL): 0.76; Gaziano et al. 2016 [18] (US): 0.76
10060315_Table_1,"Borges et al. 2020 [26]: PT; Chin et al. 2020 [27]: AU; McMurray et al. 2018 [41]: DK; Lacey et al. 2018 [38]: CR; McMurray et al. 2018 [41]: CO; Lacey et al. 2018 [39]: BR; Liang et al. 2018 [19]: SG; Lee et al. 2018 [40]: SG; Krittyaphong et al. 2018 [36]: TH; Dâ€™Angiolella et al. 2017 [29]: IT; Ramos et al. 2017 [43]: NL; Fann et al. 2017 [31]: TW; King et al. 2016 [35]: US; PBAC (HTA), 2016 [60]: AU; van der Pol et al. 2019 [48]: DE; Zueger et al. 2018 [52]: US; McMurray et al. 2018 [41]: UK; Gandjour and Ostwald 2018 [32]: DE; Zaca 2018 [50]: IT; Ademi et al. 2017 [25]: CH; van der Pol et al. 2017 [21]: NL; Gaziano et al. 2016 [18]: US; NICE (HTA), 2016 [17]: UK; SMC (HTA), 2016 [59]: SC",What upper 95% confidence intervals are calculated in these studies?,"Borges et al. 2020 [26] (PT): â‚¬36,059; Chin et al. 2020 [27] (AU): AU$76,100; McMurray et al. 2018 [41] (DK): Kr285,710; Lacey et al. 2018 [38] (CR): â‚¡8,581,518; McMurray et al. 2018 [41] (CO): COP$55.0 Mn; Lacey et al. 2018 [39] (BR): BRL47,674; Liang et al. 2018 [19] (SG): SG$1,447,103; Krittyaphong et al. 2018 [36] (TH): THB290,000; Ramos et al. 2017 [43] (NL): â‚¬33,393; King et al. 2016 [35] (US): Dominated; van der Pol et al. 2019 [48] (DE): â‚¬135,000; Zueger et al. 2018 [52] (US): US$225,000; McMurray et al. 2018 [41] (UK): Â£26,500; Gandjour and Ostwald 2018 [32] (DE): â‚¬38,466; Zaca 2018 [50] (IT): â‚¬55,000; Ademi et al. 2017 [25] (CH): CHF38,104; van der Pol et al. 2017 [21] (NL): â‚¬45,000; Gaziano et al. 2016 [18] (US): US$75,301; SMC (HTA), 2016 [59] (SC): Â£34,000"
6262601_Table_2.,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2015,What are the citations for these studies?,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2015
6262601_Table_2.,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2016,In which years were these studies published?,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2015
6262601_Table_2.,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2017,Which countries are covered in these studies?,"Dranitsaris et al.7: Canada; Dranitsaris et al.27: Netherlands; Dranitsaris et al.28: France, Austria; Dranitsaris et al.26: Canada"
6262601_Table_2.,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2018,What are the costs per VTE avoided in these studies?,"Dranitsaris et al.7: $Can27,700; Dranitsaris et al.27: â‚¬8,400; Dranitsaris et al.28 (France): â‚¬11,800; Dranitsaris et al.28 (Austria): â‚¬8,700; Dranitsaris et al.26: $Can41,200"
6262601_Table_2.,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2019,Do these studies include a renal subgroup?,Dranitsaris et al.7: No; Dranitsaris et al.27: Yes; Dranitsaris et al.28: Yes; Dranitsaris et al.26: Yes
6262601_Table_2.,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2020,What are the costs per QALY gained in these studies?,"Dranitsaris et al.7: $Can13,800; Dranitsaris et al.27: â‚¬4,700; Dranitsaris et al.28 (France): â‚¬6,600; Dranitsaris et al.28 (Austria): â‚¬4,900; Dranitsaris et al.26: $Can23,100"
6262601_Table_2.,Dranitsaris et al.7: 2005; Dranitsaris et al.27: 2015; Dranitsaris et al.28: 2015; Dranitsaris et al.26: 2021,Do these studies include a renal subgroup?,Dranitsaris et al.7: No; Dranitsaris et al.27: Yes; Dranitsaris et al.28: Yes; Dranitsaris et al.26: Yes
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2019,What are the references for these studies?,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2019
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2020,In which years were these studies published?,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2019
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2021,Which countries are covered in these studies?,"Hiligsmann et al. [27]: France; Ethgen et al. [21]: Belgium; Silverman et al. [25]: USA; Hiligsmann et al. [28]: Belgium; Parthan et al. [26]: Sweden; Hiligsmann et al. [40]: Belgium; Kouta et al. [23]: USA; Kreck et al. [18]: Germany; Schousboe et al. [22]: USA; Van Staa et al. [20]: UK; Borgstrom et al. [24]: Sweden; Fleurence et al. [39]: UK; Chan et al. [29]: Taiwan, China; Makras et al. [30]: Greece; Lippuner et al. [32]: Switzerland; Tosteson et al. [31]: USA; Kanis et al. [33]: Sweden; Ito et al.[17]: USA"
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2022,What populations are examined in these studies?,"Hiligsmann et al. [27]: General population (women and men) aged 60 years and older; Ethgen et al. [21]: General population, patients (women and men) with osteoporosis and a PVF or hip fracture aged 50 years and older; Silverman et al. [25]: Men aged 75 years and older with osteoporosis; Hiligsmann et al. [28]: Patients (women and men) aged 60 years and older with osteoporosis; Parthan et al. [26]: Men aged 75 years and older with osteoporosis; Hiligsmann et al. [40]: Men aged 65â€“90 years with BMD T-score â‰¤âˆ’2.5 or PVF; Kouta et al. [23]: Men aged 70 years with locally advanced or high-risk localized prostate cancer starting a 2-year course of ADT after radiation therapy; Kreck et al. [18]: Patients (women and men) with osteopenia or osteoporosis due to inflammatory bowel disease; Schousboe et al. [22]: White men aged 65 years and older with osteoporosis; Van Staa et al. [20]: Patients (women and men) aged 40 years and older who were prescribed an oral GC and who were registered in the GPRD; Borgstrom et al. [24]: Men aged 55â€“80 years with low bone mass and radiographically identified CV; Fleurence et al. [39]: Patients (women and men) aged 70 years and older who were at high risk and general risk of fracture; Chan et al. [29]: Patients (women and men) aged 50 years and older at different probabilities of MOF and hip fracture; Makras et al. [30]: Patients (women and men) aged 50 years and older at different probabilities of MOF and hip fracture; Lippuner et al. [32]: Patients (women and men) aged 50 years and older at different probabilities for a MOF; Tosteson et al. [31]: Patients (women and men) aged 50 years and older at different probabilities for a hip fracture; Kanis et al. [33]: Patients (women and men) aged 50 years and older at different probabilities for a hip fracture; Ito et al.[17]: Community-dwelling men aged 65 years who had fallen at least once in the past year"
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2023,What perspectives are used in these studies?,Hiligsmann et al. [27]: Healthcare; Ethgen et al. [21]: Healthcare; Silverman et al. [25]: Healthcare; Hiligsmann et al. [28]: Healthcare; Parthan et al. [26]: Healthcare; Hiligsmann et al. [40]: Healthcare; Kouta et al. [23]: Societal; Kreck et al. [18]: Societal; Schousboe et al. [22]: Societal; Van Staa et al. [20]: Healthcare; Borgstrom et al. [24]: Societal and healthcare; Fleurence et al. [39]: Healthcare; Chan et al. [29]: Healthcare; Makras et al. [30]: Healthcare; Lippuner et al. [32]: Healthcare; Tosteson et al. [31]: Healthcare; Kanis et al. [33]: Healthcare and societal; Ito et al.[17]: Societal; Pisu et al. [16]: Societal
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2024,What types of models are employed in these studies?,Hiligsmann et al. [27]: Markov microsimulation; Ethgen et al. [21]: Markov microsimulation; Silverman et al. [25]: Markov cohort; Hiligsmann et al. [28]: Markov microsimulation; Parthan et al. [26]: Markov cohort; Hiligsmann et al. [40]: Markov microsimulation; Kouta et al. [23]: Markov cohort; Kreck et al. [18]: Markov cohort; Schousboe et al. [22]: Markov microsimulation; Van Staa et al. [20]: Markov microsimulation; Borgstrom et al. [24]: Markov cohort; Fleurence et al. [39]: Markov cohort; Chan et al. [29]: Markov cohort; Makras et al. [30]: Markov cohort; Lippuner et al. [32]: Markov cohort; Tosteson et al. [31]: Markov cohort; Kanis et al. [33]: Markov cohort; Ito et al.[17]: Markov cohort
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2025,What outcome measures are used in these studies?,Hiligsmann et al. [27]: QALY; Ethgen et al. [21]: LY; Silverman et al. [25]: QALY; Hiligsmann et al. [28]: QALY; Parthan et al. [26]: QALY; Hiligsmann et al. [40]: QALY; Kouta et al. [23]: QALY; Kreck et al. [18]: QALY; Schousboe et al. [22]: QALY; Van Staa et al. [20]: QALY; Borgstrom et al. [24]: QALY; Fleurence et al. [39]: QALY; Chan et al. [29]: QALY; Makras et al. [30]: QALY; Lippuner et al. [32]: QALY; Tosteson et al. [31]: QALY; Kanis et al. [33]: QALY; Ito et al.[17]: QALY
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2026,What time horizons are considered in these studies?,Hiligsmann et al. [27]: Lifetime; Ethgen et al. [21]: Lifetime; Silverman et al. [25]: Lifetime; Hiligsmann et al. [28]: Lifetime; Parthan et al. [26]: Lifetime; Hiligsmann et al. [40]: Lifetime; Kouta et al. [23]: Lifetime; Kreck et al. [18]: 10 years; Schousboe et al. [22]: Lifetime; Van Staa et al. [20]: 6 years; Borgstrom et al. [24]: Lifetime; Fleurence et al. [39]: Lifetime; Chan et al. [29]: NR; Makras et al. [30]: Lifetime; Lippuner et al. [32]: Lifetime; Tosteson et al. [31]: Lifetime; Kanis et al. [33]: Lifetime; Ito et al.[17]: Lifetime; Pisu et al. [16]: NR
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2027,What types of costs are analyzed in these studies?,Hiligsmann et al. [27]: Direct costs; Ethgen et al. [21]: Direct costs; Silverman et al. [25]: Direct costs; Hiligsmann et al. [28]: Direct costs; Parthan et al. [26]: Direct costs; Hiligsmann et al. [40]: Direct costs; Kouta et al. [23]: Direct costs; Kreck et al. [18]: Direct and indirect costs; Schousboe et al. [22]: Direct and indirect costs; Van Staa et al. [20]: Direct costs; Borgstrom et al. [24]: Direct and indirect costs; Fleurence et al. [39]: Direct costs; Chan et al. [29]: Direct costs; Makras et al. [30]: Direct costs; Lippuner et al. [32]: Direct costs; Tosteson et al. [31]: Direct costs; Kanis et al. [33]: Direct costs; Ito et al.[17]: Direct cost
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2028,What discount rates for costs and QALYs are applied in these studies?,"Hiligsmann et al. [27]: 3%, 3%; Ethgen et al. [21]: 3%, 1.5%; Silverman et al. [25]: 3%, 3%; Hiligsmann et al. [28]: 3%, 1.5%; Parthan et al. [26]: 3%, 3%; Hiligsmann et al. [40]: 3%, 1.5%; Kouta et al. [23]: 3%, 3%; Kreck et al. [18]: 5%, 5%; Schousboe et al. [22]: 3%, 3%; Van Staa et al. [20]: 6%, 1.5%; Borgstrom et al. [24]: 3%, 3%; Fleurence et al. [39]: 6%, 6%; Chan et al. [29]: 1.36%, 1.36%; Makras et al. [30]: NR; Lippuner et al. [32]: 3%, 3%; Tosteson et al. [31]: 3%, 3%; Kanis et al. [33]: 3%, 3%; Ito et al.[17]: 3%, 3%"
10020287_Table_1,Hiligsmann et al. [27]: 2017; Ethgen et al. [21]: 2015; Silverman et al. [25]: 2015; Hiligsmann et al. [28]: 2014; Parthan et al. [26]: 2014; Hiligsmann et al. [40]: 2013; Kouta et al. [23]: 2010; Kreck et al. [18]: 2008; Schousboe et al. [22]: 2007; Van Staa et al. [20]: 2007; Borgstrom et al. [24]: 2004; Fleurence et al. [39]: 2004; Chan et al. [29]: 2017; Makras et al. [30]: 2015; Lippuner et al. [32]: 2012; Tosteson et al. [31]: 2008; Kanis et al. [33]: 2005; Ito et al.[17]: 2020; Pisu et al. [16]: 2029,What are the funding sources for these studies?,"Hiligsmann et al. [27]: CNIEL; Ethgen et al. [21]: None; Silverman et al. [25]: Amgen Inc.; Hiligsmann et al. [28]: SMB Belgium; Parthan et al. [26]: NR; Hiligsmann et al. [40]: Servier; Kouta et al. [23]: None; Kreck et al. [18]: German Federal Ministry of Education and Research; Schousboe et al. [22]: National Institutes of Health funding; Van Staa et al. [20]: None; Borgstrom et al. [24]: Merck and Co., Inc.; Fleurence et al. [39]: Eli Lilly and UK MedicalResearch Council; Chan et al. [29]: Grant DOH102-TD-M-113-102006; Makras et al. [30]: NR; Lippuner et al. [32]: MSD Switzerland AG; Tosteson et al. [31]: National OsteoporosisFoundation and NationalInstitutes of Health; Kanis et al. [33]: IOF, Pfizer, Alliance for Better Bone Health, IGEA,Lilly Research Centre, Hologic, Novartis, Wyet, and Roche; Ito et al.[17]: NR; Pisu et al. [16]: NR"
11366214_T1,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52,Who are the authors of these studies?,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52
11366214_T1,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52,In which years were these studies conducted?,Carlson et al33: 2011; Bayle et al44: 2013; Bajaj et al30: 2014; Kalluri et al41: 2015; Hess et al37: 2016; Thongprasert et al48: 2017; Goldstein et al35: 2017; Aguiar et al49: 2017; Norum et al47: 2017; Bly et al31: 2018; Graham et al36: 2018; Signorovitch et al38: 2019; Westerink et al45: 2020; Monirul et al53: 2020; Cheng et al46: 2020; Stargardter et al39: 2021; Rachev et al43: 2021; Patel et al42: 2021; Cai et al32: 2021; Abraham et al29: 2022; Duff et al34: 2022; Matsuda et al50: 2023; Silas et al40: 2023; Tang et al51: 2023; Tsai et al52: 2023
11366214_T1,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52,Which countries are covered in these studies?,"Carlson et al33: US; Bayle et al44: France; Bajaj et al30: US; Kalluri et al41: Canada; Hess et al37: US; Thongprasert et al48: Thailand; Goldstein et al35: US; Aguiar et al49: Brazil, Argentina, Peru; Norum et al47: Norway; Bly et al31: US; Graham et al36: US; Signorovitch et al38: US; Westerink et al45: The Netherlands; Monirul et al53: France; Cheng et al46: Greece; Stargardter et al39: US; Rachev et al43: Belgium, Slovenia, Austria, Italy; Patel et al42: Canada; Cai et al32: US; Abraham et al29: US; Duff et al34: US; Matsuda et al50: Japan; Silas et al40: US; Tang et al51: Japan; Tsai et al52: Taiwan"
11366214_T1,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52,What interventions are evaluated in these studies?,"Carlson et al33: Erlotinib; Bayle et al44: Fixed-dose nivolumab and pembrolizumab; Bajaj et al30: Erlotinib; Kalluri et al41: Rapid on-site evaluation; Hess et al37: Ramucirumab + docetaxel; Thongprasert et al48: Crizotinib; Goldstein et al35: Pembrolizumab (personalized dosing); Aguiar et al49: Pembrolizumab; Norum et al47: Pembrolizumab; Bly et al31: Necitumumab+gemcitabine+cisplatin; Graham et al36: Afatinib; Signorovitch et al38: Comprehensive genomic profiling; Westerink et al45: Afatinib; Monirul et al53: Nivolumab and pembrolizumab (fixed dose); Cheng et al46: (1) Plasma test, (2) combined testing (tissue and plasma test), (3) reflex testing; Stargardter et al39: Tepotinib; Rachev et al43: Anti-PD-1/PD-L1; Patel et al42: Comprehensive genomic profiling; Cai et al32: Capmatinib; Abraham et al29: Trilaciclib; Duff et al34: Pralsetinib; Matsuda et al50: Next-generation sequencing; Silas et al40: Next-generation sequencing (75% in house and 25% external); Tang et al51: Comprehensive genomic profiling; Tsai et al52: Comprehensive genomic profiling"
11366214_T1,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52,What comparators are used in these studies?,"Carlson et al33: SoC; Bayle et al44: Flexible-dose nivolumab and pembrolizumab; Bajaj et al30: Chemotherapy; Kalluri et al41: SoC; Hess et al37: SoC; Thongprasert et al48: SoC; Goldstein et al35: Pembrolizumab (fixed dosing); Aguiar et al49: SoC; Norum et al47: Docetaxel and pemetrexed; Bly et al31: SoC; Graham et al36: gefitinib; Signorovitch et al38: SoC; Westerink et al45: Osimertinib; Monirul et al53: Nivolumab and pembrolizumab (flexible dose); Cheng et al46: Tissue biopsy only; Stargardter et al39: Capmatinib, crizotinib, and SoC; Rachev et al43: SoC; Patel et al42: SoC; Cai et al32: SoC; Abraham et al29: SoC; Duff et al34: Selpercatinib, cabozantinib, pembrolizumab, and pemetrexed/carboplatin combination therapy; Matsuda et al50: Single-gene testing; Silas et al40: Next-generation sequencing (100% external); Tang et al51: SoC; Tsai et al52: Single-gene testing"
11366214_T1,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52,What are the time horizons in years for these studies?,Carlson et al33: 1; Bayle et al44: 1; Bajaj et al30: 1; Kalluri et al41: 1; Hess et al37: 1; Thongprasert et al48: 3; Goldstein et al35: 1; Aguiar et al49: 5; Norum et al47: 1; Bly et al31: 3; Graham et al36: 5; Signorovitch et al38: 1; Westerink et al45: 5; Monirul et al53: 1; Cheng et al46: 1; Stargardter et al39: 3; Rachev et al43: 5; Patel et al42: 3; Cai et al32: 3; Abraham et al29: 5; Duff et al34: 3; Matsuda et al50: 3; Silas et al40: 5; Tang et al51: 1; Tsai et al52: 5
11366214_T1,Carlson et al33: Carlson et al33; Bayle et al44: Bayle et al44; Bajaj et al30: Bajaj et al30; Kalluri et al41: Kalluri et al41; Hess et al37: Hess et al37; Thongprasert et al48: Thongprasert et al48; Goldstein et al35: Goldstein et al35; Aguiar et al49: Aguiar et al49; Norum et al47: Norum et al47; Bly et al31: Bly et al31; Graham et al36: Graham et al36; Signorovitch et al38: Signorovitch et al38; Westerink et al45: Westerink et al45; Monirul et al53: Monirul et al53; Cheng et al46: Cheng et al46; Stargardter et al39: Stargardter et al39; Rachev et al43: Rachev et al43; Patel et al42: Patel et al42; Cai et al32: Cai et al32; Abraham et al29: Abraham et al29; Duff et al34: Duff et al34; Matsuda et al50: Matsuda et al50; Silas et al40: Silas et al40; Tang et al51: Tang et al51; Tsai et al52: Tsai et al52,What perspectives are used in these studies?,"Carlson et al33: Commercial payer; Bayle et al44: Single payer; Bajaj et al30: Commercial payer; Kalluri et al41: Hospital diagnostic unit perspective (University of Alberta Hospital); Hess et al37: Commercial payer, Medicare, hospital; Thongprasert et al48: Single payer; Goldstein et al35: Societal perspective; Aguiar et al49: Single payer; Norum et al47: Single payer; Bly et al31: Commercial payer, Medicare; Graham et al36: Commercial payer; Signorovitch et al38: Commercial payer; Westerink et al45: Single payer; Monirul et al53: Single payer; Cheng et al46: Single payer; Stargardter et al39: Commercial payer; Rachev et al43: Single payer; Patel et al42: Single payer; Cai et al32: Commercial payer; Abraham et al29: Commercial payer; Duff et al34: Commercial payer; Matsuda et al50: Single payer; Silas et al40: Hospital perspective; Tang et al51: Single payer; Tsai et al52: Single payer"
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23,What references are cited in these studies?,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 24,What model structures are used in these studies?,Wehler et al. (27): Cost calculation based on IQVIA CDM; Gout-Zwart et al. (19): Cost calculation based on a decision tree model; Laranjeira et al. (21): Cost calculation; Catic et al. (15): Cost calculation; Marga et al. (18): Cost calculation; Elsisi et al. (17): Cost calculation; Deerochanawong et al. (16): International T2DM budget impact model; Stefano et al. (14): Cost calculation; Lane et al. (20): Cost calculation
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 25,What time horizons are considered in these studies?,Wehler et al. (27): 5 years; Gout-Zwart et al. (19): 3 years; Laranjeira et al. (21): 5 years; Catic et al. (15): 3 years; Marga et al. (18): 4 years; Elsisi et al. (17): 3 years; Deerochanawong et al. (16): 3 years; Stefano et al. (14): 3 years; Lane et al. (20): 1 year
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 26,What discounted rates are applied in these studies?,Wehler et al. (27): No; Gout-Zwart et al. (19): No; Laranjeira et al. (21): No; Catic et al. (15): No; Marga et al. (18): No; Elsisi et al. (17): No; Deerochanawong et al. (16): 3.00%; Stefano et al. (14): NR; Lane et al. (20): No
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 27,What treatment strategies are compared in these studies between intervention 1 and intervention 2?,Wehler et al. (27): Oral semaglutide 14 mg vs. Oral sitagliptin 100 mg; Gout-Zwart et al. (19): Metformin SR vs. metformin IR; Laranjeira et al. (21): Long-acting insulin analogs vs. NPH insulin; Catic et al. (15): With vs. without linagliptin; Marga et al. (18): CSII vs. MII; Elsisi et al. (17): Dapagliflozin vs. standard of care; Deerochanawong et al. (16): BIAsp 30 vs. BHI 30; Stefano et al. (14): Increase vs. current use of liraglutide; Lane et al. (20): Insulin degludec vs. Insulin glargine U100
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 28,What is the uptake of the new intervention in these studies?,"Wehler et al. (27): 14, 25, 50, 75, and 100%; Gout-Zwart et al. (19): 100%; Laranjeira et al. (21): 20, 25, 30, 35, and 40%; Catic et al. (15): 2, 3, and 5%; Marga et al. (18): 100%; Elsisi et al. (17): 5, 10, and 15%; Deerochanawong et al. (16): 1.24, 2.48, and 3.72%; Stefano et al. (14): increase: 16, 17, 18% current: 14.52, 13.62, and 13.20%; Lane et al. (20): 100%"
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 29,What market shares are reported for the new intervention in these studies?,"Wehler et al. (27): 14, 25, 50, 75, and 100%; Gout-Zwart et al. (19): 100%; Laranjeira et al. (21): 20, 25, 30, 35, and 40%; Catic et al. (15): 2, 3, and 5%; Marga et al. (18): 100%; Elsisi et al. (17): 5, 10, and 15%; Deerochanawong et al. (16): 1.24, 2.48, and 3.72%; Stefano et al. (14): increase: 16, 17, 18% current: 14.52, 13.62, and 13.20%; Lane et al. (20): 100%"
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 30,What scopes of cost are considered in these studies?,"Wehler et al.: Cost of drug, hypoglycemia and complications; Gout-Zwart et al.: Direct cost, including acquisition cost and condition-related cost; Laranjeira et al.: Cost of insulin; Catic et al.: Cost of drug; Marga et al.: Treatment cost (insulin + insulin pump) and cost of hypoglycemic; Elsisi et al.: Cost of drug and complications; Deerochanawong et al.: Cost of insulin, hypoglycemia and complications; Stefano et al.: Treatment cost (drug and needle); Lane et al.: Cost of insulin and hypoglycemia"
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 31,What price discounts of the drug are analyzed in these studies?,"Wehler et al.: Base case: 35.1% discount for semaglutide, 72.6% discount for sitagliptin; Sensitivity analyses: 40%, 50% and 60% reduction in the WAC cost for oral semaglutide; Gout-Zwart et al.: NR; Laranjeira et al.: Long-acting insulin analog: 62.5% of the regulated price; Catic et al.: No; Marga et al.: Sensitivity analysis: âˆ’10% monthly cost of the pump kit; Elsisi et al.: Sensitivity analysis: Â± 25% of drug cost; Deerochanawong et al.: NR; Stefano et al.: Ex-factory prices were used including discounted prices; Lane et al.: Rebate scenario analysis"
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 32,What sensitivity analyses are conducted in these studies?,Wehler et al.: one-way; Gout-Zwart et al.: one-way; Laranjeira et al.: one-way and multivariate; Catic et al.: No; Marga et al.: one-way; Elsisi et al.: one-way; Deerochanawong et al.: one-way; Stefano et al.: No; Lane et al.: No
8639520_Table_2,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 33,What incremental budget impact values are calculated between intervention 1 and intervention 2 in these studies?,"Wehler et al.: Cost per member per month: +$0.08, +$0.14, +$0.28, +$0.41, +$0.55 in year 1 to year 5 Total annual cost: +$4.6 million, +$8.3 million, +$16.5 million, +$24.8 million, 33.0 million in year 1 to year 5 A 71.6% WAC discount would be required for oral semaglutide 14 mg to generate 5-year per patient costs equal to sitagliptin 100 mg; Gout-Zwart et al.: Total annual cost: â€“â‚¬232,323, â€“â‚¬645,742, â€“â‚¬180,4271 in year 1 to year 3 (cumulative saving of â‚¬1,962,335 during 3 years); Laranjeira et al.: Total annual cost: +$28.6 million, +$36.0 million, +$43.5 million, +$51.1 million and +$58.8 million in 2015â€“2019 (cumulative increased $217.9 million during 5 years); Catic et al.: Total annual cost: â€“â‚¬18,194, â€“â‚¬235,570 and â€“â‚¬699,472 in 2016â€“2018; Marga et al.: Cost per patient per year: â€“â‚¬ 9,821 Total annual cost of a hypothetical cohort of 100 patients: â€“â‚¬ 982,023; Elsisi et al.: Total annual cost from societal perspective: -EGP 121 million, -EGP 243 million and -EGP 365 million in year 1 to year 3 (cumulative saving of EGP 731 million during 3 years) total annual cost from payer's perspective: -EGP 71 million, -EGP 143 million, and -EGP 215 million in year 1 to year 3 (cumulative saving of EGP 430 million during 3 years); Deerochanawong et al.: Cost per patient per year: +$0.97, +$1.96, +$2.9 in year 1 to year 3; Total annual cost: +$771,349, +$151,8218, +$221,6747 in year 1 to year 3; Stefano et al.: Cost per patient per year: +â‚¬8.04, +â‚¬18.18, +â‚¬25 in 2014â€“2016; Total annual cost: +â‚¬2.1 million, +â‚¬4.9 million, +â‚¬6.7 million in 2014~2016; Lane et al.: Cost per patient per year: +$312 for T1DMBBT, +$907 for T2DMBOT; Cost per member per month: +$0.04 for T1DMBBT, +$0.80 for T2DMBOT; Total annual cost: +$0.51 million for T1DMBBT, +$9.62 million for T2DMBOT; Rebates of 7.3% (T1DM) and 10.6% (T2DM) were required for IDeg to break-even with IGlar at the full list price."
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 13,What references are cited in these studies?,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 13
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 14,What perspectives are adopted in these studies?,Wehler et al. (27): Adopted; Gout-Zwart et al. (19): Adopted; Laranjeira et al. (21): Adopted; Catic et al. (15): Adopted; Marga et al. (18): Adopted; Elsisi et al. (17): Adopted; Deerochanawong et al. (16): Adopted; Stefano et al. (14): Adopted; Lane et al. (20): Adopted; Nita et al. (23): Adopted; Saunders et al. (24): Adopted; Shah et al. (25): Adopted; Weatherall et al. (26): Adopted; Xuan et al. (12): Adopted; Liu et al. (11): Adopted; Guan et al. (10): Adopted; Napoli et al. (22): Adopted; Agirrezabal et al. (13): Not adopted
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 15,What are the target population estimates in these studies?,Wehler et al. (27): âˆš; Gout-Zwart et al. (19): âˆš; Laranjeira et al. (21): âˆš; Catic et al. (15): âˆš; Marga et al. (18): ; Elsisi et al. (17): ; Deerochanawong et al. (16): âˆš; Stefano et al. (14): âˆš; Lane et al. (20): âˆš; Nita et al. (23): âˆš; Saunders et al. (24): âˆš; Shah et al. (25): âˆš; Weatherall et al. (26): âˆš; Xuan et al. (12): âˆš; Liu et al. (11): âˆš; Guan et al. (10): âˆš; Napoli et al. (22): âˆš; Agirrezabal et al. (13): 
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 16,What time horizons are considered in these studies?,Wehler et al. (27): âˆš; Gout-Zwart et al. (19): âˆš; Laranjeira et al. (21): âˆš; Catic et al. (15): âˆš; Marga et al. (18): âˆš; Elsisi et al. (17): âˆš; Deerochanawong et al. (16): âˆš; Stefano et al. (14): âˆš; Lane et al. (20): âˆš; Nita et al. (23): âˆš; Saunders et al. (24): âˆš; Shah et al. (25): âˆš; Weatherall et al. (26): âˆš; Xuan et al. (12): âˆš; Liu et al. (11): âˆš; Guan et al. (10): âˆš; Napoli et al. (22): âˆš; Agirrezabal et al. (13): 
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 17,What hypothetical scenarios are explored in these studies?,Wehler et al. (27): âˆš; Gout-Zwart et al. (19): âˆš; Laranjeira et al. (21): âˆš; Catic et al. (15): âˆš; Marga et al. (18): âˆš; Elsisi et al. (17): âˆš; Deerochanawong et al. (16): âˆš; Stefano et al. (14): âˆš; Lane et al. (20): âˆš; Nita et al. (23): ; Saunders et al. (24): âˆš; Shah et al. (25): âˆš; Weatherall et al. (26): âˆš; Xuan et al. (12): âˆš; Liu et al. (11): âˆš; Guan et al. (10): âˆš; Napoli et al. (22): âˆš; Agirrezabal et al. (13): 
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 18,What comparators are used in these studies?,Wehler et al. (27): âˆš; Gout-Zwart et al. (19): âˆš; Laranjeira et al. (21): âˆš; Catic et al. (15): âˆš; Marga et al. (18): âˆš; Elsisi et al. (17): âˆš; Deerochanawong et al. (16): âˆš; Stefano et al. (14): âˆš; Lane et al. (20): âˆš; Nita et al. (23): ; Saunders et al. (24): âˆš; Shah et al. (25): âˆš; Weatherall et al. (26): âˆš; Xuan et al. (12): âˆš; Liu et al. (11): âˆš; Guan et al. (10): âˆš; Napoli et al. (22): âˆš; Agirrezabal et al. (13): âˆš
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 19,How are the frameworks described in these studies?,Wehler et al. (27): Framework description provided; Gout-Zwart et al. (19): Framework description provided; Laranjeira et al. (21): Framework description not provided; Catic et al. (15): Framework description provided; Marga et al. (18): Framework description not provided; Elsisi et al. (17): Framework description provided; Deerochanawong et al. (16): Framework description provided; Stefano et al. (14): Framework description not provided; Lane et al. (20): Framework description provided; Nita et al. (23): Framework description not provided; Saunders et al. (24): Framework description provided; Shah et al. (25): Framework description provided; Weatherall et al. (26): Framework description provided; Xuan et al. (12): Framework description provided; Liu et al. (11): Framework description provided; Guan et al. (10): Framework description provided; Napoli et al. (22): Framework description provided; Agirrezabal et al. (13): Framework description not provided
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 20,What data collection methods and sources are utilized in these studies?,Wehler et al. (27): Data collection and sources are utilized.; Gout-Zwart et al. (19): Data collection and sources are utilized.; Laranjeira et al. (21): Data collection and sources are utilized.; Catic et al. (15): Data collection and sources are utilized.; Marga et al. (18): Data collection and sources are utilized.; Elsisi et al. (17): Data collection and sources are utilized.; Deerochanawong et al. (16): Data collection and sources are utilized.; Stefano et al. (14): Data collection and sources are utilized.; Lane et al. (20): Data collection and sources are utilized.; Nita et al. (23): Data collection and sources are utilized.; Saunders et al. (24): Data collection and sources are utilized.; Shah et al. (25): Data collection and sources are utilized.; Weatherall et al. (26): Data collection and sources are utilized.; Xuan et al. (12): Data collection and sources are utilized.; Liu et al. (11): Data collection and sources are utilized.; Guan et al. (10): Data collection and sources are utilized.; Napoli et al. (22): Data collection and sources are utilized.; Agirrezabal et al. (13): Data collection and sources are not utilized.
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 21,How is validation conducted in these studies?,Wehler et al. (27): Validation is conducted.; Gout-Zwart et al. (19): Validation is conducted.; Laranjeira et al. (21): Validation is conducted.; Catic et al. (15): Validation is not conducted.; Marga et al. (18): Validation is not conducted.; Elsisi et al. (17): Validation is conducted.; Deerochanawong et al. (16): Validation is not conducted.; Stefano et al. (14): Validation is not conducted.; Lane et al. (20): Validation is not conducted.; Nita et al. (23): Validation is not conducted.; Saunders et al. (24): Validation is not conducted.; Shah et al. (25): Validation is not conducted.; Weatherall et al. (26): Validation is not conducted.; Xuan et al. (12): Validation is not conducted.; Liu et al. (11): Validation is not conducted.; Guan et al. (10): Validation is not conducted.; Napoli et al. (22): Validation is not conducted.; Agirrezabal et al. (13): Validation is not conducted.
8639520_Table_3,Wehler et al.: 27; Gout-Zwart et al.: 19; Laranjeira et al.: 21; Catic et al.: 15; Marga et al.: 18; Elsisi et al.: 17; Deerochanawong et al.: 16; Stefano et al.: 14; Lane et al.: 20; Nita et al.: 23; Saunders et al.: 24; Shah et al.: 25; Weatherall et al.: 26; Xuan et al.: 12; Liu et al.: 11; Guan et al.: 10; Napoli et al.: 22; Agirrezabal et al.: 22,What sensitivity analyses are performed in these studies?,Wehler et al. (27): Performed; Gout-Zwart et al. (19): Performed; Laranjeira et al. (21): Performed; Catic et al. (15): Not performed; Marga et al. (18): Performed; Elsisi et al. (17): Performed; Deerochanawong et al. (16): Performed; Stefano et al. (14): Not performed; Lane et al. (20): Not performed; Nita et al. (23): Performed; Saunders et al. (24): Performed; Shah et al. (25): Not performed; Weatherall et al. (26): Performed; Xuan et al. (12): Not performed; Liu et al. (11): Performed; Guan et al. (10): Performed; Napoli et al. (22): Not performed; Agirrezabal et al. (13): Not performed
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,Who are the authors of these studies?,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What are the titles of these studies?,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,In which years were these studies published?,Brown et al19: 1998; Vintzileos et al17: 2000; Vanara et al13: 2004; Pinto et al18: 2014; Mistry et al14: 2013; Chung et al15: 2020; Finneran et al16: 2019
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,Which countries are covered in these studies?,Brown et al19: UK; Vintzileos et al17: USA; Vanara et al13: Italy; Pinto et al18: USA; Mistry et al14: UK; Chung et al15: USA; Finneran et al16: USA
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What are the study populations in these studies?,Brown et al19: Pregnant womenEvaluate lethal anomalies in the fetus; Vintzileos et al17: Pregnant women with low obstetric risk (fetus malformations); Vanara et al13: Pregnant women between the 19th and 21st weekEvaluate structural fetal malformations; Pinto et al18: Pregnant women with low obstetric riskEvaluate the presence of CHD in the fetus; Mistry et al14: Pregnant women with â€œstandard riskâ€ to evaluate the presence of CHD in the fetus; Chung et al15: Women who got pregnant through IVF divided into 2 subgroups: IVF with conventional fertilization and IVF with ICSI; Finneran et al16: Pregnant women with a diagnosis of pregestational diabetes
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What perspectives are used in these studies?,Brown et al19: NHS; Vintzileos et al17: Society; Vanara et al13: Sanitary Authority; Pinto et al18: Payer; Mistry et al14: NHS; Chung et al15: Society; Finneran et al16: Not reported
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What interventions are analyzed in these studies?,"Brown et al19: Routine US during 1st trimester; Vintzileos et al17: US in a tertiary-level center; Vanara et al13: Structured gestational screening program with US to detect fetus malformations.; Pinto et al18: US during the 2nd trimester with 4C view and subsequent referral to MFM, (4C MFM); Mistry et al14: CHD screening with telemedicine; Chung et al15: Anatomical ultrasonographySelective fetal echocardiography after abnormal detailed anatomical study; Finneran et al16: US"
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What comparisons are made in these studies?,"Brown et al19: Routine US during 1st trimester vs. Do not perform US, US and NT in the 1st trimester, US in 2nd trimester, US in 3rd trimester, Different combinations between options; Vintzileos et al17: US in a tertiary-level center vs. US in primary- and secondary-level centers.; Vanara et al13: Structured gestational screening program with US to detect fetus malformations vs. No structured screening program; Pinto et al18: US during the 2nd trimester with 4C view and subsequent referral to MFM vs. US during 2nd trimester with 4C and subsequent referral to a pediatric cardiologist, US during 2nd trimester with 4C + outflow tracts, subsequent referral to MFM, US during 2nd trimester with 4C + outflow tracts, subsequent referral to pediatric cardiologist, US during 2nd trimester with 4C + outflow tracts performed by MFM, subsequent referral to pediatric cardiologist, Stepped screening with NT in the 1st trimester, followed by US with view of outflow tracts in the 2nd trimester, Universal fetal echocardiography; Mistry et al14: CHD screening with telemedicine vs. Usual in-person management; Chung et al15: Anatomical ultrasonography, Selective fetal echocardiography after abnormal detailed anatomical study vs. Fetal echocardiography for all IVF pregnancies with ICSI, Fetal echocardiography for all IVF pregnancies; Finneran et al16: US vs. Echocardiography for all patients with elevated A1c hemoglobin, Selective echocardiography only after an abnormal US"
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What types of economic evaluations are conducted in these studies?,Brown et al19: Cost-effectiveness; Vintzileos et al17: Cost-benefit; Vanara et al13: Cost-effectiveness; Pinto et al18: Cost effectiveness; Mistry et al14: Cost utility; Chung et al15: Cost utility; Finneran et al16: Cost effectiveness
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What outcome indicators are used in these studies?,Brown et al19: Detected anomalies; Vintzileos et al17: Avoided costs; Vanara et al13: Detected anomalies; Pinto et al18: CHD cases detected; Mistry et al14: QALY; Chung et al15: QALY and CHD cases detected; Finneran et al16: CHD cases detected
11127739_Table_1.,Brown et al19: Choosing options for ultrasound screening in pregnancy and comparing cost effectiveness: a decision analysis approach; Vintzileos et al17: Routine second-trimester ultrasonography in the United States: a cost-benefit analysis; Vanara et al13: Economic evaluation of ultrasound screening options for structural fetal malformations; Pinto et al18: Cost-effectiveness of prenatal screening strategies for congenital heart disease; Mistry et al14: The cost-effectiveness of prenatal detection for congenital heart disease using telemedicine screening; Chung et al15: The cost-effectiveness of prenatal congenital heart defect screening methods in In vitro fertilization (IVF) pregnancies; Finneran et al16: The accuracy and cost-effectiveness of selective fetal echocardiography for the diagnosis of congenital heart disease in patients with pregestational diabetes stratified by hemoglobin A1c,What are the sources and types of costs considered in these studies?,"Brown et al19: Direct medical costs. Sources: Literature review and NHS reported rates; Vintzileos et al17: Direct and indirect costs. Source: Waitzman et al (1994 and 1998); Vanara et al13: Direct costs from NHS records. Source: Vintzileos et al (2000); Pinto et al18: Direct medical costs. Source: 2012 National Medicare Rates; Mistry et al14: Direct costs. Sources: Literature review and expert opinions; Chung et al15: Direct and indirect costs. Sources: Literature review, Medicare, and Medicaid; Finneran et al16: Direct medical cost. Source: Medicare rates"
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 13,What references are cited in these studies?,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 13
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 14,In which years were these studies conducted?,Wehler et al. (27): 2020; Gout-Zwart et al. (19): 2020; Laranjeira et al. (21): 2016; Catic et al. (15): 2017; Marga et al. (18): 2017; Elsisi et al. (17): 2020; Deerochanawong et al. (16): 2018; Stefano et al. (14): 2015; Lane et al. (20): 2018; Nita et al. (23): 2012; Saunders et al. (24): 2014; Shah et al. (25): 2018; Weatherall et al. (26): 2017; Xuan et al. (12): 2019; Liu et al. (11): 2018; Guan et al. (10): 2016; Napoli et al. (22): 2020; Agirrezabal et al. (13): 2020
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 15,Which countries are covered in these studies?,Wehler et al. (27): United State; Gout-Zwart et al. (19): Netherlands; Laranjeira et al. (21): Brazil; Catic et al. (15): Bosnia and Herzegovina; Marga et al. (18): Spain; Elsisi et al. (17): Egypt; Deerochanawong et al. (16): Thailand; Stefano et al. (14): Italy; Lane et al. (20): United State; Nita et al. (23): Brazil; Saunders et al. (24): United State; Shah et al. (25): United State; Weatherall et al. (26): United State; Xuan et al. (12): China; Liu et al. (11): China; Guan et al. (10): China; Napoli et al. (22): Italy; Agirrezabal et al. (13): England
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 16,Are these studies sponsored by pharmaceutical industries?,Wehler et al. (27): Yes; Gout-Zwart et al. (19): Yes; Laranjeira et al. (21): No; Catic et al. (15): NR; Marga et al. (18): Yes; Elsisi et al. (17): Yes; Deerochanawong et al. (16): Yes; Stefano et al. (14): Yes; Lane et al. (20): Yes; Nita et al. (23): Yes; Saunders et al. (24): Yes; Shah et al. (25): Yes; Weatherall et al. (26): Yes; Xuan et al. (12): NR; Liu et al. (11): NR; Guan et al. (10): NR; Napoli et al. (22): Yes; Agirrezabal et al. (13): NR
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 17,What perspectives are used in these studies?,Wehler et al. (27): Payer; Gout-Zwart et al. (19): Payer; Laranjeira et al. (21): Public health system; Catic et al. (15): Payer; Marga et al. (18): National Healthcare Service; Elsisi et al. (17): Payer & society; Deerochanawong et al. (16): Payer; Stefano et al. (14): National Healthcare Service; Lane et al. (20): Payer; Nita et al. (23): Private health care system; Saunders et al. (24): Payer; Shah et al. (25): Payer; Weatherall et al. (26): Payer; Xuan et al. (12): Payer; Liu et al. (11): Payer; Guan et al. (10): Payer; Napoli et al. (22): National Healthcare Service; Agirrezabal et al. (13): NR
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 18,What types of research are conducted in these studies?,Wehler et al. (27): BIA only; Gout-Zwart et al. (19): BIA only; Laranjeira et al. (21): BIA only; Catic et al. (15): BIA only; Marga et al. (18): BIA only; Elsisi et al. (17): BIA only; Deerochanawong et al. (16): BIA only; Stefano et al. (14): BIA only; Lane et al. (20): BIA only; Nita et al. (23): CEA & BIA; Saunders et al. (24): CEA & BIA; Shah et al. (25): CEA & BIA; Weatherall et al. (26): BIA only; Xuan et al. (12): BIA only; Liu et al. (11): BIA only; Guan et al. (10): BIA only; Napoli et al. (22): BIA only; Agirrezabal et al. (13): BIA only
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 19,Which research foundations are associated with these studies?,Wehler et al. (27): Model; Gout-Zwart et al. (19): Model; Laranjeira et al. (21): Model; Catic et al. (15): Model; Marga et al. (18): Model; Elsisi et al. (17): Model; Deerochanawong et al. (16): Model; Stefano et al. (14): Model; Lane et al. (20): Model; Nita et al. (23): Model; Saunders et al. (24): Model; Shah et al. (25): Model; Weatherall et al. (26): Model; Xuan et al. (12): Model; Liu et al. (11): Model; Guan et al. (10): Model; Napoli et al. (22): Model; Agirrezabal et al. (13): RWD
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 20,What interventions are examined in these studies?,Wehler et al. (27): Oral semaglutide; Gout-Zwart et al. (19): Metformin SR; Laranjeira et al. (21): Long-acting insulin analogs; Catic et al. (15): Linagliptin; Marga et al. (18): Continuous subcutaneous insulin infusion (CSII); Elsisi et al. (17): Dapagliflozin; Deerochanawong et al. (16): Biphasic insulin aspart30 (BIAsp 30); Stefano et al. (14): Liraglutide; Lane et al. (20): Insulin degludec; Nita et al. (23): Saxagliptine; Saunders et al. (24): Stepwise addition (SWA) of bolus insulin; Shah et al. (25): Liraglutide; Weatherall et al. (26): Insulin degludec; Xuan et al. (12): Benaglutide; Liu et al. (11): Dapagliflozin; Guan et al. (10): Vildagliptin; Napoli et al. (22): Insulin glargine U300; Agirrezabal et al. (13): Insulin glargine biosimilars (AbasaglarÂ®)
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 21,What are the target populations in these studies?,"Wehler et al. (27): T2DM uncontrolled with metformin and received sitagliptin treatment; Gout-Zwart et al. (19): T2DM used metformin IR but suffered from AEs and newly diagnosed T2DM; Laranjeira et al. (21): T1DM; Catic et al. (15): T2DM with DPP-4i treatment; Marga et al. (18): T1DM that experienced recurrent severe hypoglycemia episodes; Elsisi et al. (17): T2DM; Deerochanawong et al. (16): T2DM who needed insulin; Stefano et al. (14): T2DM patients receiving GLP-1, DPP-4i and SGLT-2i treatments; Lane et al. (20): T1DMBBT and T2DMBOT; Nita et al. (23): T2DM with uncontrolled blood glucose on metformin; Saunders et al. (24): T2DM patients intensifying to FBB or SWA; Shah et al. (25): T2DM that received GLP-1 treatment; Weatherall et al. (26): T1DMBBT,T2DMBOT and T2DMBBT; Xuan et al. (12): T2DM received treatments; Liu et al. (11): T2DM received treatments; Guan et al. (10): T2DM received OAD treatments; Napoli et al. (22): T2DM insulin-naÃ¯ve patients; Agirrezabal et al. (13): NA"
8639520_Table_1,Wehler et al. (27): 27; Gout-Zwart et al. (19): 19; Laranjeira et al. (21): 21; Catic et al. (15): 15; Marga et al. (18): 18; Elsisi et al. (17): 17; Deerochanawong et al. (16): 16; Stefano et al. (14): 14; Lane et al. (20): 20; Nita et al. (23): 23; Saunders et al. (24): 24; Shah et al. (25): 25; Weatherall et al. (26): 26; Xuan et al. (12): 12; Liu et al. (11): 11; Guan et al. (10): 10; Napoli et al. (22): 22; Agirrezabal et al. (13): 22,What are the sizes of the target populations in these studies?,"Wehler et al. (27): 1,993 cases in a health plan of 1 million members; and 662,835 cases nationwide; Gout-Zwart et al. (19): 640,000 metformin IR treatment cases and 67,000 newly cases; Laranjeira et al. (21): 621,941~640,918 cases in 2015~2019; Catic et al. (15): 2,624 cases; Marga et al. (18): NA; Elsisi et al. (17): 2,053,908 cases for societal perspective and 1,207,698 cases for payer's perspective; Deerochanawong et al. (16): 0.79 million, 1.77 million, 7.51 million cases in year 1 to year 3; Stefano et al. (14): 269,813 cases; Lane et al. (20): 1,662 T1DMBBT and 10,602 T2DMBOT in a health plan with 1 million members; Nita et al. (23): A health plan with 1 million individuals; Saunders et al. (24): 6,015 cases in a health plan with 1 million members; Shah et al. (25): 1,130, 1,287, 1,518, 1,762 and 1,937 cases in year 1 to year 5, in a health plan with 1 million members; Weatherall et al. (26): 59,780 T1DMBBT, 383,145 T2DMBOT and 171,325 T2DMBBT in a health plan with 35 million members; Xuan et al. (12): 23.4, 23.6, 23.8, 23.9 and 24.0 million cases in 2019~2023; Liu et al. (11): 33.06, 33.24, 33.41, 33.58, and 33.75 million patients in 2018â€“2022; Guan et al. (10): 4.15, 4.60, 5.09, 5.64, 6.26, and 6.95 million patient-years in 2015â€“2020; Napoli et al. (22): 55,318 cases; Agirrezabal et al. (13): NA"
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,Who are the authors of these studies?,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,What model structures are used in these studies?,Carlson et al33: NR; Bayle et al44: Cost calculator; Bajaj et al30: Cost calculator; Kalluri et al41: Cost calculator; Hess et al37: Cost calculator; Thongprasert et al48: Markov; Goldstein et al35: Cost calculator; Aguiar et al49: NR; Norum et al47: NR; Bly et al31: NR; Graham et al36: Cost calculator; Signorovitch et al38: Cost calculator; Westerink et al45: Cost calculator; Monirul et al53: Cost calculator; Cheng et al46: Cost calculator; Stargardter et al39: NR; Rachev et al43: PSM
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,Do these studies use an open or closed cohort?,Carlson et al33: Closed; Bayle et al44: Closed; Bajaj et al30: Closed; Kalluri et al41: Closed; Hess et al37: NR; Thongprasert et al48: Open; Goldstein et al35: Closed; Aguiar et al49: NR; Norum et al47: Closed; Bly et al31: Open; Graham et al36: Open; Signorovitch et al38: NR; Westerink et al45: Open; Monirul et al53: Closed; Cheng et al46: NR; Stargardter et al39: Open; Rachev et al43: Closed
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,What population calculations are performed in these studies?,"Carlson et al33: Expected number of persons diagnosed with locally advanced or metastatic NSCLC => patients likely to be treated with first-line agent => patients treated with platinum-based doublet chemotherapy without bevacizumab => patients receiving chemotherapy who do not progress after 4 cycles and remain eligible for erlotinib MTx; Bayle et al44: Hospital records; Bajaj et al30: The proportion of patients in the health plan was applied to the SEER age specific incidence rates => multiplied by the proportion of tumors expected to be squamous vs nonsquamous histology, and the prevalence of EGFR mutations in each histology type; Kalluri et al41: Lung cancer in Alberta incidence => proportion eligible according in SEER; Hess et al37: Incidence of NSCLC => proportion of right type of disease => proportion of second line; Thongprasert et al48: Incidence of lung cancer in adults => incidence of NSCLC in lung cancer patients => incidence of advanced NSCLC in NSCLC patients => incidence of nonsquamous cells in advanced NSCLC patients => incidence of positive ALK tests (by FISH) => proportion of correct line of treatment for intervention; Goldstein et al35: Lung cancer deaths in the US => percentage with NSCLC => percentage with mutation => percentage with PD-L1 response; Aguiar et al49: Prevalence in each country => eligible for immunotherapy (first or second line); Norum et al47: Lung cancer prevalence => proportion NSCLC => stage => clinician opinion of eligibility of patients => enough PD-L1 expression; Bly et al31: Proportion metastatic squamous NSCLC patients => proportion first line; Graham et al36: Patients with metastatic NSCLC => patients with mutations => patients of interest; Signorovitch et al38: NR; Westerink et al45: Incidence assumed from NSCLC population with EGFR mutation; Monirul et al53: From hospital data using ICD codes; Cheng et al46: Epidemiological estimates applied to age-standardized country-specific annual incidence of lung cancer; Stargardter et al39: Proportion with mutation => ratio first line vs second line => projected mutation testing rates; Rachev et al43: Country population => newly diagnosed patients with advanced stages => p"
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,How is market uptake addressed in these studies?,Carlson et al33: Yes; Bayle et al44: NR; Bajaj et al30: No; Kalluri et al41: No; Hess et al37: No; Thongprasert et al48: No; Goldstein et al35: No; Aguiar et al49: No; Norum et al47: NR; Bly et al31: Yes; Graham et al36: Yes; Signorovitch et al38: No; Westerink et al45: No; Monirul et al53: No; Cheng et al46: NR; Stargardter et al39: Yes
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,Do these studies account for treatment switching?,Carlson et al33: Yes; Bayle et al44: NR; Bajaj et al30: No; Kalluri et al41: No; Hess et al37: No; Thongprasert et al48: Yes; Goldstein et al35: No; Aguiar et al49: No; Norum et al47: NR; Bly et al31: Yes; Graham et al36: Yes; Signorovitch et al38: No; Westerink et al45: No; Monirul et al53: No; Cheng et al46: NR; Stargardter et al39: Yes; Rachev et al43: NR
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,What cost types are supported in these studies?,"Carlson et al33: Drugs, inpatient and outpatient care, and hospitalization; Bayle et al44: Drug acquisition; Bajaj et al30: Treatment, administration, adverse events; Kalluri et al41: Procedure, wages; Hess et al37: Drugs; Thongprasert et al48: Drugs, ALK testing by FISH, adverse event treatment, administration and monitoring, and best supportive care; Goldstein et al35: Drug acquisition; Aguiar et al49: Treatment, adverse events, drug infusion, hospitalizations as well as supportive care, and postprogression therapies; Norum et al47: PD-L1 testing, radiology (CT scan, MRI), drugs, pulmonologist/oncologist/nurse, pharmacy, and traveling expenses; Bly et al31: Treatment, grade â‰¥3 adverse events, and disease; Graham et al36: Drugs, adverse events, testing, disease management; Signorovitch et al38: Diagnostic tests, biopsy, anticancer drug and administration, and all medical service incurred by patients with metastatic NSCLC; Westerink et al45: Treatment, mutation testing, and adverse events; Monirul et al53: Drugs; Cheng et al46: Drugs; Stargardter et al39: Drug, adverse event, and biomarker testing"
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,What sensitivity analyses are conducted in these studies?,Carlson et al33: 1-way DSA; Bayle et al44: NR; Bajaj et al30: 1-way DSA; Kalluri et al41: 1-way DSA; Hess et al37: 1-way DSA; Thongprasert et al48: 1-way DSA; Goldstein et al35: 1-way DSA; Aguiar et al49: NR; Norum et al47: 1-way DSA; Bly et al31: 1-way DSA; Graham et al36: 1-way DSA; Signorovitch et al38: 1-way DSA; Westerink et al45: 1-way DSA; Monirul et al53: 1-way DSA; Cheng et al46: 1-way DSA; Stargardter et al39: 1-way DSA; Rachev et al43: NR
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,Are time-varying factors considered in these studies?,Carlson et al33: No; Bayle et al44: No; Bajaj et al30: No; Kalluri et al41: No; Hess et al37: No; Thongprasert et al48: Yes; Goldstein et al35: No; Aguiar et al49: No; Norum et al47: No; Bly et al31: Yes; Graham et al36: NR; Signorovitch et al38: No; Westerink et al45: Yes; Monirul et al53: No; Cheng et al46: Yes; Stargardter et al39: No
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,What percentages are reported in these studies?,Carlson et al33: 42-100; Bayle et al44: NR; Bajaj et al30: 90; Kalluri et al41: 100; Hess et al37: 15; Thongprasert et al48: 100; Goldstein et al35: 35; Aguiar et al49: 100; Norum et al47: NR; Bly et al31: 4.4-14.7; Graham et al36: 5; Signorovitch et al38: 2-10; Westerink et al45: 100; Monirul et al53: 100; Cheng et al46: NR; Stargardter et al39: 13.9-22.8 (naive) 6.7-11.2 (previously treated); Rachev et al43: p
11366214_T3,Carlson et al33: answer specific to Carlson et al33; Bayle et al44: answer specific to Bayle et al44; Bajaj et al30: answer specific to Bajaj et al30; Kalluri et al41: answer specific to Kalluri et al41; Hess et al37: answer specific to Hess et al37; Thongprasert et al48: answer specific to Thongprasert et al48; Goldstein et al35: answer specific to Goldstein et al35; Aguiar et al49: answer specific to Aguiar et al49; Norum et al47: answer specific to Norum et al47; Bly et al31: answer specific to Bly et al31; Graham et al36: answer specific to Graham et al36; Signorovitch et al38: answer specific to Signorovitch et al38; Westerink et al45: answer specific to Westerink et al45; Monirul et al53: answer specific to Monirul et al53; Cheng et al46: answer specific to Cheng et al46; Stargardter et al39: answer specific to Stargardter et al39; Rachev et al43: answer specific to Rachev et al43,What data sources are utilized in these studies?,"Carlson et al33: Market Research Data, SEER; Bayle et al44: NR; Bajaj et al30: Assumption; Kalluri et al41: Assumption; Hess et al37: Assumption; Thongprasert et al48: Assumption; Goldstein et al35: Assumption; Aguiar et al49: Assumption; Norum et al47: NR; Bly et al31: Assumption; Graham et al36: Assumption; Signorovitch et al38: Assumption; Westerink et al45: Assumption; Monirul et al53: Assumption; Cheng et al46: NR; Stargardter et al39: Market Research Data; Rachev et al43: NR"
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201432,What comparisons between RARP and LRP are made in these studies?,"Ratchanon 201531: RARP is not cost-effective compared to LRP with a cost of 2,407,180 baht/QALY or US$227K/QALY.; Close 2013/ Ramsay 201216 40: RARP is cost-effective compared to LRP if the volume is greater than 150, with a cost of GBPÂ£18,329/QALY or US$31K/QALY.; Cooperberg 201317: No difference in effectiveness between RARP and LRP, and RARP has a lower cost.; Teljeur 201432: No specific cost-effectiveness comparison reported between RARP and LRP."
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201433,How do these studies reference or utilize the findings from Ratchanon 201531?,Close 2013/ Ramsay 201216: No reference or utilization of Ratchanon 201531 findings is mentioned.; Cooperberg 201317: No reference or utilization of Ratchanon 201531 findings is mentioned.; Teljeur 201432: No reference or utilization of Ratchanon 201531 findings is mentioned.; MSAC 200635: No reference or utilization of Ratchanon 201531 findings is mentioned.; O'Malley 200736: No reference or utilization of Ratchanon 201531 findings is mentioned.; HohwÃ¼ 201119: No reference or utilization of Ratchanon 201531 findings is mentioned.; HIQA 201138: No reference or utilization of Ratchanon 201531 findings is mentioned.; AHT 201733: No reference or utilization of Ratchanon 201531 findings is mentioned.; HQO 201718: No reference or utilization of Ratchanon 201531 findings is mentioned.; Parackal 202037: No reference or utilization of Ratchanon 201531 findings is mentioned.; de Oliveira 202134: No reference or utilization of Ratchanon 201531 findings is mentioned.
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201434,What cost in baht is reported in these studies?,Ratchanon 201531: 120â€‰359 baht
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201435,What cost in US dollars is reported in these studies?,"Ratchanon 201531: US$11,385; Close 2013/ Ramsay 201216 40: US$2,464; Cooperberg 201317: Low risk: US$âˆ’732, Intermediate risk: US$âˆ’1268, High risk: US$âˆ’129; Teljeur 201432: Not reported; MSAC 200635: US$3,613 for ED; US$4,348 for UI; O'Malley 200736: US$2,049; HohwÃ¼ 201119: US$7,093; HIQA 201138: US$3,730; AHT 201733: US$7,813; HQO 201718: US$5,702; Parackal 202037: US$1,457; de Oliveira 202134: US$4,368"
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201436,What significance level or p-value is used in these studies?,"Ratchanon 201531: 0.05; Close 2013/ Ramsay 201216 40: 0.08; Cooperberg 201317: Low risk: 0, Intermediate risk: 0.1, High risk: 0; Teljeur 201432: No reported; MSAC 200635: 0.10 for ED; 0.01 for UI; O'Malley 200736: 0.09; HohwÃ¼ 201119: âˆ’0.07; HIQA 201138: 0.09; AHT 201733: 0.19; HQO 201718: 0.001; Parackal 202037: 0.07; de Oliveira 202134: 0.41"
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201437,What is the cost per QALY in baht reported in these studies?,Ratchanon 201531: 2â€‰407â€‰180 baht/QALY
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201438,What is the cost per QALY in US dollars reported in these studies?,Ratchanon 201531: US$227K/QALY; Close 2013/ Ramsay 201216: US$31K/QALY; Cooperberg 201317: ICER not calculated; Teljeur 201432: Not reported; MSAC 200635: US$36K/QALY for ED; US$435K/QALY for UI; O'Malley 200736: US$40K/QALY; HohwÃ¼ 201119: US$101K/extra successful treatment; HIQA 201138: US$30K/QALY; AHT 201733: US$41K/QALY; HQO 201718: US$5M/QALY; Parackal 202037: US$22K/QALY; de Oliveira 202134: US$11K/QALY
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201439,What alternative cost per QALY in baht is mentioned in these studies?,Ratchanon 201531: 160K baht per QALY
9490571_Table_2,Ratchanon 201531; Ramsay 201216 ; Cooperberg 201317:; Teljeur 201440,What conclusions do these studies draw about the cost-effectiveness of RARP?,Ratchanon 201531: RARP is not cost-effective; Close 2013/ Ramsay 201216 40: RARP is cost-effective if volume >150; Cooperberg 201317: No difference in effectiveness and RARP lower cost; Teljeur 201432: Not reported; MSAC 200635: Lack of data; O'Malley 200736: RARP cost-effective; HohwÃ¼ 201119: RARP not cost-effective; HIQA 201138: No specified threshold in Ireland; AHT 201733: RARP cost-effective; HQO 201718: RARP not cost-effective; Parackal 202037: RARP cost-effective; de Oliveira 202134: RARP cost-effective
